143B
|
IC50 |
|
Cytotoxicity against human 143B cells measured after 72 hrs by Celltiter-Glo assay
Cytotoxicity against human 143B cells measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31820976]
|
16HBE14o-
|
GI50 |
0.18 μM
Compound: Adriamycin
|
Growth inhibition of human 16HBE cells by sulforhodamine B assay
Growth inhibition of human 16HBE cells by sulforhodamine B assay
|
[PMID: 24650643]
|
184B5
|
GI50 |
1.15 μM
Compound: Doxorubicin
|
Cytotoxicity against human 184B5 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human 184B5 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29670691]
|
184B5
|
GI50 |
1.2 μM
Compound: Doxorubicin
|
Antiproliferative activity against human 184B5 cells after 72 hrs by MTT assay
Antiproliferative activity against human 184B5 cells after 72 hrs by MTT assay
|
[PMID: 30071406]
|
1A9
|
EC50 |
0.1 μM
Compound: doxorubicin
|
Cytotoxicity against human 1A9 cells after 72 hrs
Cytotoxicity against human 1A9 cells after 72 hrs
|
[PMID: 17378530]
|
3Y1 cell line
|
GI50 |
3.8 nM
Compound: adriamycin
|
Cytotoxicity against rat 3Y1 cells after 72 hrs by MTT assay
Cytotoxicity against rat 3Y1 cells after 72 hrs by MTT assay
|
[PMID: 10691710]
|
4T1
|
IC50 |
0.481 μM
Compound: Doxorubicin
|
Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783]
|
4T1
|
IC50 |
0.99 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
[PMID: 27496212]
|
4T1
|
IC50 |
90 nM
Compound: Doxorubicin
|
Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
|
[PMID: 35213166]
|
5637
|
IC50 |
|
Antiproliferative activity against human 5637 cell line by MTT assay
Antiproliferative activity against human 5637 cell line by MTT assay
|
[PMID: 16913700]
|
5-8F
|
IC50 |
|
Antiproliferative activity against human 5-8F cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human 5-8F cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 36709571]
|
769-P
|
IC50 |
0.45 μM
Compound: Doxorubicin
|
Anticancer activity against human 769-P cells by MTT assay
Anticancer activity against human 769-P cells by MTT assay
|
[PMID: 31404864]
|
786-0
|
GI50 |
|
Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26454648]
|
786-0
|
GI50 |
0.02 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human 786-0 cells by sulforhodamine B assay
Cytotoxicity against human 786-0 cells by sulforhodamine B assay
|
[PMID: 26913941]
|
786-0
|
GI50 |
0.025 μg/mL
Compound: DOX; Doxo
|
Antiproliferative activity against human 786-0 cells after 48 hrs by SRB assay
Antiproliferative activity against human 786-0 cells after 48 hrs by SRB assay
|
[PMID: 26859070]
|
786-0
|
GI50 |
|
Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21041092]
|
786-0
|
GI50 |
|
Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
|
[PMID: 28505535]
|
786-0
|
IC50 |
0.13 μM
Compound: Doxorubicin
|
Cytotoxicity against human 786-O cells assessed as growth inhibition by MTS assay
Cytotoxicity against human 786-O cells assessed as growth inhibition by MTS assay
|
[PMID: 24824796]
|
786-0
|
GI50 |
0.13 μM
Compound: Doxorubicin hydrochloride, NSC 123127
|
Cytotoxicity against human 786-0 cells after 48 hrs by SRB assay
Cytotoxicity against human 786-0 cells after 48 hrs by SRB assay
|
[PMID: 23871905]
|
786-0
|
GI50 |
0.13 μM
Compound: Doxorubicin
|
Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29102177]
|
786-0
|
GI50 |
0.13 μM
Compound: Doxorubicin
|
Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28329730]
|
786-0
|
GI50 |
0.15 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Cytotoxicity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 26561866]
|
786-0
|
GI50 |
|
Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 25062010]
|
786-0
|
GI50 |
|
Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 31247374]
|
786-0
|
GI50 |
0.16 μM
Compound: Doxorubicin
|
Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 33477019]
|
786-0
|
GI50 |
0.18 μg/mL
Compound: Doxorubicin
|
Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22410248]
|
A 172
|
IC50 |
|
Antiproliferative activity against human A-172 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
Antiproliferative activity against human A-172 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
|
[PMID: 34968902]
|
A 172
|
IC50 |
|
Cytotoxicity against human A172 cells after 72 hrs by MTT assay
Cytotoxicity against human A172 cells after 72 hrs by MTT assay
|
[PMID: 30659997]
|
A204
|
IC50 |
0.006482 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A204 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay
Antiproliferative activity against human A204 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay
|
[PMID: 30540463]
|
A2058
|
CC50 |
1.79 μM
Compound: Doxorubicin
|
Cytotoxicity against human A2058 cells after 72 hrs by MTT assay
Cytotoxicity against human A2058 cells after 72 hrs by MTT assay
|
[PMID: 29792325]
|
A2058
|
EC50 |
|
Dark toxicity in human A2058 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Dark toxicity in human A2058 cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
[PMID: 29172528]
|
A2780
|
GI50 |
|
Cytotoxicity against human A2780 cells after 48 hrs by SRB assay
Cytotoxicity against human A2780 cells after 48 hrs by SRB assay
|
[PMID: 20673627]
|
A2780
|
GI50 |
|
Anticancer activity against human A2780 cells by SRB method
Anticancer activity against human A2780 cells by SRB method
|
[PMID: 22104151]
|
A2780
|
GI50 |
|
Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21737288]
|
A2780
|
IC50 |
0.0096 μM
Compound: Doxirubicin
|
Concentration required to inhibit A2780-cell growth by 50%
Concentration required to inhibit A2780-cell growth by 50%
|
[PMID: 9703471]
|
A2780
|
EC50 |
0.01 μM
Compound: Doxorubicin
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
[PMID: 33049606]
|
A2780
|
EC50 |
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32956968]
|
A2780
|
IC50 |
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32422522]
|
A2780
|
IC50 |
0.02 μM
Compound: doxorubicin
|
Antiproliferative activity against human A2780 cells after 3 days by MTT assay
Antiproliferative activity against human A2780 cells after 3 days by MTT assay
|
[PMID: 19093883]
|
A2780
|
IC50 |
0.044 μM
Compound: Doxorubicin
|
Cytotoxicity against human A2780 cells assessed as intracellular ATP level after 72 hrs by luminometry
Cytotoxicity against human A2780 cells assessed as intracellular ATP level after 72 hrs by luminometry
|
[PMID: 21354800]
|
A2780
|
IC50 |
0.05 μM
Compound: Doxorubicin
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33823396]
|
A2780
|
IC50 |
0.1 μM
Compound: adriamycin
|
Cytotoxicity against human A2780 cells by MTT assay
Cytotoxicity against human A2780 cells by MTT assay
|
[PMID: 17190442]
|
A2780
|
IC50 |
|
Cytotoxicity against human A2780 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 30599418]
|
A2780
|
GI50 |
|
Growth inhibition of human A2780 cells after 48 hrs by SRB assay
Growth inhibition of human A2780 cells after 48 hrs by SRB assay
|
[PMID: 20031423]
|
A2780
|
GI50 |
|
Growth inhibition of human A2780 cells by SRB assay
Growth inhibition of human A2780 cells by SRB assay
|
[PMID: 22361684]
|
A2780
|
GI50 |
|
Anticancer activity against human A2780 cells by SRB method
Anticancer activity against human A2780 cells by SRB method
|
[PMID: 21676506]
|
A2780
|
GI50 |
|
Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 23849207]
|
A2780
|
GI50 |
|
Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22364746]
|
A2780
|
GI50 |
|
Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 18657979]
|
A2780
|
GI50 |
|
Cytotoxicity against human A2780 cells after 24 hrs by WST-1 assay
Cytotoxicity against human A2780 cells after 24 hrs by WST-1 assay
|
[PMID: 20732817]
|
A2780
|
GI50 |
0.17 μM
Compound: adriamycin
|
Cytotoxicity against human A2780 cells after 24 hrs by SRB method
Cytotoxicity against human A2780 cells after 24 hrs by SRB method
|
[PMID: 18262426]
|
A2780
|
GI50 |
0.17 μM
Compound: ADR, Adriamycin
|
Growth inhibition of human A2780 cells by SRB method
Growth inhibition of human A2780 cells by SRB method
|
[PMID: 18207392]
|
A2780
|
IC50 |
0.18 μM
Compound: ADM; DOX
|
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31491611]
|
A2780
|
IC50 |
|
Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
|
[PMID: 26386603]
|
A2780
|
IC50 |
0.33 μM
Compound: Adriamycin
|
Cytotoxicity against human A2780 cells by MTT assay
Cytotoxicity against human A2780 cells by MTT assay
|
[PMID: 22070654]
|
A2780
|
IC50 |
|
Cytotoxicity against human A2780 cells by SRB assay
Cytotoxicity against human A2780 cells by SRB assay
|
[PMID: 18656370]
|
A2780
|
IC50 |
|
Cytotoxicity against human A2780 cells by sulforhodamine B assay
Cytotoxicity against human A2780 cells by sulforhodamine B assay
|
[PMID: 17822905]
|
A2780
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTS assay
|
[PMID: 33348171]
|
A2780
|
IC50 |
0.6 μM
Compound: Adriamycin
|
Cytotoxicity against human A2780 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26356746]
|
A2780
|
IC50 |
|
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32996316]
|
A2780
|
IC50 |
|
Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 27149641]
|
A2780
|
IC50 |
1.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human A2780 cells after 24 hrs by MTT assay
Cytotoxicity against human A2780 cells after 24 hrs by MTT assay
|
[PMID: 26252628]
|
A2780
|
IC50 |
|
Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method
Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method
|
[PMID: 25061803]
|
A2780
|
IC50 |
23 nM
Compound: doxorubicin
|
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
|
[PMID: 23886686]
|
A-375
|
EC50 |
0.009 μM
Compound: Doxorubicin
|
Induction of senescence in human A-375 cells treated for 3 days by Hoechst staining based imaging analysis
Induction of senescence in human A-375 cells treated for 3 days by Hoechst staining based imaging analysis
|
[PMID: 33859796]
|
A-375
|
EC50 |
|
Induction of senescence-like phenotype in human A-375 cells assessed as increase in morphological changes after 72 hrs by staining based imaging assay
Induction of senescence-like phenotype in human A-375 cells assessed as increase in morphological changes after 72 hrs by staining based imaging assay
|
[PMID: 33268144]
|
A-375
|
IC50 |
0.01 μM
Compound: doxorubicin
|
Cytotoxicity against human A375 cells after 24 hrs by MTT assay
Cytotoxicity against human A375 cells after 24 hrs by MTT assay
|
[PMID: 18281125]
|
A-375
|
IC50 |
0.01 μM
Compound: doxorubicin
|
Cytotoxicity against human A375 cells after 24 hrs by MTT assay
Cytotoxicity against human A375 cells after 24 hrs by MTT assay
|
[PMID: 17400463]
|
A-375
|
IC50 |
0.01 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
|
[PMID: 25937235]
|
A-375
|
IC50 |
0.024 μM
Compound: Doxorubicin
|
Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783]
|
A-375
|
IC50 |
|
Antiproliferative activity against human A375 cells after 72 hrs by MTT assay
Antiproliferative activity against human A375 cells after 72 hrs by MTT assay
|
[PMID: 21496972]
|
A-375
|
IC50 |
0.19 μM
Compound: ADM; DOX
|
Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31491611]
|
A-375
|
IC50 |
|
Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
|
[PMID: 35612499]
|
A-375
|
IC50 |
|
Antiproliferative activity against human A-375 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human A-375 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35818137]
|
A-375
|
IC50 |
|
Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay
|
[PMID: 29597166]
|
A-375
|
IC50 |
0.4 μM
Compound: Doxorubicin
|
Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29789258]
|
A-375
|
IC50 |
0.4 μM
Compound: Doxorubicin
|
Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
|
[PMID: 35271771]
|
A-375
|
IC50 |
|
Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 23639650]
|
A-375
|
IC50 |
|
Cytotoxicity against human A375 cells after 72 hrs by MTT assay
Cytotoxicity against human A375 cells after 72 hrs by MTT assay
|
[PMID: 26280921]
|
A-375
|
IC50 |
|
Cytotoxicity against human A375 cells after 72 hrs by MTT assay
Cytotoxicity against human A375 cells after 72 hrs by MTT assay
|
[PMID: 25874331]
|
A-375
|
IC50 |
1.2 μM
Compound: Doxorubicin
|
Anticancer activity against human A375 cells by MTT assay
Anticancer activity against human A375 cells by MTT assay
|
10.1039/C4MD00219A
|
A-375
|
IC50 |
1.8 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human A375 cells after 24 hrs by MTT assay
Cytotoxicity against human A375 cells after 24 hrs by MTT assay
|
[PMID: 12608856]
|
A-375
|
IC50 |
2.1 μM
Compound: Doxorubicin
|
Cytotoxicity against human A-375 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A-375 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32975117]
|
A-375
|
IC50 |
5.51 μM
Compound: Doxorubicin
|
Anticancer activity against human A375 cells after 48 hrs by MTT assay
Anticancer activity against human A375 cells after 48 hrs by MTT assay
|
[PMID: 22136907]
|
A-375
|
IC50 |
|
Antiproliferative activity against human A375 cells for 24 hrs by MTT assay
Antiproliferative activity against human A375 cells for 24 hrs by MTT assay
|
[PMID: 24929289]
|
A-375
|
IC50 |
7.01 μM
Compound: Doxorubicin
|
Cytotoxicity against human A375 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
Cytotoxicity against human A375 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
|
[PMID: 30433783]
|
A-375
|
IC50 |
|
Cytotoxicity against human A375 cells after 48 hrs by MTT assay
Cytotoxicity against human A375 cells after 48 hrs by MTT assay
|
[PMID: 25563891]
|
A-431
|
GI50 |
0.0012 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A431 cells by SRB assay
Antiproliferative activity against human A431 cells by SRB assay
|
[PMID: 19394218]
|
A-431
|
IC50 |
|
Anticancer activity against human A431 cells after 48 hrs by MTT assay
Anticancer activity against human A431 cells after 48 hrs by MTT assay
|
[PMID: 22209733]
|
A-431
|
IC50 |
0.05 μM
Compound: adriamycin
|
Growth inhibition of human A431 cells by MTT assay
Growth inhibition of human A431 cells by MTT assay
|
[PMID: 17049252]
|
A-431
|
IC50 |
|
Cytotoxicity against human A431 cells measured after 72 hrs by Celltiter-Glo assay
Cytotoxicity against human A431 cells measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31820976]
|
A-431
|
GI50 |
0.18 μM
Compound: Doxorubicin
|
Growth inhibition of human A431 cells after 2 days by SRB assay
Growth inhibition of human A431 cells after 2 days by SRB assay
|
[PMID: 22000924]
|
A-431
|
GI50 |
0.18 μM
Compound: Doxorubicine
|
Growth inhibition of human A431 cells after 2 days by sulforhodamine B assay
Growth inhibition of human A431 cells after 2 days by sulforhodamine B assay
|
[PMID: 20045222]
|
A-431
|
IC50 |
0.19 μM
Compound: Doxorubicin
|
Cytotoxicity against human A431 cells after 72 hrs by MTT assay
Cytotoxicity against human A431 cells after 72 hrs by MTT assay
|
[PMID: 18692939]
|
A-431
|
IC50 |
0.37 μM
Compound: Doxorubicin
|
Cytotoxicity against human A431 cells after 48 hrs by MTT assay
Cytotoxicity against human A431 cells after 48 hrs by MTT assay
|
[PMID: 20846862]
|
A-431
|
EC50 |
0.7 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 35567964]
|
A-431
|
ED50 |
1.2 x 10 -2 μg/mL
Compound: Adriamycin
|
Cytotoxicity against human A431 cells by MTT assay
Cytotoxicity against human A431 cells by MTT assay
|
[PMID: 7714533]
|
A-431
|
IC50 |
|
Cytotoxicity against human A431 cells by SRB assay
Cytotoxicity against human A431 cells by SRB assay
|
[PMID: 24890652]
|
A-431
|
IC50 |
1.43 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 31546197]
|
A498
|
ED50 |
0.00286 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 11087592]
|
A498
|
ED50 |
0.0156 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A-498 cells after 7 days by MTT assay
Cytotoxicity against human A-498 cells after 7 days by MTT assay
|
[PMID: 10514307]
|
A498
|
IC50 |
0.035 μM
Compound: adriamycin
|
Antitumor activity against human A498 cells by methylene blue staining method
Antitumor activity against human A498 cells by methylene blue staining method
|
[PMID: 17656091]
|
A498
|
GI50 |
0.1 μM
Compound: Doxorubicin hydrochloride, NSC 123127
|
Cytotoxicity against human A498 cells after 48 hrs by SRB assay
Cytotoxicity against human A498 cells after 48 hrs by SRB assay
|
[PMID: 23871905]
|
A498
|
GI50 |
0.1 μM
Compound: Doxorubicin
|
Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29102177]
|
A498
|
GI50 |
0.1 μM
Compound: Doxorubicin
|
Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28329730]
|
A498
|
ED50 |
1 x 10 -2 μg/mL
Compound: Adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 9214729]
|
A498
|
ED50 |
1 x 10 -2 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 8882434]
|
A498
|
ED50 |
1.1 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
10.1021/np970510f
|
A498
|
IC50 |
1.1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A498 cells after 48 hrs by SRB assay
Antiproliferative activity against human A498 cells after 48 hrs by SRB assay
|
[PMID: 30503942]
|
A498
|
ED50 |
1.13 x 10 -1 μg/mL
Compound: Adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 9322367]
|
A498
|
ED50 |
1.22 x 10 -2 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 9134750]
|
A498
|
ED50 |
1.58 x 10 -2 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 9584396]
|
A498
|
ED50 |
1.78 ng/mL
Compound: Adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 8946743]
|
A498
|
ED50 |
1.9 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 10395501]
|
A498
|
ED50 |
1.9 x 10 -2 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A-498 cells by MTT assay
Cytotoxicity against human A-498 cells by MTT assay
|
[PMID: 9917277]
|
A498
|
ED50 |
1.97 ng/mL
Compound: Adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 7494147]
|
A498
|
ED50 |
1.98 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 9599253]
|
A498
|
ED50 |
2.26 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 11325235]
|
A498
|
ED50 |
2.86 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A-498 cells after 7 days by MTT assay
Cytotoxicity against human A-498 cells after 7 days by MTT assay
|
[PMID: 15730242]
|
A498
|
ED50 |
3.2 ng/mL
Compound: Adriamycin
|
Cytotoxicity against human A498 cells by MTT assay
Cytotoxicity against human A498 cells by MTT assay
|
[PMID: 7714533]
|
A498
|
ED50 |
3.66 x 10 -4 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 8676130]
|
A498
|
ED50 |
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 9461654]
|
A498
|
IC50 |
4.9 ng/mL
Compound: Adriamycin
|
Cytotoxicity against human A498 cells by MTT assay
Cytotoxicity against human A498 cells by MTT assay
|
[PMID: 9644064]
|
A498
|
IC50 |
|
Antiproliferative activity against human A498 cells after 72 hrs by MTT assay
Antiproliferative activity against human A498 cells after 72 hrs by MTT assay
|
[PMID: 30429098]
|
A498
|
ED50 |
6.2 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 9599260]
|
A498
|
ED50 |
6.49 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A498 cells after 7 days by MTT assay
Cytotoxicity against human A498 cells after 7 days by MTT assay
|
[PMID: 8904848]
|
A549
|
GI50 |
< 0.01 μM
Compound: Doxorubicin
|
Growth inhibition of human A549 cells after 48 hrs by SRB assay
Growth inhibition of human A549 cells after 48 hrs by SRB assay
|
10.1039/C6MD00097E
|
A549
|
GI50 |
< 0.01 μM
Compound: Doxorubicin
|
Growth inhibition in human A549 cells after 48 hrs by SRB assay
Growth inhibition in human A549 cells after 48 hrs by SRB assay
|
[PMID: 31546197]
|
A549
|
GI50 |
< 0.01 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 26994690]
|
A549
|
GI50 |
< 0.01 μM
Compound: Doxorubicin
|
Growth inhibition of human A549 cells after 48 hrs by SRB assay
Growth inhibition of human A549 cells after 48 hrs by SRB assay
|
[PMID: 26067381]
|
A549
|
GI50 |
< 0.01 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 25827522]
|
A549
|
IC50 |
< 0.1 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 22330634]
|
A549
|
GI50 |
|
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21737288]
|
A549
|
IC50 |
< 1 μM
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by MTT assay
Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by MTT assay
|
10.1007/s00044-011-9884-x
|
A549
|
GI50 |
|
Antiproliferative activity against human A549 cells by MTT assay
Antiproliferative activity against human A549 cells by MTT assay
|
[PMID: 31990554]
|
A549
|
IC50 |
< 1 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 33847126]
|
A549
|
IC50 |
> 100 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 33340938]
|
A549
|
ED50 |
0.001 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19783438]
|
A549
|
ED50 |
0.001 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by sulforhodamine B method
Cytotoxicity against human A549 cells by sulforhodamine B method
|
[PMID: 12193011]
|
A549
|
IC50 |
0.001 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 22951040]
|
A549
|
IC50 |
0.0014 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by sulforhodamine B bioassay
Cytotoxicity against human A549 cells by sulforhodamine B bioassay
|
[PMID: 25098650]
|
A549
|
IC50 |
0.002 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
|
[PMID: 25981688]
|
A549
|
IC50 |
0.002 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 25466198]
|
A549
|
IC50 |
0.002 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 22483395]
|
A549
|
GI50 |
0.003 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells by SRB assay
Antiproliferative activity against human A549 cells by SRB assay
|
[PMID: 19394218]
|
A549
|
IC50 |
0.004 μM
Compound: Doxorubicin
|
Inhibitory activity against A549 cell line using MTT assay(Wild type p53)
Inhibitory activity against A549 cell line using MTT assay(Wild type p53)
|
[PMID: 10780913]
|
A549
|
ED50 |
0.0043 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 10514307]
|
A549
|
ED50 |
0.00622 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 11087592]
|
A549
|
GI50 |
0.007 μM
Compound: Adriamycin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 19405508]
|
A549
|
IC50 |
0.007 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 19435339]
|
A549
|
ED50 |
0.007 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 18314958]
|
A549
|
IC50 |
0.009 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 27010926]
|
A549
|
ED50 |
0.01 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 15921415]
|
A549
|
IC50 |
0.01 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by sulforhodamine B assay
Cytotoxicity against human A549 cells by sulforhodamine B assay
|
[PMID: 21684168]
|
A549
|
IC50 |
0.01 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 20719504]
|
A549
|
ED50 |
0.012 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by SRB method
Cytotoxicity against human A549 cells by SRB method
|
[PMID: 16252909]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27668963]
|
A549
|
GI50 |
0.016 μM
Compound: Doxorubicin
|
Cytostatic activity against human A549 cells after 5 days by SRB assay
Cytostatic activity against human A549 cells after 5 days by SRB assay
|
[PMID: 21711054]
|
A549
|
ED50 |
0.02 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 15730260]
|
A549
|
ED50 |
0.02 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 11325244]
|
A549
|
IC50 |
0.02 μg/mL
Compound: doxorubicin
|
Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time
Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time
|
[PMID: 8496904]
|
A549
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay
Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay
|
[PMID: 23634786]
|
A549
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by sulforhodamine B assay
Cytotoxicity against human A549 cells by sulforhodamine B assay
|
[PMID: 23815260]
|
A549
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
|
[PMID: 25937235]
|
A549
|
IC50 |
|
Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation
Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation
|
10.1016/S0960-894X(97)10122-6
|
A549
|
IC50 |
0.021 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
|
[PMID: 27856237]
|
A549
|
IC50 |
0.021 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 20594848]
|
A549
|
IC50 |
0.022 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 3 days by SRB assay
Cytotoxicity against human A549 cells after 3 days by SRB assay
|
[PMID: 18321715]
|
A549
|
IC50 |
0.025 μg/mL
Compound: ADR
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 18590312]
|
A549
|
IC50 |
0.025 μM
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 19028425]
|
A549
|
ED50 |
0.03 μg/mL
Compound: Adriamycin
|
Cytotoxicity against human A549 cells after 24 hrs by SRB assay
Cytotoxicity against human A549 cells after 24 hrs by SRB assay
|
[PMID: 20850305]
|
A549
|
IC50 |
0.03 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
|
[PMID: 25937235]
|
A549
|
IC50 |
0.031 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 24 hrs by SRB method
Cytotoxicity against human A549 cells after 24 hrs by SRB method
|
[PMID: 18429610]
|
A549
|
GI50 |
0.04 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 11000028]
|
A549
|
IC50 |
0.04 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 15921426]
|
A549
|
IC50 |
0.04 μg/mL
Compound: doxorubicin
|
Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay
Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 19342127]
|
A549
|
IC50 |
0.04 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay
Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay
|
[PMID: 25534608]
|
A549
|
IC50 |
0.04 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29275232]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
|
[PMID: 35255689]
|
A549
|
IC50 |
0.049 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 23544451]
|
A549
|
ED50 |
0.05 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
10.1021/np960188t
|
A549
|
IC50 |
0.05 μg/mL
Compound: doxorubicin
|
Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time
Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time
|
[PMID: 8496904]
|
A549
|
IC50 |
0.056 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
|
[PMID: 32755677]
|
A549
|
IC50 |
0.057 μg/mL
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay
|
[PMID: 32223924]
|
A549
|
GI50 |
0.06 μM
Compound: Doxorubicin hydrochloride, NSC 123127
|
Cytotoxicity against human A549/ATCC cells after 48 hrs by SRB assay
Cytotoxicity against human A549/ATCC cells after 48 hrs by SRB assay
|
[PMID: 23871905]
|
A549
|
GI50 |
0.06 μM
Compound: Doxorubicin
|
Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29102177]
|
A549
|
GI50 |
0.06 μM
Compound: Doxorubicin
|
Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28329730]
|
A549
|
GI50 |
0.062 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 20014800]
|
A549
|
GI50 |
0.07 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 24158013]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 31999451]
|
A549
|
IC50 |
0.075 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells by sulforhodamine B assay
Anticancer activity against human A549 cells by sulforhodamine B assay
|
[PMID: 19819696]
|
A549
|
IC50 |
0.08 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 19361894]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 30106296]
|
A549
|
IC50 |
0.09 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 27060757]
|
A549
|
IC50 |
0.09 μM
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay
Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay
|
10.1007/s00044-010-9517-9
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 34116381]
|
A549
|
IC50 |
0.092 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells incubated for 72 hrs by sulforhodamine B assay
|
[PMID: 32432867]
|
A549
|
ED50 |
0.1 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 3 days by MTT assay
Cytotoxicity against human A549 cells after 3 days by MTT assay
|
[PMID: 16252910]
|
A549
|
IC50 |
0.1 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay
Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay
|
[PMID: 17067159]
|
A549
|
IC50 |
0.1 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
|
[PMID: 28398051]
|
A549
|
IC50 |
0.1 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 24050254]
|
A549
|
IC50 |
0.1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 18063366]
|
A549
|
GI50 |
0.1 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 19007287]
|
A549
|
GI50 |
0.1 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 17512741]
|
A549
|
IC50 |
|
Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction)
Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction)
|
10.1016/S0960-894X(01)81264-6
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells measured after 72 hrs by Celltiter-Glo assay
Cytotoxicity against human A549 cells measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31820976]
|
A549
|
IC50 |
0.118 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells after 48 hrs by SRB assay
Anticancer activity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 17070967]
|
A549
|
ED50 |
0.12 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 9392887]
|
A549
|
IC50 |
0.12 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 27886545]
|
A549
|
IC50 |
0.12 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs
Cytotoxicity against human A549 cells after 48 hrs
|
[PMID: 17673337]
|
A549
|
IC50 |
0.124 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 25462279]
|
A549
|
IC50 |
0.124 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 28139925]
|
A549
|
IC50 |
0.13 μM
Compound: Doxorubicin
|
Cytotoxicity activity against human A549 cells incubated for 48 hrs by SRB assay
Cytotoxicity activity against human A549 cells incubated for 48 hrs by SRB assay
|
[PMID: 34119830]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 30106296]
|
A549
|
IC50 |
0.14 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 35694689]
|
A549
|
IC50 |
0.14 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 26280922]
|
A549
|
IC50 |
0.14 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 26873414]
|
A549
|
GI50 |
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 20673627]
|
A549
|
IC50 |
0.15 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 17194596]
|
A549
|
IC50 |
0.16 μM
Compound: Adriamycin
|
Cytotoxicity against human A549 cells after 24 hrs by SRB assay
Cytotoxicity against human A549 cells after 24 hrs by SRB assay
|
[PMID: 24370114]
|
A549
|
GI50 |
0.16 μM
Compound: Doxorubicin
|
Growth inhibition of human A549 cells after 72 hrs by SRB assay
Growth inhibition of human A549 cells after 72 hrs by SRB assay
|
[PMID: 18585035]
|
A549
|
IC50 |
0.16 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 20176479]
|
A549
|
IC50 |
0.17 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 6 days by MTT method
Cytotoxicity against human A549 cells after 6 days by MTT method
|
[PMID: 16309317]
|
A549
|
IC50 |
0.17 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 30902399]
|
A549
|
IC50 |
0.17 μM
Compound: Adriamycin
|
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 20593838]
|
A549
|
IC50 |
0.18 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by SRB microtiter plate assay
Cytotoxicity against human A549 cells by SRB microtiter plate assay
|
[PMID: 17585747]
|
A549
|
IC50 |
0.19 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 3 days by MTT assay
Cytotoxicity against human A549 cells after 3 days by MTT assay
|
[PMID: 15387653]
|
A549
|
IC50 |
0.19 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 24 hrs by XTT assay
Cytotoxicity against human A549 cells after 24 hrs by XTT assay
|
[PMID: 27227682]
|
A549
|
IC50 |
0.2 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 18973388]
|
A549
|
IC50 |
0.2 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT colorimetric method
Cytotoxicity against human A549 cells by MTT colorimetric method
|
[PMID: 17125220]
|
A549
|
IC50 |
0.2 μM
Compound: adriamycin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 17190442]
|
A549
|
GI50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 29112820]
|
A549
|
ED50 |
0.21 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 17315955]
|
A549
|
IC50 |
0.21 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 24 hrs by MTS assay
Cytotoxicity against human A549 cells after 24 hrs by MTS assay
|
[PMID: 30289713]
|
A549
|
IC50 |
0.22 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
|
[PMID: 24852278]
|
A549
|
IC50 |
0.22 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells by MTT reduction assay
Antiproliferative activity against human A549 cells by MTT reduction assay
|
[PMID: 33421712]
|
A549
|
IC50 |
0.223 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay
Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay
|
[PMID: 29409753]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay
|
[PMID: 27036521]
|
A549
|
IC50 |
0.24 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells incubated for 48 hrs by WST8 assay
Antiproliferative activity against human A549 cells incubated for 48 hrs by WST8 assay
|
[PMID: 31679979]
|
A549
|
IC50 |
0.258 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25019480]
|
A549
|
IC50 |
0.27 μg/mL
Compound: Doxorubicin
|
Cytotoxic activity against human A549 cells by MTT assay
Cytotoxic activity against human A549 cells by MTT assay
|
[PMID: 28366267]
|
A549
|
GI50 |
0.27 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 assessed as growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human A549 assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 21875046]
|
A549
|
IC50 |
|
Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method
Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method
|
[PMID: 25061803]
|
A549
|
IC50 |
0.29 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by XTT assay
Cytotoxicity against human A549 cells after 72 hrs by XTT assay
|
[PMID: 19647439]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
|
[PMID: 25737400]
|
A549
|
IC50 |
0.33 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 20732814]
|
A549
|
IC50 |
0.33 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 26496013]
|
A549
|
IC50 |
0.34 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30389295]
|
A549
|
IC50 |
0.34 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 21174408]
|
A549
|
IC50 |
0.35 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 3 days by MTT assay
Cytotoxicity against human A549 cells after 3 days by MTT assay
|
[PMID: 19691312]
|
A549
|
IC50 |
0.35 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
Anticancer activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
|
[PMID: 33940466]
|
A549
|
IC50 |
0.36 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells after 48 hrs by MTT assay
Anticancer activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 21641694]
|
A549
|
IC50 |
0.36 μM
Compound: Doxorubucin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 20718475]
|
A549
|
IC50 |
0.36 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT colorimetric method
Cytotoxicity against human A549 cells after 72 hrs by MTT colorimetric method
|
[PMID: 17622129]
|
A549
|
IC50 |
0.37 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 26397393]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
|
[PMID: 35612499]
|
A549
|
IC50 |
0.38 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) A549 cells assessed as survival after 3 days by crystal violet staining
Cytotoxicity against Homo sapiens (human) A549 cells assessed as survival after 3 days by crystal violet staining
|
10.1007/s00044-012-0025-y
|
A549
|
IC50 |
0.39 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) A549 cells after 3 days by MTT assay
Cytotoxicity against Homo sapiens (human) A549 cells after 3 days by MTT assay
|
10.1007/s00044-011-9903-y
|
A549
|
IC50 |
0.4 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 16724859]
|
A549
|
IC50 |
0.4 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by Alamar Blue assay
Cytotoxicity against human A549 cells by Alamar Blue assay
|
[PMID: 27536968]
|
A549
|
IC50 |
0.4 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
|
[PMID: 30869892]
|
A549
|
IC50 |
0.4 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 3 days by MTT assay
Cytotoxicity against human A549 cells after 3 days by MTT assay
|
[PMID: 18547115]
|
A549
|
IC50 |
0.4 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 4 days by MTT assay
Cytotoxicity against human A549 cells after 4 days by MTT assay
|
[PMID: 19824618]
|
A549
|
IC50 |
0.4 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 28927795]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 20334960]
|
A549
|
IC50 |
0.41 μM
Compound: Adriamycin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 23548547]
|
A549
|
IC50 |
0.411 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 24231309]
|
A549
|
IC50 |
0.414 μM
Compound: Adriamycin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 25497963]
|
A549
|
IC50 |
0.42 μg/mL
Compound: doxo
|
Cytotoxicity against human A549 cells by MTT method
Cytotoxicity against human A549 cells by MTT method
|
[PMID: 17417907]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35818137]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
|
[PMID: 29597166]
|
A549
|
IC50 |
0.44 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
10.1007/s00044-013-0777-z
|
A549
|
IC50 |
0.44 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25078311]
|
A549
|
IC50 |
0.44 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 24836071]
|
A549
|
IC50 |
0.45 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 26947606]
|
A549
|
IC50 |
0.459 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 2 days by MTT assay
Cytotoxicity against human A549 cells after 2 days by MTT assay
|
[PMID: 23932340]
|
A549
|
IC50 |
0.459 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 24287557]
|
A549
|
IC50 |
0.46 μM
Compound: Doxorubicin
|
In vitro cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay
In vitro cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay
|
[PMID: 24742385]
|
A549
|
IC50 |
0.47 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31704206]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 21983438]
|
A549
|
IC50 |
0.477 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells by MTT assay
Anticancer activity against human A549 cells by MTT assay
|
[PMID: 21570750]
|
A549
|
IC50 |
0.477 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
|
10.1039/C0MD00219D
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
|
[PMID: 31671309]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
|
[PMID: 30576904]
|
A549
|
IC50 |
0.48 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
|
[PMID: 30253344]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells after 24 hrs by SRB assay
Antiproliferative activity against human A549 cells after 24 hrs by SRB assay
|
[PMID: 30106296]
|
A549
|
IC50 |
0.5 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 35526504]
|
A549
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
|
[PMID: 31148449]
|
A549
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27015002]
|
A549
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay
Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay
|
[PMID: 23664877]
|
A549
|
IC50 |
0.51 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 21708464]
|
A549
|
IC50 |
0.51 μM
Compound: Adriamycin
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26356746]
|
A549
|
IC50 |
0.52 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 18590313]
|
A549
|
IC50 |
0.52 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21071221]
|
A549
|
IC50 |
0.53 μM
Compound: Doxorubicin
|
Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 28923382]
|
A549
|
IC50 |
0.54 μg/mL
Compound: Doxorubicin
|
Anticancer activity against human A549 cells by MTT assay
Anticancer activity against human A549 cells by MTT assay
|
[PMID: 31404864]
|
A549
|
IC50 |
0.54 μM
Compound: Adriamycin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 23434227]
|
A549
|
IC50 |
0.55 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay
Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay
|
[PMID: 28159416]
|
A549
|
IC50 |
0.55 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by Alamar blue assay
Cytotoxicity against human A549 cells by Alamar blue assay
|
[PMID: 27256910]
|
A549
|
IC50 |
0.55 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 30654238]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30615450]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 23639650]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 31820976]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells after 3 days by MTT assay
Cytotoxicity against human A549 cells after 3 days by MTT assay
|
[PMID: 21800859]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 33276990]
|
A549
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
|
[PMID: 36693198]
|
A549
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29702447]
|
A549
|
GI50 |
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 34634616]
|
A549
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 29975532]
|
A549
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 25172418]
|
A549
|
IC50 |
0.63 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 21106454]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay
|
[PMID: 29614418]
|
A549
|
IC50 |
|
Cytotoxicity activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30031974]
|
A549
|
IC50 |
0.63 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 31884407]
|
A549
|
GI50 |
0.66 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 21885166]
|
A549
|
IC50 |
0.665 μg/mL
Compound: E; DOX
|
Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
|
[PMID: 35963130]
|
A549
|
IC50 |
0.69 μM
Compound: adriamycin
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 26295905]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
|
[PMID: 25089733]
|
A549
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
|
[PMID: 32324401]
|
A549
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) A549 cells assessed as inhibition of cell growth after 3 days by MTT assay
Cytotoxicity against Homo sapiens (human) A549 cells assessed as inhibition of cell growth after 3 days by MTT assay
|
10.1007/s00044-012-0402-6
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 28865276]
|
A549
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) A549 cells by MTT assay
Cytotoxicity against Homo sapiens (human) A549 cells by MTT assay
|
10.1007/s00044-012-0370-x
|
A549
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 24300737]
|
A549
|
IC50 |
0.7 μM
Compound: Doxorubicine
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 22014995]
|
A549
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
Cytotoxicity against human A549 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
|
[PMID: 36970146]
|
A549
|
IC50 |
0.72 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 19406535]
|
A549
|
IC50 |
0.72 μM
Compound: Adriamycin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 22070654]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
|
10.1039/C2MD20302B
|
A549
|
IC50 |
0.73 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23992864]
|
A549
|
IC50 |
0.74 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 46 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 46 hrs by MTT assay
|
[PMID: 29138027]
|
A549
|
IC50 |
0.74 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 23806110]
|
A549
|
IC50 |
0.75 μM
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 48 hrs
Cytotoxicity against human A549 cells after 48 hrs
|
[PMID: 17583953]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
|
[PMID: 27397495]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 30599418]
|
A549
|
IC50 |
0.79 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 3 days by MTT assay
Cytotoxicity against human A549 cells after 3 days by MTT assay
|
[PMID: 16252914]
|
A549
|
IC50 |
0.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 26252628]
|
A549
|
IC50 |
0.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 24780595]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 24507927]
|
A549
|
IC50 |
0.8 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 30679134]
|
A549
|
IC50 |
0.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 26551342]
|
A549
|
IC50 |
0.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 21035234]
|
A549
|
IC50 |
0.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 26774921]
|
A549
|
IC50 |
0.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 26646219]
|
A549
|
IC50 |
0.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 25241926]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells by SRB method
Cytotoxicity against human A549 cells by SRB method
|
[PMID: 29144133]
|
A549
|
IC50 |
|
Cytotoxic activity against human A549 cells by SRB method
Cytotoxic activity against human A549 cells by SRB method
|
[PMID: 25611519]
|
A549
|
IC50 |
0.82 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 31404864]
|
A549
|
IC50 |
0.837 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 19860383]
|
A549
|
IC50 |
0.84 μM
Compound: Doxorubicin
|
Antitumor activity against Homo sapiens (human) A549 cells assessed as cell growth inhibition after 48 hr by MTT assay
Antitumor activity against Homo sapiens (human) A549 cells assessed as cell growth inhibition after 48 hr by MTT assay
|
10.1007/s00044-013-0497-4
|
A549
|
IC50 |
0.84 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 19689125]
|
A549
|
IC50 |
0.86 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 3 days by MTT assay
Cytotoxicity against human A549 cells after 3 days by MTT assay
|
[PMID: 18419154]
|
A549
|
IC50 |
0.86 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by WST-8 assay
Cytotoxicity against human A549 cells by WST-8 assay
|
[PMID: 29295796]
|
A549
|
IC50 |
0.87 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 25419616]
|
A549
|
IC50 |
0.89 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 4 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 4 hrs by MTT assay
|
[PMID: 30773423]
|
A549
|
IC50 |
0.89 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 28554092]
|
A549
|
IC50 |
0.9 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
10.1039/C3MD00166K
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 34323485]
|
A549
|
EC50 |
0.9 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs
Cytotoxicity against human A549 cells after 72 hrs
|
[PMID: 17378530]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 35339100]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by alamar blue assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by alamar blue assay
|
[PMID: 21797280]
|
A549
|
IC50 |
0.95 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by Alamar blue assay
Cytotoxicity against human A549 cells after 48 hrs by Alamar blue assay
|
[PMID: 20931970]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay
Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay
|
[PMID: 31784322]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 27016707]
|
A549
|
IC50 |
0.96 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
|
[PMID: 32438251]
|
A549
|
GI50 |
|
Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 35533562]
|
A549
|
IC50 |
0.97 μM
Compound: Doxorubicin
|
Cytotoxicity activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32531682]
|
A549
|
IC50 |
0.97 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 17827007]
|
A549
|
IC50 |
0.97 μM
Compound: Doxorubicin
|
Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.
Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.
|
[PMID: 14643344]
|
A549
|
IC50 |
0.98 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 25747499]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 22044164]
|
A549
|
IC50 |
1 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 32915576]
|
A549
|
IC50 |
1 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 23079527]
|
A549
|
IC50 |
1 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 21996519]
|
A549
|
IC50 |
1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay
Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay
|
[PMID: 27555286]
|
A549
|
ED50 |
1.01 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 8676130]
|
A549
|
ED50 |
1.01 x 10 -2 μg/mL
Compound: Adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 7673926]
|
A549
|
IC50 |
1.01 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
Anticancer activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 34363936]
|
A549
|
IC50 |
|
Anticancer activity against human A549 cells after 48 hrs by MTT assay
Anticancer activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 22209733]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 35341920]
|
A549
|
IC50 |
1.06 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
|
[PMID: 31962262]
|
A549
|
IC50 |
1.06 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26708114]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 31057738]
|
A549
|
ED50 |
1.1 ng/mL
Compound: Adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 7714532]
|
A549
|
ED50 |
1.1 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days
Cytotoxicity against human A549 cells after 7 days
|
[PMID: 8021648]
|
A549
|
IC50 |
1.1 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells by MTT assay
Anticancer activity against human A549 cells by MTT assay
|
10.1039/C4MD00219A
|
A549
|
GI50 |
|
Antiproliferative activity against human A549 cells incubated for 72 hrs and measured by MTT assay
Antiproliferative activity against human A549 cells incubated for 72 hrs and measured by MTT assay
|
[PMID: 35973342]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells after 48 hrs by SRB method
Cytotoxicity against human A549 cells after 48 hrs by SRB method
|
[PMID: 25933593]
|
A549
|
ED50 |
1.13 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 11325235]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35803175]
|
A549
|
IC50 |
1.18 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 22472043]
|
A549
|
IC50 |
1.2 μg/mL
Compound: Adriamycin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 17918910]
|
A549
|
IC50 |
1.2 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells measured after 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay
Antiproliferative activity against human A549 cells measured after 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay
|
[PMID: 32682198]
|
A549
|
IC50 |
1.2 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by SRB protein staining method
Cytotoxicity against human A549 cells by SRB protein staining method
|
[PMID: 25781655]
|
A549
|
GI50 |
1.21 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 31128433]
|
A549
|
IC50 |
1.21 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
|
[PMID: 31108261]
|
A549
|
IC50 |
1.21 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 25172420]
|
A549
|
IC50 |
1.21 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 24113366]
|
A549
|
IC50 |
1.21 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 23911578]
|
A549
|
IC50 |
1.21 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 23764302]
|
A549
|
IC50 |
1.28 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25703298]
|
A549
|
ED50 |
1.3 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 10395501]
|
A549
|
IC50 |
1.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 24 hrs by WST assay
Cytotoxicity against human A549 cells after 24 hrs by WST assay
|
[PMID: 25881821]
|
A549
|
IC50 |
1.303 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 29501940]
|
A549
|
IC50 |
1.32 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
|
[PMID: 32682198]
|
A549
|
IC50 |
1.4 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 22413887]
|
A549
|
IC50 |
1.4 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 29035560]
|
A549
|
IC50 |
1.43 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 31546197]
|
A549
|
IC50 |
1.445 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28462842]
|
A549
|
ED50 |
1.48 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days
Cytotoxicity against human A549 cells after 7 days
|
[PMID: 8201311]
|
A549
|
ED50 |
1.48 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days
Cytotoxicity against human A549 cells after 7 days
|
[PMID: 1593281]
|
A549
|
IC50 |
1.495 μM
Compound: Doxorubicin
|
Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783]
|
A549
|
IC50 |
1.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay
|
[PMID: 33421712]
|
A549
|
IC50 |
1.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 25453799]
|
A549
|
IC50 |
1.58 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 26330077]
|
A549
|
IC50 |
1.58 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 26264845]
|
A549
|
IC50 |
1.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
|
[PMID: 28818768]
|
A549
|
IC50 |
1.65 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 24418772]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 29289881]
|
A549
|
ED50 |
1.7 x 10 -2 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 9917277]
|
A549
|
IC50 |
1.7 μM
Compound: Doxorubicin
|
Growth inhibition of human A549 cells by MTT assay
Growth inhibition of human A549 cells by MTT assay
|
[PMID: 28916158]
|
A549
|
IC50 |
1.778 μM
Compound: Doxorubicin
|
Anti-proliferative activity against human A549 cells measured after 48 hrs by MTT assay
Anti-proliferative activity against human A549 cells measured after 48 hrs by MTT assay
|
[PMID: 27744185]
|
A549
|
ED50 |
1.78 ng/mL
Compound: Adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 8946743]
|
A549
|
IC50 |
1.78 μM
Compound: Doxorubicin
|
Cytotoxic activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxic activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 25966052]
|
A549
|
IC50 |
1.79 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 35339645]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 29129513]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
10.1007/s00044-013-0584-6
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32631552]
|
A549
|
IC50 |
1.9 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells after 48 hrs by MTT assay
Anticancer activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25615796]
|
A549
|
IC50 |
1.9 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 19632833]
|
A549
|
IC50 |
1.9 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 24012378]
|
A549
|
IC50 |
1.9 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 19394829]
|
A549
|
GI50 |
1.9 μM
Compound: Doxorubicin
|
Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay
Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay
|
[PMID: 26163220]
|
A549
|
ED50 |
1.91 x 10 -2 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 9599260]
|
A549
|
IC50 |
1.945 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28482219]
|
A549
|
IC50 |
1.986 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 26301558]
|
A549
|
IC50 |
1.99 μM
Compound: Doxorubicin
|
Cytotoxicity against human lung carcinoma A549 cell line using MTT assay
Cytotoxicity against human lung carcinoma A549 cell line using MTT assay
|
[PMID: 9873387]
|
A549
|
IC50 |
10.2 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 28886509]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 35635947]
|
A549
|
CC50 |
10.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 29792325]
|
A549
|
IC50 |
10.55 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
10.1039/C3MD00013C
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability measured after 24 hrs by MTT assay
|
[PMID: 33183865]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 36463726]
|
A549
|
IC50 |
11 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 28919340]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
|
[PMID: 28129977]
|
A549
|
GI50 |
|
Anticancer activity against human A549 cells by SRB method
Anticancer activity against human A549 cells by SRB method
|
[PMID: 22104151]
|
A549
|
IC50 |
13.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 24681979]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells after 48 hrs by alamar blue assay
Cytotoxicity against human A549 cells after 48 hrs by alamar blue assay
|
[PMID: 25468043]
|
A549
|
IC50 |
14.7 nM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
|
[PMID: 31655432]
|
A549
|
IC50 |
140 nM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
|
[PMID: 35213166]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
|
[PMID: 34592435]
|
A549
|
IC50 |
15.07 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
10.1039/C2MD20023F
|
A549
|
IC50 |
15.07 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 22386528]
|
A549
|
ED50 |
152 μM
Compound: doxorubicin
|
Antitumor activity against human A549 cells after 24 hrs by MTT assay
Antitumor activity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 17482824]
|
A549
|
IC50 |
17 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 34838335]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
|
[PMID: 33611191]
|
A549
|
IC50 |
18.56 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28262524]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as inhibition of proliferation after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as inhibition of proliferation after 72 hrs by SRB assay
|
[PMID: 34116158]
|
A549
|
ED50 |
2 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 8882437]
|
A549
|
IC50 |
|
Cytotoxicity against against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30340899]
|
A549
|
IC50 |
2.1 μM
Compound: Doxo (I)
|
Antiproliferative activity against human A549 cells by MTT assay
Antiproliferative activity against human A549 cells by MTT assay
|
10.1039/C4MD00228H
|
A549
|
IC50 |
2.1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
|
[PMID: 34838335]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 31765156]
|
A549
|
IC50 |
2.12 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 26874744]
|
A549
|
IC50 |
2.12 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25462233]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 27149641]
|
A549
|
IC50 |
2.18 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells after 48 hrs by MTT assay
Anticancer activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 22136907]
|
A549
|
IC50 |
2.2 ng/mL
Compound: Adriamycin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 9644064]
|
A549
|
IC50 |
2.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 21425785]
|
A549
|
IC50 |
2.2 μM
Compound: adriamycin
|
Cytotoxicity against human A549 cells by rapid colorimetric assay
Cytotoxicity against human A549 cells by rapid colorimetric assay
|
[PMID: 19585998]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells by MTT assay
Antiproliferative activity against human A549 cells by MTT assay
|
[PMID: 20171108]
|
A549
|
IC50 |
|
Inhibition of topoisomerase 2 in human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Inhibition of topoisomerase 2 in human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 30846253]
|
A549
|
IC50 |
2.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29789258]
|
A549
|
IC50 |
2.31 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 33352388]
|
A549
|
IC50 |
2.34 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 26948541]
|
A549
|
ED50 |
2.43 x 10 -2 μg/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 8904848]
|
A549
|
IC50 |
2.48 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
|
10.1039/C5MD00581G
|
A549
|
IC50 |
2.58 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31883489]
|
A549
|
IC50 |
2.6 x 10 -1 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by XTT assay
Cytotoxicity against human A549 cells after 72 hrs by XTT assay
|
[PMID: 20619940]
|
A549
|
IC50 |
2.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 25300819]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs
|
[PMID: 32736079]
|
A549
|
IC50 |
2.7 μM
Compound: Adriamycin
|
Cytotoxicity against human A549 cells by MTT colorimetric method
Cytotoxicity against human A549 cells by MTT colorimetric method
|
[PMID: 23043498]
|
A549
|
IC50 |
2.8 μM
Compound: Adriamycin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 22647719]
|
A549
|
IC50 |
2.8 μM
Compound: Adriamycin
|
Growth inhibition of human A549 cells by MTT assay
Growth inhibition of human A549 cells by MTT assay
|
[PMID: 21721519]
|
A549
|
IC50 |
2.81 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 27015609]
|
A549
|
IC50 |
|
Growth inhibition of human A549 cells after 48 hrs by MTT assay
Growth inhibition of human A549 cells after 48 hrs by MTT assay
|
[PMID: 29509413]
|
A549
|
ED50 |
2.94 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 9584396]
|
A549
|
ED50 |
2.94 ng/mL
Compound: Adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 7673936]
|
A549
|
IC50 |
22 nM
Compound: doxorubicin
|
Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.
Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.
|
[PMID: 10956214]
|
A549
|
IC50 |
228.2 nM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29886322]
|
A549
|
IC50 |
|
Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay
Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay
|
10.1007/s00044-012-0018-x
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
|
[PMID: 31653441]
|
A549
|
IC50 |
258 nM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay
|
[PMID: 33465696]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 25912674]
|
A549
|
IC50 |
3 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability by DAPI staining based assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability by DAPI staining based assay
|
[PMID: 33461146]
|
A549
|
IC50 |
3.03 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25594739]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32996316]
|
A549
|
ED50 |
3.1 x 10 -4 μg/mL
Compound: Adriamycin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 7714533]
|
A549
|
IC50 |
3.118 μg/mL
Compound: ADM
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 25862199]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells after 72 hrs by cell titer glo assay
Antiproliferative activity against human A549 cells after 72 hrs by cell titer glo assay
|
[PMID: 24161704]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25563891]
|
A549
|
IC50 |
|
Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 27149641]
|
A549
|
IC50 |
3.16 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 30500683]
|
A549
|
IC50 |
3.19 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 33148490]
|
A549
|
IC50 |
3.2 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
10.1039/C4MD00566J
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay
|
[PMID: 32631524]
|
A549
|
IC50 |
3.28 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 22542958]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
|
[PMID: 27055942]
|
A549
|
IC50 |
3.3 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells by MTT assay
Antiproliferative activity against human A549 cells by MTT assay
|
[PMID: 31546197]
|
A549
|
IC50 |
|
Antineoplastic activity against human A549 cells measured after 36 hrs by MTT assay
Antineoplastic activity against human A549 cells measured after 36 hrs by MTT assay
|
[PMID: 30746067]
|
A549
|
IC50 |
3.4 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25453802]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 30398868]
|
A549
|
ED50 |
3.41 ng/mL
Compound: Adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 7494147]
|
A549
|
IC50 |
3.41 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by CCK8 assay
Cytotoxicity against human A549 cells by CCK8 assay
|
[PMID: 29452840]
|
A549
|
ED50 |
3.56 ng/mL
Compound: Adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 7673935]
|
A549
|
ED50 |
3.56 ng/mL
Compound: Adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 7494150]
|
A549
|
IC50 |
3.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 94 hrs by MTT assay
Cytotoxicity against human A549 cells after 94 hrs by MTT assay
|
[PMID: 21868138]
|
A549
|
ED50 |
3.67 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 9599253]
|
A549
|
IC50 |
3.69 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 22472043]
|
A549
|
ED50 |
3.93 ng/mL
Compound: Adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 9322367]
|
A549
|
IC50 |
3.97 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 31404864]
|
A549
|
IC50 |
3.98 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
10.1007/s00044-013-0784-0
|
A549
|
IC50 |
4 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 23792352]
|
A549
|
IC50 |
4 μM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 23748152]
|
A549
|
IC50 |
4.11 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 24095746]
|
A549
|
IC50 |
4.36 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 30503942]
|
A549
|
ED50 |
4.47 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
10.1021/np970510f
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 6 days by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 6 days by MTT assay
|
[PMID: 32653698]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
|
[PMID: 30746062]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 28427016]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 28135634]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 27231128]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 26720155]
|
A549
|
ED50 |
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 9461654]
|
A549
|
ED50 |
4.99 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 9014350]
|
A549
|
IC50 |
426 nM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by XTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by XTT assay
|
[PMID: 29190084]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 30878835]
|
A549
|
IC50 |
5 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells by MTT assay
Antiproliferative activity against human A549 cells by MTT assay
|
[PMID: 29072457]
|
A549
|
ED50 |
5.04 x 10 -4 μg/mL
Compound: Adriamycin
|
Cytotoxicity against human A549 cells after 7 days
Cytotoxicity against human A549 cells after 7 days
|
[PMID: 1453182]
|
A549
|
ED50 |
5.06 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 8882434]
|
A549
|
IC50 |
5.1 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 27894044]
|
A549
|
IC50 |
5.13 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 35367708]
|
A549
|
ED50 |
5.3 ng/mL
Compound: Adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 9214729]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 31589431]
|
A549
|
IC50 |
5.32 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
|
[PMID: 27476117]
|
A549
|
IC50 |
5.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay
|
[PMID: 34223162]
|
A549
|
IC50 |
5.58 nM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as cell viability after 5 days by cell viability analyzer
Cytotoxicity against human A549 cells assessed as cell viability after 5 days by cell viability analyzer
|
[PMID: 26291039]
|
A549
|
IC50 |
5.93 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
|
[PMID: 32311607]
|
A549
|
ED50 |
59.5 nM
Compound: doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 17655260]
|
A549
|
IC50 |
6.13 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as cell viability by SRB assay
Cytotoxicity against human A549 cells assessed as cell viability by SRB assay
|
[PMID: 26022842]
|
A549
|
ED50 |
6.22 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 days by MTT assay
Cytotoxicity against human A549 cells after 7 days by MTT assay
|
[PMID: 15730242]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells measured after 24 hrs by MTT assay
Cytotoxicity against human A549 cells measured after 24 hrs by MTT assay
|
[PMID: 31104996]
|
A549
|
IC50 |
6.61 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 22182926]
|
A549
|
IC50 |
69.33 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells by MTT assay
Anticancer activity against human A549 cells by MTT assay
|
[PMID: 25743216]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
|
10.1039/C5MD00513B
|
A549
|
GI50 |
7.25 μM
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 24 hrs by SRB method
Cytotoxicity against human A549 cells after 24 hrs by SRB method
|
[PMID: 18262426]
|
A549
|
GI50 |
|
Growth inhibition of human A549 cells after 48 hrs by SRB assay
Growth inhibition of human A549 cells after 48 hrs by SRB assay
|
[PMID: 20031423]
|
A549
|
GI50 |
|
Growth inhibition of human A549 cells by SRB assay
Growth inhibition of human A549 cells by SRB assay
|
[PMID: 22361684]
|
A549
|
GI50 |
|
Anticancer activity against human A549 cells by SRB method
Anticancer activity against human A549 cells by SRB method
|
[PMID: 21676506]
|
A549
|
GI50 |
7.25 μM
Compound: ADR, Adriamycin
|
Growth inhibition of human A549 cells by SRB method
Growth inhibition of human A549 cells by SRB method
|
[PMID: 18207392]
|
A549
|
GI50 |
|
Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 23849207]
|
A549
|
GI50 |
|
Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22364746]
|
A549
|
GI50 |
|
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 18657979]
|
A549
|
GI50 |
|
Cytotoxicity against human A549 cells after 24 hrs by WST-1 assay
Cytotoxicity against human A549 cells after 24 hrs by WST-1 assay
|
[PMID: 20732817]
|
A549
|
IC50 |
7.47 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 24607876]
|
A549
|
IC50 |
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 26494582]
|
A549
|
IC50 |
7.86 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 30108986]
|
A549
|
IC50 |
7.88 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 18440233]
|
A549
|
IC50 |
740 nM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 30172625]
|
A549
|
IC50 |
8.05 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 25140752]
|
A549
|
GI50 |
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 26513642]
|
A549
|
IC50 |
8.5 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells incubated for 48 hrs by SRB assay
Cytotoxicity against human A549 cells incubated for 48 hrs by SRB assay
|
[PMID: 26048808]
|
A549
|
IC50 |
8.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 33766771]
|
A549
|
IC50 |
8.73 μM
Compound: Doxorubicin
|
Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36439979]
|
A549
|
ED50 |
9.2 ng/mL
Compound: adriamycin
|
Cytotoxicity against human A549 cells after 7 hrs by MTT assay
Cytotoxicity against human A549 cells after 7 hrs by MTT assay
|
[PMID: 7623031]
|
A549
|
IC50 |
9.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 20846862]
|
A549
|
IC50 |
9.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 35526504]
|
A549
|
IC50 |
9.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25655719]
|
A549
|
IC50 |
90 μM
Compound: Doxorubicin
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
|
[PMID: 33016067]
|
A549/CDDP
|
IC50 |
|
Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay
Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay
|
[PMID: 29509413]
|
A673
|
IC50 |
|
Cytotoxicity against human A673 cells measured after 72 hrs by Celltiter-Glo assay
Cytotoxicity against human A673 cells measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31820976]
|
A673
|
IC50 |
0.17 μM
Compound: Doxorubicin
|
Cytotoxicity against human A673 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
Cytotoxicity against human A673 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
|
[PMID: 23600925]
|
A673
|
EC50 |
0.39 μM
Compound: Doxorubicin
|
Induction of apoptosis in human A673 cells assessed as caspase-3 activation after 24 hrs by luminescence assay
Induction of apoptosis in human A673 cells assessed as caspase-3 activation after 24 hrs by luminescence assay
|
[PMID: 23600925]
|
A704
|
IC50 |
2 μM
Compound: Doxorubicin
|
Cytotoxicity against human A704 cells after 72 hrs by MTT assay
Cytotoxicity against human A704 cells after 72 hrs by MTT assay
|
[PMID: 19406535]
|
ACHN
|
IC50 |
|
Antiproliferative activity against human ACHN cell line by MTT assay
Antiproliferative activity against human ACHN cell line by MTT assay
|
[PMID: 16913700]
|
ACHN
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Antiproliferative activity against human ACHN cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human ACHN cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 34851111]
|
ACHN
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human ACHN cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
Cytotoxicity against human ACHN cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
|
[PMID: 28617598]
|
ACHN
|
IC50 |
|
Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay
Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay
|
[PMID: 31869654]
|
ACHN
|
IC50 |
0.04 μM
Compound: Doxorubicin
|
Antiproliferative activity against human ACHN cells after 96 hrs by MTT assay
Antiproliferative activity against human ACHN cells after 96 hrs by MTT assay
|
[PMID: 19053767]
|
ACHN
|
GI50 |
0.08 μM
Compound: Doxorubicin hydrochloride, NSC 123127
|
Cytotoxicity against human ACHN cells after 48 hrs by SRB assay
Cytotoxicity against human ACHN cells after 48 hrs by SRB assay
|
[PMID: 23871905]
|
ACHN
|
GI50 |
|
Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by SRB assay
Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by SRB assay
|
[PMID: 30253887]
|
ACHN
|
GI50 |
|
Cytotoxicity against human ACHN cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Cytotoxicity against human ACHN cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 28870801]
|
ACHN
|
GI50 |
0.08 μM
Compound: Doxorubicin
|
Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29102177]
|
ACHN
|
GI50 |
0.08 μM
Compound: Doxorubicin
|
Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28329730]
|
ACHN
|
GI50 |
|
Anticancer activity against human ACNH cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
Anticancer activity against human ACNH cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
|
[PMID: 34500188]
|
ACHN
|
GI50 |
|
Cytotoxicity against human ACHN cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human ACHN cells after 72 hrs by sulforhodamine B assay
|
[PMID: 27096046]
|
ACHN
|
GI50 |
|
Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 25953156]
|
ACHN
|
GI50 |
0.22 μM
Compound: Doxorubicin
|
Anticancer activity against human ACHN cells by SRB assay
Anticancer activity against human ACHN cells by SRB assay
|
[PMID: 20732810]
|
ACHN
|
GI50 |
0.41 μM
Compound: Doxorubicin
|
Cytotoxicity against human ACHN cells by SRB assay
Cytotoxicity against human ACHN cells by SRB assay
|
[PMID: 19596579]
|
ACHN
|
IC50 |
0.79 μM
Compound: Doxorubicin
|
Anticancer activity against human ACHN cells after 48 hrs by MTT assay
Anticancer activity against human ACHN cells after 48 hrs by MTT assay
|
[PMID: 22136907]
|
ACHN
|
GI50 |
|
Antiproliferative activity against human ACHN cells by SRB method
Antiproliferative activity against human ACHN cells by SRB method
|
[PMID: 24835787]
|
ACHN
|
GI50 |
|
Antiproliferative activity against human ACHN cells by SRB assay
Antiproliferative activity against human ACHN cells by SRB assay
|
[PMID: 22738641]
|
ACHN
|
IC50 |
14.2 μM
Compound: doxorubicin
|
Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay
Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay
|
[PMID: 16562840]
|
ACHN
|
GI50 |
2 μM
Compound: Doxorubicin
|
Cytotoxicity against human ACHN cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human ACHN cells after 48 hrs by sulforhodamine B assay
|
[PMID: 23964644]
|
ACHN
|
IC50 |
2.08 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human ACHN cells by MTT assay
Cytotoxicity against human ACHN cells by MTT assay
|
10.1039/C4MD00566J
|
ADR5000 cell line
|
IC50 |
|
Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 24484281]
|
ADR5000 cell line
|
IC50 |
> 10 μM
Compound: Doxorubicin
|
Cytotoxicity against human CEM/ADR5000 cells after 48 hrs by MTT assay
Cytotoxicity against human CEM/ADR5000 cells after 48 hrs by MTT assay
|
[PMID: 32496057]
|
ADR5000 cell line
|
IC50 |
> 5.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human CEM/ADR5000 by CCK-8 assay
Cytotoxicity against human CEM/ADR5000 by CCK-8 assay
|
[PMID: 22884578]
|
ADR5000 cell line
|
IC50 |
> 5.2 μM
Compound: doxorubicin
|
Cytotoxicity against human CEM/ADR5000 by XTT assay
Cytotoxicity against human CEM/ADR5000 by XTT assay
|
[PMID: 20527917]
|
ADR5000 cell line
|
IC50 |
0.009 μM
Compound: Doxorubicin
|
Antiproliferative activity against human CEM/ADR5000 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human CEM/ADR5000 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 27010926]
|
ADR5000 cell line
|
IC50 |
1.61 μM
Compound: Doxorubicin
|
Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay
Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay
|
[PMID: 26260339]
|
ADR5000 cell line
|
IC50 |
1.61 μM
Compound: Doxorubicin
|
Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay
Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay
|
[PMID: 28456567]
|
ADR5000 cell line
|
IC50 |
122.96 μM
Compound: Doxorubicin
|
Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by RRA assay
Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by RRA assay
|
[PMID: 33508467]
|
ADR5000 cell line
|
IC50 |
23.27 μM
Compound: Doxorubicin
|
Cytotoxicity against human multidrug-resistant CEM/ADR5000 cells expressing p-glycoprotein by resazurin assay
Cytotoxicity against human multidrug-resistant CEM/ADR5000 cells expressing p-glycoprotein by resazurin assay
|
[PMID: 24561670]
|
ADR5000 cell line
|
EC50 |
23.27 μM
Compound: Doxorubicin
|
Cytotoxicity against human CEM/ADR5000 cells overexpressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
Cytotoxicity against human CEM/ADR5000 cells overexpressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
|
[PMID: 29937978]
|
ADR5000 cell line
|
IC50 |
30.07 μM
Compound: Doxorubicin
|
Growth inhibition of human multi-drug resistant CEM/ADR5000 cells by resazurin assay
Growth inhibition of human multi-drug resistant CEM/ADR5000 cells by resazurin assay
|
[PMID: 28121440]
|
ADR5000 cell line
|
IC50 |
30.07 μM
Compound: Doxorubicin
|
Antileukemic activity against human CEM/ADR5000 cells after 24 to 48 hrs by resazurin dye based fluorescence assay
Antileukemic activity against human CEM/ADR5000 cells after 24 to 48 hrs by resazurin dye based fluorescence assay
|
[PMID: 29560715]
|
ADR5000 cell line
|
IC50 |
30.07 μM
Compound: Doxorubicin
|
Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay
Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay
|
[PMID: 32663024]
|
ADR5000 cell line
|
EC50 |
41.54 μM
Compound: Doxorubicin
|
Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
|
[PMID: 29887512]
|
AGS
|
GI50 |
0.01 μM
Compound: Doxorubicin
|
Antiproliferative activity against human AGS assessed as growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human AGS assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 21875046]
|
AGS
|
GI50 |
0.02 μM
Compound: Doxorubicin
|
Growth inhibition of Homo sapiens (human) AGS cells after 48 hr by MTT assay
Growth inhibition of Homo sapiens (human) AGS cells after 48 hr by MTT assay
|
10.1007/s00044-012-0232-6
|
AGS
|
IC50 |
0.31 μM
Compound: adriamycin
|
Cytotoxicity against human AGS cells by MTT assay
Cytotoxicity against human AGS cells by MTT assay
|
[PMID: 17125240]
|
AGS
|
IC50 |
1.2 μM
Compound: doxorubicin
|
Cytotoxicity against human AGS cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human AGS cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 23806110]
|
AGS
|
IC50 |
|
Cytotoxicity against human AGS cells after 48 hrs by MTT assay
Cytotoxicity against human AGS cells after 48 hrs by MTT assay
|
10.1039/C2MD20270K
|
ARPE-19
|
IC50 |
0.76 μM
Compound: Doxorubicin
|
Cytotoxicity against human ARPE19 cells after 48 hrs by Alamar blue assay
Cytotoxicity against human ARPE19 cells after 48 hrs by Alamar blue assay
|
[PMID: 20931970]
|
ASPC1
|
IC50 |
< 1 μM
Compound: Doxorubicin
|
Cytotoxicity against human ASPC1 cells assessed as reduction in cell growth by MTT assay
Cytotoxicity against human ASPC1 cells assessed as reduction in cell growth by MTT assay
|
[PMID: 36734533]
|
ASPC1
|
IC50 |
< 1 μM
Compound: Doxorubicin
|
Cytotoxicity against human ASPC1 cells by SRB assay
Cytotoxicity against human ASPC1 cells by SRB assay
|
[PMID: 33371684]
|
ASPC1
|
IC50 |
0.86 μM
Compound: Doxorubicin
|
Cytotoxicity against human AsPC1 cells deficit of P53 gene incubated for 72 hrs by MTS assay
Cytotoxicity against human AsPC1 cells deficit of P53 gene incubated for 72 hrs by MTS assay
|
[PMID: 31158748]
|
ASPC1
|
IC50 |
1.87 μM
Compound: Adriamycin
|
Cytotoxicity against human AsPC1 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
Cytotoxicity against human AsPC1 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
|
[PMID: 24717154]
|
AT3B-1
|
IC50 |
167.5 μM
Compound: 1, Dox
|
Tumor killing activity in AT3B1 drug-resistant cell line by MTT assay
Tumor killing activity in AT3B1 drug-resistant cell line by MTT assay
|
[PMID: 16168650]
|
B16
|
IC50 |
< 0.001 μg/mL
Compound: 1 (doxorubicin)
|
In vitro cytotoxic concentration against mouse melanoma cell line (B16) using MTT coloration
In vitro cytotoxic concentration against mouse melanoma cell line (B16) using MTT coloration
|
[PMID: 15013011]
|
B16
|
IC50 |
< 0.1 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
|
[PMID: 22330634]
|
B16
|
IC50 |
0.001 μg/mL
Compound: 1 (doxorubicin)
|
In vitro inhibitory activity against mouse melanoma cell line (B16) using CV coloration
In vitro inhibitory activity against mouse melanoma cell line (B16) using CV coloration
|
[PMID: 15013011]
|
B16
|
IC50 |
0.03 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
|
[PMID: 18586355]
|
B16
|
IC50 |
0.03 μg/mL
Compound: doxorubicin
|
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
|
[PMID: 17827021]
|
B16
|
IC50 |
0.03 μg/mL
Compound: doxorubicin
|
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
|
[PMID: 15787450]
|
B16
|
IC50 |
0.03 μM
Compound: Doxorubicin
|
Anticancer activity against mouse B16 cells after 48 hrs by MTT assay
Anticancer activity against mouse B16 cells after 48 hrs by MTT assay
|
[PMID: 22668451]
|
B16
|
IC50 |
0.1 μM
Compound: doxorubicin
|
Cytotoxicity against murine B16 cells by MTT assay
Cytotoxicity against murine B16 cells by MTT assay
|
[PMID: 17256903]
|
B16
|
IC50 |
|
Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
|
[PMID: 21496972]
|
B16
|
IC50 |
|
Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25984840]
|
B16
|
IC50 |
|
Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
|
[PMID: 25529742]
|
B16
|
IC50 |
0.18 μM
Compound: Doxorubicin
|
Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay
Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay
|
[PMID: 25247772]
|
B16
|
IC50 |
|
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
|
[PMID: 30659997]
|
B16
|
IC50 |
0.43 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse B16 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Cytotoxicity against mouse B16 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 26934105]
|
B16
|
IC50 |
1.7 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay
Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay
|
[PMID: 22304344]
|
B16
|
IC50 |
17.67 μM
Compound: doxorubicin
|
Cytotoxicity against mouse B16 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
Cytotoxicity against mouse B16 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
|
[PMID: 26200396]
|
B16
|
IC50 |
2.78 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25594739]
|
B16
|
IC50 |
21.5 μM
Compound: Doxorubicin
|
Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
|
[PMID: 21620529]
|
B16
|
IC50 |
3.16 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against mouse B16 cells by MTT assay
Cytotoxicity against mouse B16 cells by MTT assay
|
10.1039/C4MD00566J
|
B16
|
IC50 |
670 nM
Compound: Doxorubicin
|
Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay
Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay
|
[PMID: 30172625]
|
B16
|
IC50 |
7.6 nM
Compound: Adriamycin
|
Inhibition of murine B16 melanoma cell proliferation measured by the MTT assay
Inhibition of murine B16 melanoma cell proliferation measured by the MTT assay
|
[PMID: 10377224]
|
B16-BL6
|
IC50 |
3.07 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
|
[PMID: 19689125]
|
B16-BL6
|
IC50 |
8.05 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
|
[PMID: 18440233]
|
B16-F1
|
IC50 |
0.23 μM
Compound: Doxorubicin
|
Antiproliferative activity against mouse B16-F1 cells after 72 hrs by MTT reduction assay
Antiproliferative activity against mouse B16-F1 cells after 72 hrs by MTT reduction assay
|
[PMID: 28551177]
|
B16-F10
|
IC50 |
|
Cytotoxicity against mouse B16/F10 cells measured after 72 hrs by Celltiter-Glo assay
Cytotoxicity against mouse B16/F10 cells measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31820976]
|
B16-F10
|
IC50 |
0.072 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse B16F10 cells after 48 hrs by CCK8 assay
Cytotoxicity against mouse B16F10 cells after 48 hrs by CCK8 assay
|
[PMID: 23777898]
|
B16-F10
|
IC50 |
0.12 μM
Compound: Adriamycin
|
Cytotoxicity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
Cytotoxicity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay
|
[PMID: 24717154]
|
B16-F10
|
IC50 |
|
Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay
|
[PMID: 30344912]
|
B16-F10
|
IC50 |
0.346 μM
Compound: Doxorubicin
|
Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783]
|
B16-F10
|
IC50 |
|
Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay
Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay
|
[PMID: 26005543]
|
B16-F10
|
IC50 |
2.3 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
|
[PMID: 27300257]
|
B16-F10
|
IC50 |
3.28 μM
Compound: Doxorubicin
|
Anticancer activity against mouse B16-F10 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against mouse B16-F10 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 34124677]
|
B16-F10
|
IC50 |
4.23 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay
Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay
|
[PMID: 24969014]
|
B16-F10
|
IC50 |
4.33 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse B16F10 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
Cytotoxicity against mouse B16F10 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
|
[PMID: 30433783]
|
B16-F10-luc2
|
IC50 |
|
Cytotoxicity against mouse B16-F10-Luc2 cells expressing human EGFR measured after 72 hrs by resazurin assay
Cytotoxicity against mouse B16-F10-Luc2 cells expressing human EGFR measured after 72 hrs by resazurin assay
|
[PMID: 34411983]
|
B16-F10-luc2
|
IC50 |
|
Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in absence of cetuximab by resazurin assay
Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in absence of cetuximab by resazurin assay
|
[PMID: 34411983]
|
B16-F10-luc2
|
IC50 |
|
Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in presence of 3.3 uM cetuximab by resazurin assay
Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in presence of 3.3 uM cetuximab by resazurin assay
|
[PMID: 34411983]
|
B16-F10-luc2
|
IC50 |
|
Cytotoxicity against mouse B16-F10-Luc2 cells measured after 72 hrs by resazurin assay
Cytotoxicity against mouse B16-F10-Luc2 cells measured after 72 hrs by resazurin assay
|
[PMID: 34411983]
|
BALB/3T3
|
IC50 |
0.092 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by sulforhodamine B assay
Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by sulforhodamine B assay
|
[PMID: 32432867]
|
BALB/3T3
|
IC50 |
0.11 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse BALB/3T3 cells after 72 hrs by SRB assay
Cytotoxicity against mouse BALB/3T3 cells after 72 hrs by SRB assay
|
[PMID: 26639764]
|
BALB/3T3
|
IC50 |
0.18 μM
Compound: doxorubicin
|
Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method
Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method
|
[PMID: 25644674]
|
BALB/3T3
|
IC50 |
0.31 μM
Compound: Doxorubicin
|
Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs
Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs
|
[PMID: 26163197]
|
BALB/3T3
|
GI50 |
|
Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 34634616]
|
BALB/3T3
|
GI50 |
|
Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs and measured by MTT assay
Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs and measured by MTT assay
|
[PMID: 35973342]
|
BALB/3T3
|
IC50 |
1.08 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 1 hr by sulforhodamine B assay
Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 1 hr by sulforhodamine B assay
|
[PMID: 26496013]
|
BALB/3T3
|
IC50 |
1.91 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay
Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay
|
[PMID: 23079523]
|
BALB/3T3
|
IC50 |
|
Antiproliferative activity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
Antiproliferative activity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay
|
[PMID: 31653441]
|
BALB/3T3
|
IC50 |
166 nM
Compound: Doxorubicin
|
Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay
|
[PMID: 33465696]
|
BALB/3T3
|
IC50 |
|
Antiproliferative activity against mouse BALB/3T3 cells assessed as inhibition of proliferation after 72 hrs by SRB assay
Antiproliferative activity against mouse BALB/3T3 cells assessed as inhibition of proliferation after 72 hrs by SRB assay
|
[PMID: 34116158]
|
BALB/3T3
|
IC50 |
|
Cytotoxicity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 34592435]
|
BALB/3T3
|
IC50 |
|
Cytotoxicity against mouse BALB/3T3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
Cytotoxicity against mouse BALB/3T3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
|
[PMID: 33611191]
|
BC
|
IC50 |
0.17 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human BC cells by colorimetric method
Cytotoxicity against human BC cells by colorimetric method
|
[PMID: 16989536]
|
BC
|
IC50 |
0.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human BC cells by SRB assay
Cytotoxicity against human BC cells by SRB assay
|
[PMID: 20038128]
|
BC
|
IC50 |
2.88 x 10 -4 mM
Compound: doxorubicin
|
Cytotoxicity against human BC cells by SRB assay
Cytotoxicity against human BC cells by SRB assay
|
[PMID: 16933890]
|
Bcap37
|
IC50 |
|
Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay
Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay
|
[PMID: 26900656]
|
Bcap37
|
IC50 |
|
Antiproliferative activity against human Bcap37 cells after 48 hrs by MTT assay
Antiproliferative activity against human Bcap37 cells after 48 hrs by MTT assay
|
[PMID: 26807545]
|
Bcap37
|
IC50 |
|
Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
|
[PMID: 26280921]
|
Bcap37
|
IC50 |
|
Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
|
[PMID: 25874331]
|
Bcap37
|
IC50 |
|
Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay
Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay
|
[PMID: 23124210]
|
Bcap37
|
IC50 |
|
Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay
|
10.1007/s00044-013-0854-3
|
Bcap37
|
IC50 |
|
Antiproliferative against human Bcap37 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative against human Bcap37 cells assessed as growth inhibition after 72 hrs by MTT assay
|
10.1039/C1MD00038A
|
Bcap37
|
IC50 |
|
Cytotoxicity against human Bcap37 cells after 38 hrs by MTT assay
Cytotoxicity against human Bcap37 cells after 38 hrs by MTT assay
|
[PMID: 25965778]
|
BEAS-2B
|
GI50 |
0.1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay
Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay
|
[PMID: 30071406]
|
BEAS-2B
|
GI50 |
0.13 μM
Compound: Doxorubicin
|
Cytotoxicity against human BEAS2B cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human BEAS2B cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29670691]
|
BEAS-2B
|
IC50 |
18.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
|
[PMID: 29471119]
|
BEAS-2B
|
IC50 |
2.4 μM
Compound: Doxorubicin
|
Antiproliferative activity against human BEAS2B cells after 70 hrs by alamar blue assay
Antiproliferative activity against human BEAS2B cells after 70 hrs by alamar blue assay
|
[PMID: 29471119]
|
Bel-7402
|
GI50 |
|
Antiproliferative activity against human Bel7402 cells by MTT assay
Antiproliferative activity against human Bel7402 cells by MTT assay
|
[PMID: 31990554]
|
Bel-7402
|
IC50 |
< 1 μM
Compound: doxorubicin
|
Cytotoxicity against human Bel-7402 cells by SRB assay
Cytotoxicity against human Bel-7402 cells by SRB assay
|
[PMID: 33847126]
|
Bel-7402
|
IC50 |
> 1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human Bel-7402 cells by MTT assay
Antiproliferative activity against human Bel-7402 cells by MTT assay
|
[PMID: 36089748]
|
Bel-7402
|
IC50 |
|
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 18590312]
|
Bel-7402
|
IC50 |
|
Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
|
[PMID: 18590312]
|
Bel-7402
|
IC50 |
0.021 μM
Compound: adriamycin
|
Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
|
[PMID: 19028425]
|
Bel-7402
|
IC50 |
0.049 μM
Compound: Doxorubicin
|
Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
|
[PMID: 20846862]
|
Bel-7402
|
IC50 |
|
Cytotoxicity against human Bel7402 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human Bel7402 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 20949916]
|
Bel-7402
|
IC50 |
0.12 μM
Compound: Adriamycin
|
Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay
|
[PMID: 20593838]
|
Bel-7402
|
IC50 |
|
Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25984840]
|
Bel-7402
|
IC50 |
|
Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 25529742]
|
Bel-7402
|
IC50 |
0.22 μM
Compound: Doxorubicin
|
Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay
Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay
|
[PMID: 25247772]
|
Bel-7402
|
IC50 |
0.53 μM
Compound: Adriamycin
|
Cytotoxicity against human Bel7402 cells by MTT assay
Cytotoxicity against human Bel7402 cells by MTT assay
|
[PMID: 22070654]
|
Bel-7402
|
IC50 |
0.58 μM
Compound: Doxorubicin
|
Antiproliferative activity human Bel7402 cells after 20 hrs by MTT assay
Antiproliferative activity human Bel7402 cells after 20 hrs by MTT assay
|
[PMID: 20149494]
|
Bel-7402
|
IC50 |
|
Cytotoxic activity against human Bel7402 cells by MTT method
Cytotoxic activity against human Bel7402 cells by MTT method
|
[PMID: 25611519]
|
Bel-7402
|
IC50 |
|
Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay
|
[PMID: 20932754]
|
Bel-7402
|
IC50 |
1 μM
Compound: adriamycin
|
Cytotoxicity against human Bel-7402 cells by MTT assay
Cytotoxicity against human Bel-7402 cells by MTT assay
|
[PMID: 17190442]
|
Bel-7402
|
IC50 |
|
Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
|
[PMID: 26386603]
|
Bel-7402
|
IC50 |
5 μM
Compound: Doxorubicin
|
Antitumor activity against human Bel7402 cells after 48 hrs by SRB assay
Antitumor activity against human Bel7402 cells after 48 hrs by SRB assay
|
[PMID: 20884091]
|
Bel-7402
|
IC50 |
578.2 nM
Compound: Doxorubicin
|
Antiproliferative against human Bel7402 cells assessed as cell viability after 96 hrs by MTT assay
Antiproliferative against human Bel7402 cells assessed as cell viability after 96 hrs by MTT assay
|
[PMID: 24211639]
|
BEL-7404 tumor cell line
|
IC50 |
|
Cytotoxicity against human Bel7404 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human Bel7404 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27668963]
|
BeWo
|
IC50 |
1.07 μM
Compound: Doxorubicin
|
Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay
Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 25160837]
|
BeWo
|
IC50 |
6.24 μg/mL
Compound: (20) adriamycin
|
In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay
In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay
|
[PMID: 12620075]
|
BGC-823
|
IC50 |
0.35 μM
Compound: adriamycin
|
Cytotoxicity against human BGC823 cells after 48 hrs
Cytotoxicity against human BGC823 cells after 48 hrs
|
[PMID: 17583953]
|
BGC-823
|
IC50 |
|
Antiproliferative activity against human BGC823 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human BGC823 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 30241010]
|
BGC-823
|
IC50 |
|
Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 35341920]
|
BGC-823
|
IC50 |
0.9 μM
Compound: Doxorubicin
|
Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
|
[PMID: 22749279]
|
BGC-823
|
IC50 |
1 μM
Compound: adriamycin
|
Cytotoxicity against human BGC-823 cells by MTT assay
Cytotoxicity against human BGC-823 cells by MTT assay
|
[PMID: 17190442]
|
BGC-823
|
IC50 |
1.33 μM
Compound: Adriamycin
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 23434227]
|
BGC-823
|
IC50 |
1.48 μM
Compound: Adriamycin
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 24182355]
|
BGC-823
|
IC50 |
|
Antiproliferative against human BGC823 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative against human BGC823 cells assessed as growth inhibition after 72 hrs by MTT assay
|
10.1039/C1MD00038A
|
BGC-823
|
IC50 |
4.8 μM
Compound: Doxorubicin
|
Antitumor activity against human BGC823 cells after 48 hrs by SRB assay
Antitumor activity against human BGC823 cells after 48 hrs by SRB assay
|
[PMID: 20884091]
|
BJ
|
IC50 |
|
Cytotoxicity against human BJ cells assessed as cell viability after 48 hrs by alamar blue assay
Cytotoxicity against human BJ cells assessed as cell viability after 48 hrs by alamar blue assay
|
[PMID: 21797280]
|
BJ
|
IC50 |
2.33 μM
Compound: Doxorubicin
|
Cytotoxicity against human BJ cells after 48 hrs by Alamar blue assay
Cytotoxicity against human BJ cells after 48 hrs by Alamar blue assay
|
[PMID: 20931970]
|
BJ
|
IC50 |
2.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human BJ cells after 48 hrs by Alamar Blue assay
Cytotoxicity against human BJ cells after 48 hrs by Alamar Blue assay
|
[PMID: 19473028]
|
BMDM
|
IC50 |
4.6 μM
Compound: Adriamycin
|
Cytotoxicity against mouse BMDM cells after 72 hrs by MTT assay
Cytotoxicity against mouse BMDM cells after 72 hrs by MTT assay
|
[PMID: 22616554]
|
BT-474
|
IC50 |
|
Antiproliferative activity against human BT474 cells after 48 hrs by CellTiter-Glo assay
Antiproliferative activity against human BT474 cells after 48 hrs by CellTiter-Glo assay
|
[PMID: 27769032]
|
BT-474
|
IC50 |
|
Antiproliferative activity against human BT474 cells after 24 hrs by CellTiter-Glo assay
Antiproliferative activity against human BT474 cells after 24 hrs by CellTiter-Glo assay
|
[PMID: 27769032]
|
BT-474
|
IC50 |
|
Cytotoxicity against human BT474 cells after 3 days by MTT assay
Cytotoxicity against human BT474 cells after 3 days by MTT assay
|
[PMID: 21741833]
|
BT-474
|
IC50 |
|
Antiproliferative activity against human BT474 spheroids after 3 days by CellTiter-Glo assay
Antiproliferative activity against human BT474 spheroids after 3 days by CellTiter-Glo assay
|
[PMID: 27769032]
|
BT-474
|
IC50 |
0.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human BT474 cells assessed as reduction in cell survival after 48 hrs by MTT assay
Cytotoxicity against human BT474 cells assessed as reduction in cell survival after 48 hrs by MTT assay
|
[PMID: 28494255]
|
BT-474
|
IC50 |
|
Cytotoxicity against human BT474 cells measured after 72 hrs by Celltiter-Glo assay
Cytotoxicity against human BT474 cells measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31820976]
|
BT-474
|
IC50 |
8.92 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human BT474 cells after 3 days by MTT assay
Cytotoxicity against human BT474 cells after 3 days by MTT assay
|
[PMID: 19456120]
|
BT-549
|
IC50 |
< 0.55 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay
Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay
|
[PMID: 19105653]
|
BT-549
|
IC50 |
< 0.55 μM
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) BT549 cells by neutral red staining
Cytotoxicity against Homo sapiens (human) BT549 cells by neutral red staining
|
10.1007/s00044-011-9587-3
|
BT-549
|
IC50 |
< 1.1 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay
Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay
|
[PMID: 11374943]
|
BT-549
|
IC50 |
0.008 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay
Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay
|
[PMID: 8984156]
|
BT-549
|
IC50 |
0.009 μM
Compound: Doxorubicin
|
Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 27010926]
|
BT-549
|
GI50 |
0.01 μM
Compound: Doxorubicin
|
Cytostatic activity against human BT549 cells after 5 days by SRB assay
Cytostatic activity against human BT549 cells after 5 days by SRB assay
|
[PMID: 21711054]
|
BT-549
|
IC50 |
0.01 μM
Compound: Doxorubicin
|
Cytotoxicity against human BT549 cells assessed as growth inhibition after 72 hrs by SRB assay
Cytotoxicity against human BT549 cells assessed as growth inhibition after 72 hrs by SRB assay
|
[PMID: 30457333]
|
BT-549
|
IC50 |
0.045 μM
Compound: Doxorubicin
|
Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye based assay
Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye based assay
|
[PMID: 29317147]
|
BT-549
|
IC50 |
0.11 μM
Compound: Doxorubicin
|
Cytotoxicity against human BT549 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
Cytotoxicity against human BT549 cells after 72 hrs by resazurin/resorufin-based fluorescence assay
|
[PMID: 23600925]
|
BT-549
|
IC50 |
0.17 μM
Compound: Doxorubicin
|
Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay relative to control
Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay relative to control
|
[PMID: 25975638]
|
BT-549
|
GI50 |
0.23 μM
Compound: Doxorubicin hydrochloride, NSC 123127
|
Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
|
[PMID: 23871905]
|
BT-549
|
GI50 |
0.23 μM
Compound: Doxorubicin
|
Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29102177]
|
BT-549
|
GI50 |
0.23 μM
Compound: Doxorubicin
|
Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28329730]
|
BT-549
|
IC50 |
0.6 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human BT549 cells by neutral red assay
Cytotoxicity against human BT549 cells by neutral red assay
|
[PMID: 17976995]
|
BT-549
|
IC50 |
0.8 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human BT549 cells after 48 hrs by Neutral Red dye
Cytotoxicity against human BT549 cells after 48 hrs by Neutral Red dye
|
[PMID: 20550123]
|
BT-549
|
IC50 |
1 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human BT549 cells after 48 hrs by neutral red staining
Cytotoxicity against human BT549 cells after 48 hrs by neutral red staining
|
[PMID: 15165136]
|
BT-549
|
IC50 |
1.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human BT549 cells after 48 hrs by Neutral red assay
Cytotoxicity against human BT549 cells after 48 hrs by Neutral red assay
|
[PMID: 19658408]
|
BT-549
|
IC50 |
1.3 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye staining
Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye staining
|
[PMID: 19928902]
|
BT-549
|
IC50 |
1.35 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay
Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay
|
[PMID: 27769668]
|
BT-549
|
IC50 |
1.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red assay
Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red assay
|
[PMID: 26005918]
|
BT-549
|
IC50 |
1.96 μM
Compound: doxorubicin
|
Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay
Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay
|
[PMID: 19879765]
|
BT-549
|
IC50 |
2.6 μM
Compound: doxorubicin
|
Cytotoxicity against human BT549 cells assessed as viable cells by neutral red dye method
Cytotoxicity against human BT549 cells assessed as viable cells by neutral red dye method
|
[PMID: 22530813]
|
BT-549
|
IC50 |
3.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human BT549 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
Cytotoxicity against human BT549 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
|
[PMID: 27618204]
|
BT-549
|
IC50 |
3.7 μM
Compound: doxorubicin
|
Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay
Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay
|
[PMID: 23547843]
|
BXPC-3
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
|
[PMID: 25937235]
|
BXPC-3
|
IC50 |
0.4 μM
Compound: DOX, Doxorubicin
|
Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay
|
[PMID: 24095089]
|
BXPC-3
|
IC50 |
0.56 μM
Compound: Doxorubicin
|
Antiproliferative activity against human BxPC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human BxPC3 cells after 48 hrs by MTT assay
|
[PMID: 28554092]
|
BXPC-3
|
IC50 |
1.78 μM
Compound: Doxorubicin
|
Antiproliferative activity against human BxPC3 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
Antiproliferative activity against human BxPC3 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 26253231]
|
BXPC-3
|
IC50 |
13 μM
Compound: Doxorubicin
|
Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay
Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay
|
[PMID: 27173802]
|
BXPC-3
|
IC50 |
13.56 μM
Compound: Doxorubicin
|
Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay
Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay
|
[PMID: 29573910]
|
BXPC-3
|
IC50 |
14.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28254167]
|
BXPC-3
|
IC50 |
9.12 μM
Compound: Doxorubicin
|
Growth inhibition of human BxPC3 cells after 48 hrs by MTT assay
Growth inhibition of human BxPC3 cells after 48 hrs by MTT assay
|
[PMID: 30072225]
|
C2D cell line
|
IC50 |
46.5 nM
Compound: Doxorubicin
|
Inhibitory concentration to inhibit growth of C2D prostate cancer cell line by using MTT assay
Inhibitory concentration to inhibit growth of C2D prostate cancer cell line by using MTT assay
|
[PMID: 14971910]
|
C2G cell line
|
IC50 |
28.7 nM
Compound: Doxorubicin
|
Inhibitory concentration to inhibit growth of C2G prostate cancer cell line by using MTT assay
Inhibitory concentration to inhibit growth of C2G prostate cancer cell line by using MTT assay
|
[PMID: 14971910]
|
C-33-A
|
IC50 |
0.28 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human C33A cells after 48 hrs by SRB assay
Cytotoxicity against human C33A cells after 48 hrs by SRB assay
|
[PMID: 20732814]
|
C-33-A
|
IC50 |
0.82 μM
Compound: Doxorubicin
|
Cytotoxicity against human C33A cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human C33A cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21071221]
|
C3H
|
IC50 |
0.04 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse C3H cells after 72 hrs by MTS assay
Cytotoxicity against mouse C3H cells after 72 hrs by MTS assay
|
[PMID: 26810263]
|
C6
|
IC50 |
|
Cytotoxicity against rat C6 cells after 72 hrs by MTT assay
Cytotoxicity against rat C6 cells after 72 hrs by MTT assay
|
[PMID: 30659997]
|
C6
|
IC50 |
|
Cytotoxicity against rat C6 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against rat C6 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 28504888]
|
C6
|
IC50 |
|
Cytotoxicity against rat C6 cells assessed as cell viability measured after 24 hrs by MTT assay
Cytotoxicity against rat C6 cells assessed as cell viability measured after 24 hrs by MTT assay
|
[PMID: 33183865]
|
C8166
|
IC50 |
|
Antiproliferative activity against human C8166 cell line by MTT assay
Antiproliferative activity against human C8166 cell line by MTT assay
|
[PMID: 16913700]
|
Ca9-22
|
IC50 |
0.09 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human sCa9-22 cells by MTT assay
Cytotoxicity against human sCa9-22 cells by MTT assay
|
[PMID: 18590313]
|
Ca9-22
|
IC50 |
0.1 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human Ca9-22 cells by MTT assay
Cytotoxicity against human Ca9-22 cells by MTT assay
|
[PMID: 18973388]
|
Ca9-22
|
IC50 |
0.14 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay
Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay
|
[PMID: 19691312]
|
Ca9-22
|
IC50 |
|
Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay
Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay
|
[PMID: 21800859]
|
Ca9-22
|
IC50 |
0.31 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human Ca9-22 cells by MTT assay
Cytotoxicity against human Ca9-22 cells by MTT assay
|
[PMID: 22413887]
|
Ca9-22
|
CC50 |
|
Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31532650]
|
Ca9-22
|
IC50 |
|
Cytotoxicity against human Ca9-22 cells after 72 hrs by MTT assay
Cytotoxicity against human Ca9-22 cells after 72 hrs by MTT assay
|
[PMID: 20334960]
|
Ca9-22
|
IC50 |
14.47 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human Ca9-22 cells by MTT assay
Cytotoxicity against human Ca9-22 cells by MTT assay
|
[PMID: 21106454]
|
Caco-2
|
IC50 |
0.02 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human Caco2 cells after 72 hrs by WST-8 assay
Cytotoxicity against human Caco2 cells after 72 hrs by WST-8 assay
|
[PMID: 25534608]
|
Caco-2
|
IC50 |
0.05 μM
Compound: Doxorubicin
|
Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs
Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs
|
[PMID: 34601029]
|
Caco-2
|
IC50 |
0.05 μM
Compound: Doxorubicine
|
Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908]
|
Caco-2
|
IC50 |
0.09 μM
Compound: Doxorubicin
|
Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216]
|
Caco-2
|
IC50 |
0.17 μM
Compound: Doxorubicin
|
Toxicity in human Caco-2 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
Toxicity in human Caco-2 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
|
[PMID: 31753515]
|
Caco-2
|
GI50 |
0.32 μM
Compound: Doxorubicin
|
Antiproliferative activity against human Caco2 cells after 2 days by sulforhodamine B assay
Antiproliferative activity against human Caco2 cells after 2 days by sulforhodamine B assay
|
[PMID: 24184076]
|
Caco-2
|
IC50 |
0.35 μM
Compound: Doxorubicin
|
Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay
Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay
|
[PMID: 24941130]
|
Caco-2
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Antitumor activity against human differentiated Caco2 cells after 24 to 48 hrs by MTT assay
Antitumor activity against human differentiated Caco2 cells after 24 to 48 hrs by MTT assay
|
[PMID: 21553829]
|
Caco-2
|
IC50 |
0.73 μM
Compound: Doxorubicin
|
Antiproliferative activity against human Caco2 cells after 48 hrs by neutral red assay
Antiproliferative activity against human Caco2 cells after 48 hrs by neutral red assay
|
[PMID: 29885574]
|
Caco-2
|
IC50 |
0.96 μM
Compound: Doxorubicin
|
Cytotoxicity against human Caco2 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human Caco2 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 26874404]
|
Caco-2
|
IC50 |
1 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human Caco-2 cells after 24 hrs
Cytotoxicity against human Caco-2 cells after 24 hrs
|
[PMID: 20207452]
|
Caco-2
|
IC50 |
1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human Caco2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human Caco2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31546197]
|
Caco-2
|
IC50 |
2.7 μM
Compound: Adriamycin
|
Cytotoxicity against human Caco2 cells by MTT assay
Cytotoxicity against human Caco2 cells by MTT assay
|
[PMID: 22946634]
|
Caco-2
|
IC50 |
|
Cytotoxicity against human Caco2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human Caco2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 32435401]
|
Caco-2
|
IC50 |
|
Antiproliferative activity against human Caco2 cells by MTT assay
Antiproliferative activity against human Caco2 cells by MTT assay
|
[PMID: 30216848]
|
Caco-2
|
IC50 |
3 μM
Compound: Doxorubicin
|
Antiproliferative activity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
Antiproliferative activity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 26874744]
|
Caco-2
|
IC50 |
|
Antiproliferative activity against human Caco2 cells by MTT assay
Antiproliferative activity against human Caco2 cells by MTT assay
|
[PMID: 28802125]
|
Caco-2
|
IC50 |
|
Anticancer activity against human Caco-2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Anticancer activity against human Caco-2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 33901898]
|
Caco-2
|
IC50 |
5 μM
Compound: Doxorubicin
|
Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay
Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay
|
[PMID: 24099994]
|
Caco-2
|
IC50 |
5.13 μM
Compound: Doxorubicin
|
Antiproliferative activity against human Caco2 cells after 72 hrs by ELISA
Antiproliferative activity against human Caco2 cells after 72 hrs by ELISA
|
[PMID: 31404864]
|
Caco-2
|
IC50 |
6.7 μM
Compound: Doxorubicin
|
Antitumor activity against human undifferentiated Caco2 cells after 24 to 48 hrs by MTT assay
Antitumor activity against human undifferentiated Caco2 cells after 24 to 48 hrs by MTT assay
|
[PMID: 21553829]
|
Caco-2
|
IC50 |
63.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 28463785]
|
Caco-2
|
IC50 |
64.2 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human Caco2 cells assessed as cell growth inhibition measured after 24 by MTT assay
Cytotoxicity against human Caco2 cells assessed as cell growth inhibition measured after 24 by MTT assay
|
[PMID: 35526504]
|
Caco-2
|
IC50 |
9.4 μM
Compound: Doxorubicin
|
Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 27843113]
|
CAKI-1
|
GI50 |
0.95 μM
Compound: Doxorubicin hydrochloride, NSC 123127
|
Cytotoxicity against human Caki1 cells after 48 hrs by SRB assay
Cytotoxicity against human Caki1 cells after 48 hrs by SRB assay
|
[PMID: 23871905]
|
CAKI-1
|
GI50 |
0.95 μM
Compound: Doxorubicin
|
Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29102177]
|
CAL-27
|
IC50 |
|
Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 36709571]
|
Calu-1
|
GI50 |
< 1 x 10 -2 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HTB-54 cells after 72 hrs by MTT assay
Antiproliferative activity against human HTB-54 cells after 72 hrs by MTT assay
|
[PMID: 30071406]
|
Calu-1
|
GI50 |
< 1 x 10 -2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HTB-54 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HTB-54 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29670691]
|
Calu-3
|
IC50 |
|
Antiproliferative activity against human Calu3 cells after 48 hrs by CellTiter-Glo assay
Antiproliferative activity against human Calu3 cells after 48 hrs by CellTiter-Glo assay
|
[PMID: 27769032]
|
Calu-3
|
IC50 |
|
Antiproliferative activity against human Calu3 cells after 24 hrs by CellTiter-Glo assay
Antiproliferative activity against human Calu3 cells after 24 hrs by CellTiter-Glo assay
|
[PMID: 27769032]
|
Cancer cell lines
|
GI50 |
0.065 μM
Compound: Doxorubicin
|
Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay
Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay
|
[PMID: 20884089]
|
Cancer cell lines
|
GI50 |
0.065 μM
Compound: Doxorubicin
|
Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay
Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay
|
[PMID: 20884089]
|
Cancer cell lines
|
GI50 |
0.065 μM
Compound: Doxorubicin
|
Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay
Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay
|
[PMID: 20884089]
|
Caov-3 cell line
|
IC50 |
< 0.1 μM
Compound: DOX, Doxorubicin
|
Antiproliferative activity against human Caov3 cells after 72 hrs by MTT assay
Antiproliferative activity against human Caov3 cells after 72 hrs by MTT assay
|
[PMID: 24095089]
|
CAPAN-1
|
IC50 |
1.7 μM
Compound: Doxorubicin
|
Cytotoxicity in human CAPAN-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity in human CAPAN-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 34082225]
|
CAPAN-1
|
IC50 |
|
Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 32428792]
|
CAPAN-1
|
IC50 |
1.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30660827]
|
carcinoma cell line
|
IC50 |
< 0.01 μM
Compound: doxorubicin
|
Inhibitory effect against murine renal cell carcinoma cell line (RENCA cells) using a BrdU-incorporation assay
Inhibitory effect against murine renal cell carcinoma cell line (RENCA cells) using a BrdU-incorporation assay
|
[PMID: 11454467]
|
CCD-841CoN
|
IC50 |
1.5 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human CCD-841CoN cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Cytotoxicity against human CCD-841CoN cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 35526504]
|
CCRF S-180
|
IC50 |
29.2 μM
Compound: Doxorubicin
|
Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
|
[PMID: 21620529]
|
CCRF S-180
|
IC50 |
9.25 μM
Compound: Doxorubicin
|
Antiproliferative activity against mouse S180 cells assessed as cell viability after 48 hrs by MTT assay
Antiproliferative activity against mouse S180 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25648297]
|
CCRF-CEM
|
IC50 |
0.003 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay
Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay
|
[PMID: 26260339]
|
CCRF-CEM
|
IC50 |
0.003 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay
|
[PMID: 28456567]
|
CCRF-CEM
|
IC50 |
0.009 μM
Compound: Doxorubicin
|
Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 27010926]
|
CCRF-CEM
|
IC50 |
0.009 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-CEM cells by resazurin assay
Cytotoxicity against human CCRF-CEM cells by resazurin assay
|
[PMID: 24561670]
|
CCRF-CEM
|
EC50 |
0.009 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
|
[PMID: 29937978]
|
CCRF-CEM
|
IC50 |
0.01 μM
Compound: Doxorubicin
|
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay
|
[PMID: 27808511]
|
CCRF-CEM
|
EC50 |
0.015 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay
|
[PMID: 29887512]
|
CCRF-CEM
|
IC50 |
0.017 μM
Compound: Doxorubicin
|
Growth inhibition of human CCRF-CEM cells by resazurin assay
Growth inhibition of human CCRF-CEM cells by resazurin assay
|
[PMID: 28121440]
|
CCRF-CEM
|
IC50 |
0.017 μM
Compound: Doxorubicin
|
Antileukemic activity against human CCRF-CEM cells after 24 to 48 hrs by resazurin dye based fluorescence assay
Antileukemic activity against human CCRF-CEM cells after 24 to 48 hrs by resazurin dye based fluorescence assay
|
[PMID: 29560715]
|
CCRF-CEM
|
IC50 |
0.02 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
|
[PMID: 18586355]
|
CCRF-CEM
|
IC50 |
0.02 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
|
[PMID: 15787450]
|
CCRF-CEM
|
GI50 |
0.02 μM
Compound: Doxorubicin
|
Growth inhibition of human CCRF-CEM cells after 2 days by MTT assay
Growth inhibition of human CCRF-CEM cells after 2 days by MTT assay
|
[PMID: 20570145]
|
CCRF-CEM
|
IC50 |
|
Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay
Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay
|
[PMID: 31869654]
|
CCRF-CEM
|
EC50 |
0.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
|
[PMID: 26320088]
|
CCRF-CEM
|
CC50 |
0.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay
|
[PMID: 26119992]
|
CCRF-CEM
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay
Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay
|
[PMID: 19053767]
|
CCRF-CEM
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by RRA assay
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by RRA assay
|
[PMID: 33508467]
|
CCRF-CEM
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay
|
[PMID: 32663024]
|
CCRF-CEM
|
IC50 |
|
Antiproliferative activity against human CCRF-CEM cell line by MTT assay
Antiproliferative activity against human CCRF-CEM cell line by MTT assay
|
[PMID: 16913700]
|
CCRF-CEM
|
IC50 |
0.037 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-CEM cells by CCK-8 assay
Cytotoxicity against human CCRF-CEM cells by CCK-8 assay
|
[PMID: 22884578]
|
CCRF-CEM
|
IC50 |
0.052 μM
Compound: Doxorubicin
|
Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay
Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay
|
[PMID: 27060757]
|
CCRF-CEM
|
IC50 |
|
Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
|
[PMID: 26633734]
|
CCRF-CEM
|
IC50 |
|
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
|
[PMID: 21144624]
|
CCRF-CEM
|
IC50 |
0.06 μM
Compound: adriamycin
|
Cytotoxicity against drug-sensitive CCRF-CEM cells after 72 hrs
Cytotoxicity against drug-sensitive CCRF-CEM cells after 72 hrs
|
[PMID: 17323939]
|
CCRF-CEM
|
GI50 |
0.08 μM
Compound: Doxorubicin hydrochloride, NSC 123127
|
Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB assay
Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB assay
|
[PMID: 23871905]
|
CCRF-CEM
|
GI50 |
0.08 μM
Compound: Doxorubicin
|
Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29102177]
|
CCRF-CEM
|
GI50 |
0.08 μM
Compound: Doxorubicin
|
Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28329730]
|
CCRF-CEM
|
IC50 |
0.09 μM
Compound: Doxorubicin
|
Antiproliferative activity against human CCRF-CEM cells assessed as cell viability after 72 hrs by MTT assay
Antiproliferative activity against human CCRF-CEM cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 24012378]
|
CCRF-CEM
|
IC50 |
0.09 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay
|
[PMID: 19394829]
|
CCRF-CEM
|
IC50 |
0.09 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
|
[PMID: 36691388]
|
CCRF-CEM
|
IC50 |
|
Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
|
[PMID: 29459273]
|
CCRF-CEM
|
IC50 |
|
Antiproliferative activity against human CEM cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human CEM cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 33974416]
|
CCRF-CEM
|
IC50 |
|
Antiproliferative activity in human CEM cells after 72 hrs by MTT assay
Antiproliferative activity in human CEM cells after 72 hrs by MTT assay
|
[PMID: 30268824]
|
CCRF-CEM
|
IC50 |
|
Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
|
[PMID: 29137865]
|
CCRF-CEM
|
IC50 |
0.11 μM
Compound: doxorubicin
|
Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
|
[PMID: 22582991]
|
CCRF-CEM
|
IC50 |
0.17 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-CEM cells after 48 hrs by MTT assay
Cytotoxicity against human CCRF-CEM cells after 48 hrs by MTT assay
|
[PMID: 32496057]
|
CCRF-CEM
|
IC50 |
0.39 μM
Compound: Doxorubicin
|
Cytostatic activity against human CEM/0 after 72 hrs by cell counting
Cytostatic activity against human CEM/0 after 72 hrs by cell counting
|
[PMID: 22555152]
|
CCRF-CEM
|
EC50 |
0.4654 μM
Compound: doxorubicin
|
Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
|
[PMID: 19743858]
|
CCRF-CEM
|
IC50 |
0.5 μM
Compound: doxorubicin
|
Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 25993619]
|
CCRF-CEM
|
IC50 |
|
Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 24484281]
|
CCRF-CEM
|
IC50 |
|
Cytotoxicity against human CCRF-CEM cells after 48 hrs by resazurin assay
Cytotoxicity against human CCRF-CEM cells after 48 hrs by resazurin assay
|
[PMID: 29107422]
|
CCRF-CEM
|
IC50 |
|
Antiproliferative activity against human CCRF-CEM cells after 48 hrs by resazurin dye-based fluorescence assay
Antiproliferative activity against human CCRF-CEM cells after 48 hrs by resazurin dye-based fluorescence assay
|
[PMID: 29665526]
|
CCRF-CEM
|
IC50 |
2.14 μM
Compound: doxorubicin
|
Cytotoxicity against human CCRF-CEM cells by XTT assay
Cytotoxicity against human CCRF-CEM cells by XTT assay
|
[PMID: 22663190]
|
CCRF-CEM
|
GI50 |
3 x 10 -2 μM
Compound: Doxorubicin
|
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay
|
[PMID: 30071406]
|
CCRF-CEM
|
EC50 |
3.078 μM
Compound: doxorubicin
|
Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
|
[PMID: 19743858]
|
CCRF-CEM
|
IC50 |
3.14 μM
Compound: Doxorubicin
|
Cytotoxicity against human CEM cells after 48 hrs by alamar blue assay
Cytotoxicity against human CEM cells after 48 hrs by alamar blue assay
|
[PMID: 22272829]
|
CCRF-CEM
|
IC50 |
3.14 μM
Compound: Doxorubicin
|
Cytotoxicity against human CEM cells after 48 hrs
Cytotoxicity against human CEM cells after 48 hrs
|
[PMID: 20873721]
|
CCRF-CEM
|
GI50 |
3.3 x 10 -2 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29670691]
|
CCRF-CEM
|
IC50 |
36.9 nM
Compound: doxorubicin
|
Cytotoxicity against human CCRF-CEM by XTT assay
Cytotoxicity against human CCRF-CEM by XTT assay
|
[PMID: 20527917]
|
CCRF-CEM
|
IC50 |
|
Inhibition of cell proliferation of human CCRF-CEM cells after 96 hrs by CellTiter assay
Inhibition of cell proliferation of human CCRF-CEM cells after 96 hrs by CellTiter assay
|
[PMID: 22276998]
|
CCRF-CEM
|
IC50 |
|
Antiproliferative activity against human CCRF-CM cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human CCRF-CM cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay
|
[PMID: 27687968]
|
CCRF-SB
|
EC50 |
0.01 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
|
[PMID: 26320088]
|
CCRF-SB
|
IC50 |
|
Antiproliferative activity against human CCRF-SB cell line by MTT assay
Antiproliferative activity against human CCRF-SB cell line by MTT assay
|
[PMID: 16913700]
|
CCRF-SB
|
IC50 |
|
Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay
Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay
|
[PMID: 31869654]
|
CCRF-SB
|
CC50 |
0.03 μM
Compound: Doxorubicin
|
Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay
|
[PMID: 26119992]
|
CCRF-SB
|
IC50 |
0.03 μM
Compound: Doxorubicin
|
Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay
Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay
|
[PMID: 19053767]
|
CEM/VLB100
|
IC50 |
3.71 μM
Compound: adriamycin
|
Cytotoxicity against vinblastine-resistant CEM/VLB100 cells after 72 hrs
Cytotoxicity against vinblastine-resistant CEM/VLB100 cells after 72 hrs
|
[PMID: 17323939]
|
CEM-VM1
|
IC50 |
0.55 μM
Compound: adriamycin
|
Cytotoxicity against teniposide-resistant CEM/VM1 cells after 72 hrs
Cytotoxicity against teniposide-resistant CEM/VM1 cells after 72 hrs
|
[PMID: 17323939]
|
CH1
|
IC50 |
0.0063 μM
Compound: Doxirubicin
|
Concentration required to inhibit CH1-cell growth by 50%
Concentration required to inhibit CH1-cell growth by 50%
|
[PMID: 9703471]
|
CHO
|
IC50 |
0.08 μM
Compound: Adriamycin
|
Cytotoxicity against CHO cells after 72 hrs by MTT assay
Cytotoxicity against CHO cells after 72 hrs by MTT assay
|
[PMID: 21721528]
|
CHO
|
CC50 |
0.6 μM
Compound: Doxorubicin
|
Cytotoxicity against CHO cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against CHO cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 25791675]
|
CHO
|
IC50 |
3.6 μM
Compound: Doxorubicin
|
Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 34782182]
|
CHO
|
CC50 |
4.65 μM
Compound: Doxorubicin
|
Cytotoxicity against CHO cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against CHO cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 32088496]
|
CHO
|
IC50 |
|
Compound was tested for the drug concentration that inhibited cell growth by 50% compared to untreated control cultures of CHO /DOX cell line
Compound was tested for the drug concentration that inhibited cell growth by 50% compared to untreated control cultures of CHO /DOX cell line
|
[PMID: 9526570]
|
CHO
|
IC50 |
6.0 x 10 -8 M
Compound: DOX
|
Drug concentration that inhibit cell growth by 50% compared to untreated control cultures of CHO cells (for 6 days at 37 degree Celsius)
Drug concentration that inhibit cell growth by 50% compared to untreated control cultures of CHO cells (for 6 days at 37 degree Celsius)
|
[PMID: 9526570]
|
CHO
|
IC50 |
9.7 μM
Compound: Adriamycin
|
Cytotoxicity against CHO cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay
Cytotoxicity against CHO cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay
|
[PMID: 21721528]
|
CHO-K1
|
IC50 |
4.2 μM
Compound: Doxorubicin
|
Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 27843113]
|
CNE
|
IC50 |
|
Antiproliferative activity against human CNE cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human CNE cells after 72 hrs by CCK-8 assay
|
[PMID: 29614418]
|
CNE-2
|
IC50 |
3.52 μM
Compound: Doxorubicin
|
Cytotoxicity against human CNE2 cells by CCK8 assay
Cytotoxicity against human CNE2 cells by CCK8 assay
|
[PMID: 29452840]
|
CNS cell
|
GI50 |
94 μM
Compound: doxorubicin
|
Cytotoxicity against human CNS cells after 48 hrs by SRB assay
Cytotoxicity against human CNS cells after 48 hrs by SRB assay
|
[PMID: 19070942]
|
COLO 201
|
IC50 |
0.8 μM
Compound: Doxorubicin
|
Growth inhibition of human Colo-201 cells by MTT assay
Growth inhibition of human Colo-201 cells by MTT assay
|
[PMID: 33901643]
|
COLO 205
|
GI50 |
|
Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
|
[PMID: 20673627]
|
COLO 205
|
GI50 |
|
Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21737288]
|
COLO 205
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Antiproliferative activity against human COLO205 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
Antiproliferative activity against human COLO205 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
|
[PMID: 25937235]
|
COLO 205
|
GI50 |
0.14 μM
Compound: adriamycin
|
Cytotoxicity against human Colo205 cells after 24 hrs by SRB method
Cytotoxicity against human Colo205 cells after 24 hrs by SRB method
|
[PMID: 18262426]
|
COLO 205
|
GI50 |
|
Growth inhibition of human COLO205 cells after 48 hrs by SRB assay
Growth inhibition of human COLO205 cells after 48 hrs by SRB assay
|
[PMID: 20031423]
|
COLO 205
|
GI50 |
|
Growth inhibition of human COLO205 cells by SRB assay
Growth inhibition of human COLO205 cells by SRB assay
|
[PMID: 22361684]
|
COLO 205
|
GI50 |
|
Anticancer activity against human COLO205 cells by SRB method
Anticancer activity against human COLO205 cells by SRB method
|
[PMID: 21676506]
|
COLO 205
|
GI50 |
|
Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 23849207]
|
COLO 205
|
GI50 |
|
Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22364746]
|
COLO 205
|
GI50 |
|
Cytotoxicity against human Colo205 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human Colo205 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 18657979]
|
COLO 205
|
GI50 |
|
Cytotoxicity against human COLO205 cells after 24 hrs by WST-1 assay
Cytotoxicity against human COLO205 cells after 24 hrs by WST-1 assay
|
[PMID: 20732817]
|
COLO 205
|
GI50 |
0.15 μM
Compound: ADR, Adriamycin
|
Growth inhibition of human Colo205 cells by SRB method
Growth inhibition of human Colo205 cells by SRB method
|
[PMID: 18207392]
|
COLO 205
|
GI50 |
0.18 μM
Compound: Doxorubicin hydrochloride, NSC 123127
|
Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
|
[PMID: 23871905]
|
COLO 205
|
GI50 |
0.18 μM
Compound: Doxorubicin
|
Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29102177]
|
COLO 205
|
GI50 |
0.18 μM
Compound: Doxorubicin
|
Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28329730]
|
COLO 205
|
IC50 |
0.26 μM
Compound: adriamycin
|
Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay
Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay
|
[PMID: 17107806]
|
COLO 205
|
IC50 |
|
Cytotoxicity against human COLO205 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human COLO205 cells assessed as cell viability after 48 hrs by MTT assay
|
10.1039/C2MD20302B
|
COLO 205
|
IC50 |
0.4 μM
Compound: Doxorubicin
|
Anticancer activity against human COLO205 cells by MTT assay
Anticancer activity against human COLO205 cells by MTT assay
|
[PMID: 21570750]
|
COLO 205
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human COLO205 cells by MTT assay
Cytotoxicity against human COLO205 cells by MTT assay
|
[PMID: 24300737]
|
COLO 205
|
IC50 |
|
Antiproliferative activity against human COLO205 cells after 72 hrs by Sulforhodamine B-stain assay
Antiproliferative activity against human COLO205 cells after 72 hrs by Sulforhodamine B-stain assay
|
[PMID: 27484508]
|
COLO 205
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 24780595]
|
COLO 205
|
IC50 |
|
Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 24507927]
|
COLO 205
|
IC50 |
1.43 μM
Compound: Doxorubicin
|
Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 31546197]
|
COLO 205
|
IC50 |
1.5 μM
Compound: Doxorubicin
|
Antitumor activity against human COLO205 cells after 24 to 48 hrs by MTT assay
Antitumor activity against human COLO205 cells after 24 to 48 hrs by MTT assay
|
[PMID: 21553829]
|
COLO 205
|
IC50 |
|
Anticancer activity against human COLO205 cells after 48 hrs by MTT assay
Anticancer activity against human COLO205 cells after 48 hrs by MTT assay
|
[PMID: 22209733]
|
COLO 205
|
GI50 |
|
Anticancer activity against human COLO205 cells by SRB method
Anticancer activity against human COLO205 cells by SRB method
|
[PMID: 22104151]
|
COLO 205
|
IC50 |
|
Cytotoxicity against human Colo205 cells by SRB assay
Cytotoxicity against human Colo205 cells by SRB assay
|
[PMID: 18656370]
|
COLO 205
|
IC50 |
|
Cytotoxicity against human Colo205 cells by sulforhodamine B assay
Cytotoxicity against human Colo205 cells by sulforhodamine B assay
|
[PMID: 17822905]
|
COLO 205
|
IC50 |
2.1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition by MTT assay
Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition by MTT assay
|
[PMID: 34838335]
|
COLO 205
|
IC50 |
2.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 35293752]
|
COLO 205
|
IC50 |
|
Cytotoxicity against human COLO205 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Cytotoxicity against human COLO205 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 31589431]
|
COLO 320
|
IC50 |
7.4 μM
Compound: Doxorubicin
|
Cytotoxicity against human COLO 320 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human COLO 320 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 35293752]
|
COR-L23
|
IC50 |
20.1 nM
Compound: Doxorubicin
|
Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line
Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line
|
[PMID: 11806724]
|
COS-7
|
IC50 |
2.05 μM
Compound: Doxorubicin
|
Cytotoxicity against African green monkey COS7 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against African green monkey COS7 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 31404864]
|
COS-7
|
IC50 |
3.04 μM
Compound: Doxorubicin
|
Growth inhibition of African green monkey COS7 cells by MTT assay
Growth inhibition of African green monkey COS7 cells by MTT assay
|
[PMID: 28147307]
|
CRL-7065 cell line
|
EC50 |
0.9 μM
Compound: Doxorubicin
|
Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay
Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay
|
[PMID: 26320088]
|
CWR22R
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
|
[PMID: 34851111]
|
CWR22R
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay
|
[PMID: 28617598]
|
CWR22R
|
IC50 |
6.32 μM
Compound: Doxorubicin
|
Growth inhibition of human 22Rv1 cells after 48 hrs by MTT assay
Growth inhibition of human 22Rv1 cells after 48 hrs by MTT assay
|
[PMID: 30072225]
|
DA-3 cell line
|
IC50 |
|
Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay
Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay
|
[PMID: 24900668]
|
Daoy
|
GI50 |
0.016 μM
Compound: Doxorubicin
|
Antiproliferative activity against human DaOY cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human DaOY cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 30360625]
|
Daoy
|
IC50 |
0.0629 μM
Compound: Doxorubicin
|
Antiproliferative activity against human Daoy cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human Daoy cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 34325324]
|
Daoy
|
IC50 |
|
Cytotoxicity against human DaOY cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue cell viability assay
Cytotoxicity against human DaOY cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue cell viability assay
|
[PMID: 31347843]
|
Daudi
|
IC50 |
|
Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay
Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay
|
[PMID: 25998504]
|
Daudi
|
IC50 |
0.3 μM
Compound: adriamycin
|
Cytotoxicity against human Daudi cells under deem light after 96 hrs by MTT assay
Cytotoxicity against human Daudi cells under deem light after 96 hrs by MTT assay
|
[PMID: 17993275]
|
Detroit 562
|
IC50 |
1.26 μM
Compound: Doxorubicin
|
Cytotoxicity against human Detroit 562 cells assessed as reduction in cell viability after 4 hrs by MTT assay
Cytotoxicity against human Detroit 562 cells assessed as reduction in cell viability after 4 hrs by MTT assay
|
[PMID: 30773423]
|
DLD-1
|
ED50 |
0.1 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human DLD1 cells after 3 days by MTT assay
Cytotoxicity against human DLD1 cells after 3 days by MTT assay
|
[PMID: 16252910]
|
DLD-1
|
IC50 |
0.1 μM
Compound: adriamycin
|
Antitumor activity against human DLD1 cells by methylene blue staining method
Antitumor activity against human DLD1 cells by methylene blue staining method
|
[PMID: 17656091]
|
DLD-1
|
ED50 |
0.57 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human DLD1 cells by MTT assay
Cytotoxicity against human DLD1 cells by MTT assay
|
[PMID: 15104488]
|
DLD-1
|
IC50 |
|
Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay
Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay
|
[PMID: 25247771]
|
DLD-1
|
IC50 |
10.2 μM
Compound: Doxorubicin
|
Anticancer activity against human DLD-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Anticancer activity against human DLD-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 30772606]
|
DLD-1
|
IC50 |
145 nM
Compound: Doxorubicin
|
Cytotoxicity against human DLD1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human DLD1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 30429975]
|
DLD-1
|
IC50 |
2.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human DLD1 cells by Alamar Blue assay
Cytotoxicity against human DLD1 cells by Alamar Blue assay
|
[PMID: 27536968]
|
DLD-1
|
IC50 |
2.78 μM
Compound: Doxorubicin
|
Cytotoxicity against human DLD1 cells after 72 hrs by alamar blue assay
Cytotoxicity against human DLD1 cells after 72 hrs by alamar blue assay
|
[PMID: 28159416]
|
DLD-1
|
IC50 |
2.78 μM
Compound: Doxorubicin
|
Cytotoxicity against human DLD1 cells by Alamar blue assay
Cytotoxicity against human DLD1 cells by Alamar blue assay
|
[PMID: 27256910]
|
DU-145
|
GI50 |
< 0.01 μM
Compound: Doxorubicin
|
Growth inhibition of human DU145 cells after 48 hrs by SRB assay
Growth inhibition of human DU145 cells after 48 hrs by SRB assay
|
10.1039/C6MD00097E
|
DU-145
|
GI50 |
< 0.01 μM
Compound: Doxorubicin
|
Growth inhibition in human DU145 cells after 48 hrs by SRB assay
Growth inhibition in human DU145 cells after 48 hrs by SRB assay
|
[PMID: 31546197]
|
DU-145
|
GI50 |
|
Cytotoxicity against 10'5 CFU/mL human DU145 cells after 48 hrs by SRB assay
Cytotoxicity against 10'5 CFU/mL human DU145 cells after 48 hrs by SRB assay
|
[PMID: 21794959]
|
DU-145
|
IC50 |
< 2.94 μM
Compound: Doxorubicin
|
Inhibition of proliferation of human DU145 cells after 72 hrs by XTT assay
Inhibition of proliferation of human DU145 cells after 72 hrs by XTT assay
|
[PMID: 20810194]
|
DU-145
|
IC50 |
0.01 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as cell survival after 24 hrs by XTT assay
Cytotoxicity against human DU145 cells assessed as cell survival after 24 hrs by XTT assay
|
[PMID: 25059501]
|
DU-145
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
|
[PMID: 25937235]
|
DU-145
|
IC50 |
|
Cytotoxicity against human DU145 cells measured after 72 hrs by Celltiter-Glo assay
Cytotoxicity against human DU145 cells measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31820976]
|
DU-145
|
GI50 |
0.06 μM
Compound: Doxorubicin
|
Growth inhibition of human DU145 cells after 72 hrs by SRB assay
Growth inhibition of human DU145 cells after 72 hrs by SRB assay
|
[PMID: 18585035]
|
DU-145
|
IC50 |
|
Antiproliferative activity against human DU145 cells after 72 hrs by Sulforhodamine B-stain assay
Antiproliferative activity against human DU145 cells after 72 hrs by Sulforhodamine B-stain assay
|
[PMID: 27484508]
|
DU-145
|
IC50 |
0.1 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
|
[PMID: 19361894]
|
DU-145
|
GI50 |
0.1081 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 31534659]
|
DU-145
|
GI50 |
0.11 μM
Compound: Doxorubicin hydrochloride, NSC 123127
|
Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
|
[PMID: 23871905]
|
DU-145
|
GI50 |
0.11 μM
Compound: Doxorubicin
|
Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29102177]
|
DU-145
|
GI50 |
0.11 μM
Compound: Doxorubicin
|
Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28329730]
|
DU-145
|
IC50 |
0.12 μM
Compound: Doxorubicin
|
Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay
|
[PMID: 25799376]
|
DU-145
|
IC50 |
0.13 μM
Compound: doxorubicin
|
Cytotoxicity against human DU145 cells by SRB microtiter plate assay
Cytotoxicity against human DU145 cells by SRB microtiter plate assay
|
[PMID: 17585747]
|
DU-145
|
GI50 |
0.134 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay
Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 31059248]
|
DU-145
|
IC50 |
|
Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108718]
|
DU-145
|
IC50 |
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 23218718]
|
DU-145
|
IC50 |
0.2 μM
Compound: DOX, Doxorubicin
|
Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay
Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay
|
[PMID: 24095089]
|
DU-145
|
EC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells after 96 hrs by MTT assay
Cytotoxicity against human DU145 cells after 96 hrs by MTT assay
|
[PMID: 26320088]
|
DU-145
|
IC50 |
0.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU-145 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
Cytotoxicity against human DU-145 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
|
[PMID: 36970146]
|
DU-145
|
GI50 |
0.35 μM
Compound: Doxorubicin
|
Growth inhibition of human DU145 cells after 2 days by MTT assay
Growth inhibition of human DU145 cells after 2 days by MTT assay
|
[PMID: 20138760]
|
DU-145
|
IC50 |
0.363 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
|
[PMID: 30654238]
|
DU-145
|
IC50 |
0.4 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 30660827]
|
DU-145
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25655719]
|
DU-145
|
IC50 |
0.52 μM
Compound: adriamycin
|
Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay
Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay
|
[PMID: 25936262]
|
DU-145
|
IC50 |
0.53 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 24530030]
|
DU-145
|
IC50 |
|
Cytotoxicity in human DU-145 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
Cytotoxicity in human DU-145 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
|
[PMID: 33064004]
|
DU-145
|
IC50 |
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 21885273]
|
DU-145
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells by MTT assay
Cytotoxicity against human DU145 cells by MTT assay
|
[PMID: 26586599]
|
DU-145
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells by MTT assay
Cytotoxicity against human DU145 cells by MTT assay
|
[PMID: 25172418]
|
DU-145
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells by MTT assay
Cytotoxicity against human DU145 cells by MTT assay
|
[PMID: 24300737]
|
DU-145
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells incubated for 24 hrs by MTT asasy
Cytotoxicity against human DU145 cells incubated for 24 hrs by MTT asasy
|
[PMID: 28615134]
|
DU-145
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as cell growth inhibition by MTT assay
Cytotoxicity against human DU145 cells assessed as cell growth inhibition by MTT assay
|
[PMID: 27187861]
|
DU-145
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 26774921]
|
DU-145
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 26646219]
|
DU-145
|
IC50 |
0.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells by MTT assay
Cytotoxicity against human DU145 cells by MTT assay
|
[PMID: 25241926]
|
DU-145
|
IC50 |
0.86 μM
Compound: Adriamycin
|
Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
|
[PMID: 25481396]
|
DU-145
|
IC50 |
0.86 μM
Compound: Adriamycin
|
Cytotoxicity against human DU145 cells after 2 days
Cytotoxicity against human DU145 cells after 2 days
|
[PMID: 22318164]
|
DU-145
|
IC50 |
0.895 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28462842]
|
DU-145
|
IC50 |
0.95 μM
Compound: Adriamycin
|
Cytotoxicity against human DU145 cells after 2 days by CCK8 assay
Cytotoxicity against human DU145 cells after 2 days by CCK8 assay
|
[PMID: 26361737]
|
DU-145
|
GI50 |
0.95 μM
Compound: Doxorubicin
|
Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay
Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay
|
[PMID: 26163220]
|
DU-145
|
IC50 |
1 μM
Compound: Adriamycin
|
Cytotoxicity against human DU145 cells after 2 days
Cytotoxicity against human DU145 cells after 2 days
|
[PMID: 21601964]
|
DU-145
|
IC50 |
1.08 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 26948541]
|
DU-145
|
IC50 |
1.1 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by XTT assay
Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by XTT assay
|
[PMID: 33540356]
|
DU-145
|
IC50 |
1.1 μM
Compound: Adriamycin
|
Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis
Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis
|
[PMID: 22503656]
|
DU-145
|
IC50 |
1.3 μM
Compound: Doxorubicin
|
Anticancer activity against human DU145 cells after 48 hrs by MTT assay
Anticancer activity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 25615796]
|
DU-145
|
IC50 |
1.38 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 26264845]
|
DU-145
|
IC50 |
1.4 μM
Compound: Doxorubicin
|
Anticancer activity against human DU-145 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
Anticancer activity against human DU-145 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 34363936]
|
DU-145
|
IC50 |
1.41 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 27015609]
|
DU-145
|
IC50 |
1.428 μM
Compound: Doxorubicin
|
Anti-proliferative activity against human DU145 cells measured after 48 hrs by MTT assay
Anti-proliferative activity against human DU145 cells measured after 48 hrs by MTT assay
|
[PMID: 27744185]
|
DU-145
|
IC50 |
|
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
|
[PMID: 22819942]
|
DU-145
|
IC50 |
1.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
[PMID: 27496212]
|
DU-145
|
IC50 |
1.622 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28482219]
|
DU-145
|
IC50 |
1.75 μM
Compound: Adriamycin
|
Cytotoxicity against human DU145 cells by MTT assay
Cytotoxicity against human DU145 cells by MTT assay
|
[PMID: 21115246]
|
DU-145
|
IC50 |
1.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay
|
[PMID: 33421712]
|
DU-145
|
IC50 |
1.807 μM
Compound: Doxorubicin
|
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 29501940]
|
DU-145
|
IC50 |
1.82 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26708114]
|
DU-145
|
IC50 |
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 29289881]
|
DU-145
|
IC50 |
1.9 μM
Compound: Adriamycin
|
Cytotoxicity against human DU145 cells after 4 days by MTT assay
Cytotoxicity against human DU145 cells after 4 days by MTT assay
|
[PMID: 21704436]
|
DU-145
|
IC50 |
1.909 μM
Compound: Doxorubicin
|
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 26301558]
|
DU-145
|
IC50 |
1.91 μM
Compound: Doxorubicin
|
Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay
Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay
|
[PMID: 28923381]
|
DU-145
|
IC50 |
1.94 μM
Compound: Doxorubicin
|
Anticancer activity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Anticancer activity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 26330077]
|
DU-145
|
IC50 |
10.86 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 22818039]
|
DU-145
|
IC50 |
12.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 21429743]
|
DU-145
|
IC50 |
13.24 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
|
[PMID: 22687747]
|
DU-145
|
IC50 |
17.67 μM
Compound: Doxorubicin
|
Anticancer activity against human DU145 cells by MTT assay
Anticancer activity against human DU145 cells by MTT assay
|
[PMID: 25743216]
|
DU-145
|
IC50 |
|
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 29129513]
|
DU-145
|
IC50 |
2.4 μM
Compound: Doxorubicin
|
Anticancer activity against human DU145 cells by MTT assay
Anticancer activity against human DU145 cells by MTT assay
|
10.1039/C4MD00219A
|
DU-145
|
IC50 |
2.4 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
|
[PMID: 28818768]
|
DU-145
|
IC50 |
2.45 μM
Compound: Doxo (I)
|
Antiproliferative activity against human DU145 cells by MTT assay
Antiproliferative activity against human DU145 cells by MTT assay
|
10.1039/C4MD00228H
|
DU-145
|
IC50 |
2.49 μM
Compound: Doxorubicin
|
Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 26542964]
|
DU-145
|
IC50 |
|
Antiproliferative activity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32631552]
|
DU-145
|
IC50 |
2.68 μM
Compound: Adriamycin
|
Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay
|
[PMID: 24013413]
|
DU-145
|
IC50 |
23.48 μM
Compound: Adriamycin
|
Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
|
[PMID: 22276650]
|
DU-145
|
IC50 |
3.11 μM
Compound: Doxorubicin
|
Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31883489]
|
DU-145
|
IC50 |
|
Cytotoxicity against human DU145 cells after 48 hrs by SRB method
Cytotoxicity against human DU145 cells after 48 hrs by SRB method
|
[PMID: 25933593]
|
DU-145
|
IC50 |
3.27 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells after 72 hrs by XTT assay
Cytotoxicity against human DU145 cells after 72 hrs by XTT assay
|
10.1007/s00044-013-0558-8
|
DU-145
|
IC50 |
3.9 nM
Compound: doxorubicin
|
Anticancer activity against human DU145 cells after 72 hrs by XTT assay
Anticancer activity against human DU145 cells after 72 hrs by XTT assay
|
[PMID: 18829316]
|
DU-145
|
IC50 |
4.06 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 25462233]
|
DU-145
|
IC50 |
4.75 μM
Compound: Doxorubicin
|
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 26907155]
|
DU-145
|
IC50 |
|
Cytotoxicity against human DU145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 31589431]
|
DU-145
|
IC50 |
|
Cytotoxicity against human DU145 cells after 2 days
Cytotoxicity against human DU145 cells after 2 days
|
[PMID: 24904965]
|
DU-145
|
IC50 |
5.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25594739]
|
DU-145
|
IC50 |
|
Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay
|
10.1039/C5MD00513B
|
DU-145
|
IC50 |
|
Cytotoxicity against human androgen-independent DU145 cells by MTT assay
Cytotoxicity against human androgen-independent DU145 cells by MTT assay
|
[PMID: 22326399]
|
DU-145
|
IC50 |
6 μM
Compound: doxorubicin
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 23748152]
|
DU-145
|
IC50 |
|
Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
|
[PMID: 21885273]
|
DU-145
|
IC50 |
8.19 μM
Compound: Doxorubicin
|
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 24607876]
|
EA.hy 926
|
IC50 |
4.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 27843113]
|
EBC-1
|
IC50 |
305.1 nM
Compound: Doxorubicin
|
Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay
Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay
|
[PMID: 28412159]
|
ECa-109 cell line
|
IC50 |
2.06 μM
Compound: Doxorubicin
|
Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32866757]
|
Ehrlich
|
IC50 |
> 10 μM
Compound: doxorubicin
|
Cytotoxicity against mouse Ehrlich ascites carcinoma cells after 24 hrs by MTT assay
Cytotoxicity against mouse Ehrlich ascites carcinoma cells after 24 hrs by MTT assay
|
[PMID: 18281125]
|
Ehrlich
|
IC50 |
> 10 μM
Compound: doxorubicin
|
Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay
Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay
|
[PMID: 17400463]
|
Ehrlich
|
IC50 |
0.35 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse EAC after 3 days by MTT assay
Cytotoxicity against mouse EAC after 3 days by MTT assay
|
[PMID: 8350087]
|
Ehrlich
|
IC50 |
37.4 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against mouse EAC cells assessed as cell growth inhibition measured after 2 hrs by trypan blue exclusion assay
Cytotoxicity against mouse EAC cells assessed as cell growth inhibition measured after 2 hrs by trypan blue exclusion assay
|
[PMID: 27894044]
|
Ehrlich
|
IC50 |
37.5 μg/mL
Compound: Doxorubicin
|
Antitumor activity against mouse EAC cells assessed as non viable cells after 2 hrs by trypan blue exclusion test
Antitumor activity against mouse EAC cells assessed as non viable cells after 2 hrs by trypan blue exclusion test
|
[PMID: 20149941]
|
Ehrlich
|
IC50 |
38 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against mouse EAC assessed as non-viable cells after 2 hrs by trypan blue exclusion test
Cytotoxicity against mouse EAC assessed as non-viable cells after 2 hrs by trypan blue exclusion test
|
[PMID: 21112675]
|
Ehrlich
|
IC50 |
38 μg/mL
Compound: doxorubicin
|
Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion
Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion
|
[PMID: 19944497]
|
Ehrlich
|
IC50 |
4.18 μM
Compound: doxorubicin
|
Cytotoxicity against mouse EAC after 24 hrs by MTT assay
Cytotoxicity against mouse EAC after 24 hrs by MTT assay
|
[PMID: 19128861]
|
Ehrlich
|
IC50 |
5.22 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay
Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay
|
[PMID: 22542958]
|
Ehrlich
|
IC50 |
52 μg/mL
Compound: Doxorubicin
|
Antitumor activity against mouse EAC after 2 hrs by trypan blue exclusion assay
Antitumor activity against mouse EAC after 2 hrs by trypan blue exclusion assay
|
[PMID: 19853327]
|
Ehrlich
|
IC50 |
69.9 μM
Compound: Doxorubicin
|
Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion assay
Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion assay
|
[PMID: 20413187]
|
EKVX
|
GI50 |
0.41 μM
Compound: Doxorubicin hydrochloride, NSC 123127
|
Cytotoxicity against human EKVX cells after 48 hrs by SRB assay
Cytotoxicity against human EKVX cells after 48 hrs by SRB assay
|
[PMID: 23871905]
|
EKVX
|
GI50 |
0.41 μM
Compound: Doxorubicin
|
Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29102177]
|
EKVX
|
GI50 |
0.41 μM
Compound: Doxorubicin
|
Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28329730]
|
EL4
|
IC50 |
0.67 μg/mL
Compound: (20) adriamycin
|
In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay
In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay
|
[PMID: 12620075]
|
EMT6
|
ED50 |
< 0.0001 μM
Compound: Adriamycin
|
Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.
Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.
|
[PMID: 7452674]
|
EMT6
|
ED50 |
0.012 μM
Compound: Adriamycin
|
Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.
Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.
|
[PMID: 7452674]
|
EOL1
|
IC50 |
0.001269 μM
Compound: Doxorubicin
|
Antiproliferative activity against human EOL1 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay
Antiproliferative activity against human EOL1 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay
|
[PMID: 30540463]
|
Epithelial cell
|
IC50 |
9.787 nM
Compound: Doxorubicin
|
Cytotoxicity against albino rat epithelial rat by MTT assay
Cytotoxicity against albino rat epithelial rat by MTT assay
|
[PMID: 34116327]
|
Erythrocyte
|
EC50 |
> 200 μg/mL
Compound: Dox
|
Hemolytic toxicity in mouse erythrocytes assessed as induction of cell membrane disruption incubated for 30 mins by hemoglobin release based spectrophotometry
Hemolytic toxicity in mouse erythrocytes assessed as induction of cell membrane disruption incubated for 30 mins by hemoglobin release based spectrophotometry
|
[PMID: 25147145]
|
Erythrocyte
|
EC50 |
> 50 μg/mL
Compound: DOXO
|
Toxicity in mouse erythrocytes assessed as hemolytic activity after 30 mins by spectrophotometry
Toxicity in mouse erythrocytes assessed as hemolytic activity after 30 mins by spectrophotometry
|
[PMID: 19947600]
|
F460pv8/eto
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Inhibitory activity against F460pv8/eto cell line using MTT assay
Inhibitory activity against F460pv8/eto cell line using MTT assay
|
[PMID: 10780913]
|
FaDu
|
IC50 |
|
Antiproliferative activity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 36709571]
|
FaDu
|
IC50 |
0.68 μM
Compound: Doxorubicin
|
Cytotoxicity against human FADU cells assessed as reduction in cell viability after 4 hrs by MTT assay
Cytotoxicity against human FADU cells assessed as reduction in cell viability after 4 hrs by MTT assay
|
[PMID: 30773423]
|
Fibroblast
|
IC50 |
0.005 μM
Compound: Doxorubicin
|
Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216]
|
Fibroblast
|
IC50 |
0.015 μM
Compound: Doxorubicine
|
Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908]
|
Fibroblast
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs
Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs
|
[PMID: 34601029]
|
Fibroblast
|
IC50 |
0.03 μM
Compound: Doxorubicin
|
Toxicity in human skin fibroblasts assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
Toxicity in human skin fibroblasts assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
|
[PMID: 31753515]
|
Fibroblast
|
IC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity in human Fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity in human Fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 34082225]
|
Fibroblast
|
IC50 |
1.3 x 10 -11 μM
Compound: Doxo
|
Cytotoxicity against human gingival fibroblast cells after 48 hrs by alamar blue assay
Cytotoxicity against human gingival fibroblast cells after 48 hrs by alamar blue assay
|
[PMID: 25468043]
|
Fibroblast
|
IC50 |
67 μM
Compound: Doxorubicin
|
Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay
|
[PMID: 36691388]
|
Fibroblast
|
IC50 |
7.86 μM
Compound: Doxorubicin
|
Antiproliferative activity against human dermal fibroblast cells after 72 hrs
Antiproliferative activity against human dermal fibroblast cells after 72 hrs
|
[PMID: 25127463]
|
G-361
|
GI50 |
< 1 x 10 -1 μM
Compound: ADR
|
Cytotoxicity against Homo sapiens (human) G361 cells by SRB assay
Cytotoxicity against Homo sapiens (human) G361 cells by SRB assay
|
10.1007/s00044-012-0084-0
|
G-361
|
IC50 |
|
Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay
Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay
|
[PMID: 31869654]
|
G-361
|
IC50 |
|
Antiproliferative activity against human G361 cell line by MTT assay
Antiproliferative activity against human G361 cell line by MTT assay
|
[PMID: 16913700]
|
GES1
|
IC50 |
|
Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay
Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay
|
[PMID: 25462264]
|
GOTO
|
IC50 |
4.73 nM
Compound: Doxorubicin
|
Cytotoxicity against human GOTO cells after 3 days by MTT assay
Cytotoxicity against human GOTO cells after 3 days by MTT assay
|
[PMID: 20356655]
|
GOTO
|
IC50 |
4.73 nM
Compound: Doxorubicin
|
Cytotoxicity against human GOTO cells by MTT assay
Cytotoxicity against human GOTO cells by MTT assay
|
[PMID: 19345581]
|
H22
|
IC50 |
36.51 μM
Compound: Doxorubicin
|
Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
|
[PMID: 21620529]
|
H69AR
|
IC50 |
< 1 μM
Compound: Doxorubicin
|
Cytotoxicity against human NCI-H69AR cells assessed as reduction in cell growth by MTT assay
Cytotoxicity against human NCI-H69AR cells assessed as reduction in cell growth by MTT assay
|
[PMID: 36734533]
|
HA22T cell line
|
IC50 |
0.31 μM
Compound: adriamycin
|
Cytotoxicity against human HA22T cells after 72 hrs by MTT assay
Cytotoxicity against human HA22T cells after 72 hrs by MTT assay
|
[PMID: 17107806]
|
HaCaT
|
GI50 |
< 0.025 μg/mL
Compound: DOX; Doxo
|
Cytotoxicity against human HaCaT cells after 48 hrs by SRB assay
Cytotoxicity against human HaCaT cells after 48 hrs by SRB assay
|
[PMID: 26859070]
|
HaCaT
|
GI50 |
|
Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26454648]
|
HaCaT
|
GI50 |
< 0.046 μM
Compound: Doxorubicin
|
Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay
|
[PMID: 33214037]
|
HaCaT
|
IC50 |
0.01 μM
Compound: Doxorubicin
|
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 4 days by CellTiter 96 aqueous one solution assay
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 4 days by CellTiter 96 aqueous one solution assay
|
[PMID: 31596585]
|
HaCaT
|
IC50 |
|
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30615450]
|
HaCaT
|
IC50 |
0.03 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216]
|
HaCaT
|
GI50 |
|
Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 25062010]
|
HaCaT
|
GI50 |
|
Growth inhibition of human HaCaT cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
Growth inhibition of human HaCaT cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay
|
[PMID: 28505535]
|
HaCaT
|
IC50 |
0.23 μM
Compound: Doxorubicin
|
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 31753514]
|
HaCaT
|
IC50 |
0.235 μM
Compound: Doxorubicin
|
Cytotoxicity against human HaCaT cells assessed as growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human HaCaT cells assessed as growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 31383628]
|
HaCaT
|
IC50 |
|
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31678743]
|
HaCaT
|
IC50 |
0.52 μM
Compound: Doxorubicin
|
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30389295]
|
HaCaT
|
IC50 |
0.53 μM
Compound: Doxorubicin
|
Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 26934105]
|
HaCaT
|
GI50 |
|
Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 35533562]
|
HaCaT
|
GI50 |
|
Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 34634616]
|
HaCaT
|
GI50 |
|
Antiproliferative activity against human HaCaT cells incubated for 72 hrs and measured by MTT assay
Antiproliferative activity against human HaCaT cells incubated for 72 hrs and measured by MTT assay
|
[PMID: 35973342]
|
HaCaT
|
IC50 |
|
Cytotoxicity activity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity activity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30031974]
|
HaCaT
|
IC50 |
3.26 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HaCaT cells assessed as cell shrinkage after 24 hrs by SRB assay
Cytotoxicity against human HaCaT cells assessed as cell shrinkage after 24 hrs by SRB assay
|
[PMID: 24269165]
|
HaCaT
|
IC50 |
50 μM
Compound: Doxorubicin
|
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
|
[PMID: 35271771]
|
HBL-100
|
IC50 |
0.08 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HBL100 cells after 70 hrs by alamar blue assay
Antiproliferative activity against human HBL100 cells after 70 hrs by alamar blue assay
|
[PMID: 29471119]
|
HBL-100
|
IC50 |
0.24 μM
Compound: Doxorubicin
|
Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay
Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay
|
[PMID: 19361894]
|
HBL-100
|
IC50 |
8.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human HBL100 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
Cytotoxicity against human HBL100 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
|
[PMID: 29471119]
|
HCC 2998
|
GI50 |
0.26 μM
Compound: Doxorubicin hydrochloride, NSC 123127
|
Cytotoxicity against human HCC2998 cells after 48 hrs by SRB assay
Cytotoxicity against human HCC2998 cells after 48 hrs by SRB assay
|
[PMID: 23871905]
|
HCC 2998
|
GI50 |
0.26 μM
Compound: Doxorubicin
|
Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29102177]
|
HCC 2998
|
GI50 |
0.26 μM
Compound: Doxorubicin
|
Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28329730]
|
HCC1937
|
IC50 |
0.44 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCC1937 cells after 48 hrs by SRB assay
Antiproliferative activity against human HCC1937 cells after 48 hrs by SRB assay
|
[PMID: 29407962]
|
HCC1954
|
IC50 |
|
Cytotoxicity against human HCC1954 cells measured after 72 hrs by Celltiter-Glo assay
Cytotoxicity against human HCC1954 cells measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31820976]
|
HCC70
|
IC50 |
0.05 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCC70 cells assessed as growth inhibition after 72 hrs by SRB assay
Cytotoxicity against human HCC70 cells assessed as growth inhibition after 72 hrs by SRB assay
|
[PMID: 30457333]
|
HCT-116
|
GI50 |
|
Antiproliferative activity against human HCT116 cells by MTT assay
Antiproliferative activity against human HCT116 cells by MTT assay
|
[PMID: 31990554]
|
HCT-116
|
IC50 |
< 1 μM
Compound: doxorubicin
|
Cytotoxicity against human HCT-116 cells by SRB assay
Cytotoxicity against human HCT-116 cells by SRB assay
|
[PMID: 33847126]
|
HCT-116
|
IC50 |
> 8 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 31836446]
|
HCT-116
|
IC50 |
0.007 ug
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by SRB assay
Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by SRB assay
|
[PMID: 27393950]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27668963]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay
|
[PMID: 31431364]
|
HCT-116
|
GI50 |
0.011 μM
Compound: Doxorubicin
|
Cytostatic activity against human HCT116 cells after 5 days by SRB assay
Cytostatic activity against human HCT116 cells after 5 days by SRB assay
|
[PMID: 21711054]
|
HCT-116
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
10.1039/C4MD00371C
|
HCT-116
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 24530030]
|
HCT-116
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
|
[PMID: 25937235]
|
HCT-116
|
IC50 |
0.023 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 31264855]
|
HCT-116
|
GI50 |
0.023 μM
Compound: Doxorubicin
|
Tested for in vitro concentration required to inhibit growth by 50% against HCT116 human colon cancer cell line
Tested for in vitro concentration required to inhibit growth by 50% against HCT116 human colon cancer cell line
|
[PMID: 11755363]
|
HCT-116
|
IC50 |
0.037 μM
Compound: adriamycin
|
Antitumor activity against human HCT116 cells by methylene blue staining method
Antitumor activity against human HCT116 cells by methylene blue staining method
|
[PMID: 17656091]
|
HCT-116
|
IC50 |
0.05 μM
Compound: Doxorubicine
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908]
|
HCT-116
|
IC50 |
0.05 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216]
|
HCT-116
|
IC50 |
0.069 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 25462279]
|
HCT-116
|
IC50 |
0.07 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 27060757]
|
HCT-116
|
IC50 |
0.07 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 20846862]
|
HCT-116
|
IC50 |
0.07 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 27448912]
|
HCT-116
|
IC50 |
0.07 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 24780599]
|
HCT-116
|
GI50 |
0.08 μM
Compound: Doxorubicin hydrochloride, NSC 123127
|
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
|
[PMID: 23871905]
|
HCT-116
|
GI50 |
0.08 μM
Compound: Doxorubicin
|
Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29102177]
|
HCT-116
|
GI50 |
0.08 μM
Compound: Doxorubicin
|
Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28329730]
|
HCT-116
|
IC50 |
0.08 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs
|
[PMID: 34601029]
|
HCT-116
|
IC50 |
0.09 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
|
[PMID: 21215623]
|
HCT-116
|
IC50 |
0.09 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay
|
[PMID: 32755677]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 29459273]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay
|
[PMID: 31784322]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells measured after 72 hrs by Celltiter-Glo assay
Cytotoxicity against human HCT116 cells measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31820976]
|
HCT-116
|
IC50 |
0.1 μM
Compound: Doxorubicin
|
Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 34082225]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 30659997]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 29137865]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 26890118]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 27016707]
|
HCT-116
|
IC50 |
0.1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT reduction assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT reduction assay
|
[PMID: 28551177]
|
HCT-116
|
IC50 |
0.1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method
|
[PMID: 25937235]
|
HCT-116
|
IC50 |
0.11 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 31836446]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 26633734]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 21144624]
|
HCT-116
|
IC50 |
0.12 μM
Compound: Doxorubicin
|
Toxicity in human HCT-116 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
Toxicity in human HCT-116 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay
|
[PMID: 31753515]
|
HCT-116
|
GI50 |
0.13 μM
Compound: Doxorubicine
|
Growth inhibition of human HCT116 cells after 2 days by sulforhodamine B assay
Growth inhibition of human HCT116 cells after 2 days by sulforhodamine B assay
|
[PMID: 20045222]
|
HCT-116
|
IC50 |
0.15 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27341379]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 26142490]
|
HCT-116
|
GI50 |
0.15 μM
Compound: Adriamycin
|
Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24686011]
|
HCT-116
|
GI50 |
0.15 μM
Compound: Adriamycin
|
Growth inhibition of human HCT116 cells by sulforhodamine B assay
Growth inhibition of human HCT116 cells by sulforhodamine B assay
|
[PMID: 24650643]
|
HCT-116
|
EC50 |
0.16 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 35567964]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 21444205]
|
HCT-116
|
IC50 |
0.18 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 26280922]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 25998504]
|
HCT-116
|
IC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxic activity against human HCT116 cells incubated for 48 hrs by MTT assay
Cytotoxic activity against human HCT116 cells incubated for 48 hrs by MTT assay
|
[PMID: 28055219]
|
HCT-116
|
IC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 36044031]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 32428792]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells by SRB method
Cytotoxicity against human HCT116 cells by SRB method
|
[PMID: 29144133]
|
HCT-116
|
IC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells by SRB assay
Cytotoxicity against human HCT116 cells by SRB assay
|
[PMID: 26561719]
|
HCT-116
|
IC50 |
|
Cytotoxic activity against human HCT116 cells by SRB method
Cytotoxic activity against human HCT116 cells by SRB method
|
[PMID: 25611519]
|
HCT-116
|
IC50 |
0.21 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 34778772]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 33479619]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29660689]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 28818447]
|
HCT-116
|
IC50 |
0.21 μM
Compound: Adriamycin
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 24370114]
|
HCT-116
|
IC50 |
0.22 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 31836446]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108718]
|
HCT-116
|
IC50 |
0.23 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition by MTT assay
|
[PMID: 24398294]
|
HCT-116
|
IC50 |
0.24 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 48 hrs by neutral red dye based assay
Cytotoxicity against human HCT116 cells after 48 hrs by neutral red dye based assay
|
[PMID: 29317147]
|
HCT-116
|
IC50 |
0.25 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells incubated for 48 hrs by WST8 assay
Antiproliferative activity against human HCT116 cells incubated for 48 hrs by WST8 assay
|
[PMID: 31679979]
|
HCT-116
|
IC50 |
0.25 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 48 hrs by WST8 assay
Cytotoxicity against human HCT116 cells after 48 hrs by WST8 assay
|
[PMID: 25163667]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 31999451]
|
HCT-116
|
IC50 |
0.286 μg/mL
Compound: DOX
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 20722446]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against doxorubicin sensitive human HCT-116 cells measured after 72 hrs by MTT assay
Antiproliferative activity against doxorubicin sensitive human HCT-116 cells measured after 72 hrs by MTT assay
|
[PMID: 35612499]
|
HCT-116
|
EC50 |
0.29 μM
Compound: Doxorubicin
|
Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs
Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs
|
[PMID: 19282188]
|
HCT-116
|
IC50 |
0.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
|
[PMID: 31403289]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT-116 assessed as growth inhibition measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 assessed as growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 34902732]
|
HCT-116
|
IC50 |
0.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 22749279]
|
HCT-116
|
IC50 |
0.31 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28327308]
|
HCT-116
|
IC50 |
0.31 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 27886545]
|
HCT-116
|
IC50 |
0.33 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as effect on cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as effect on cell viability measured after 48 hrs by MTT assay
|
[PMID: 27521588]
|
HCT-116
|
IC50 |
0.34 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
|
[PMID: 33261897]
|
HCT-116
|
IC50 |
0.34 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT 116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
Antiproliferative activity against human HCT 116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
|
[PMID: 31962262]
|
HCT-116
|
IC50 |
0.34 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells expressing wild type p53 incubated for 72 hrs by MTS assay
Cytotoxicity against human HCT116 cells expressing wild type p53 incubated for 72 hrs by MTS assay
|
[PMID: 31158748]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against p53 expressing human HCT116 cells after 96 hrs by MTS assay
Antiproliferative activity against p53 expressing human HCT116 cells after 96 hrs by MTS assay
|
[PMID: 26890119]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 25247771]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay
|
[PMID: 35612499]
|
HCT-116
|
IC50 |
0.36 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 27080182]
|
HCT-116
|
IC50 |
0.38 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells deficient in p53 incubated for 72 hrs by MTS assay
Cytotoxicity against human HCT116 cells deficient in p53 incubated for 72 hrs by MTS assay
|
[PMID: 31158748]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against p53 deficient human HCT116 cells after 96 hrs by MTS assay
Antiproliferative activity against p53 deficient human HCT116 cells after 96 hrs by MTS assay
|
[PMID: 26890119]
|
HCT-116
|
IC50 |
0.38 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by SRB assay
Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 26947606]
|
HCT-116
|
GI50 |
0.4 μM
Compound: Doxorubicin
|
Growth inhibition of human HCT116 cells after 2 days by MTT assay
Growth inhibition of human HCT116 cells after 2 days by MTT assay
|
[PMID: 20570145]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 30429098]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells by MTT assay
Cytotoxicity against human HCT116 cells by MTT assay
|
[PMID: 21983438]
|
HCT-116
|
IC50 |
0.4 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
|
10.1039/C0MD00219D
|
HCT-116
|
IC50 |
0.41 μM
Compound: adriamycin
|
Cytotoxicity against human HCT116 cells by MTT assay
Cytotoxicity against human HCT116 cells by MTT assay
|
[PMID: 17125240]
|
HCT-116
|
IC50 |
0.467 μM
Compound: Doxorubicin
|
Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay
Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay
|
[PMID: 35694689]
|
HCT-116
|
IC50 |
0.477 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25703298]
|
HCT-116
|
IC50 |
0.48 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 30783501]
|
HCT-116
|
IC50 |
0.48 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT-116 p53+/+ cells assessed as reduction in cell viability after 72 hrs by RRA assay
Cytotoxicity against human HCT-116 p53+/+ cells assessed as reduction in cell viability after 72 hrs by RRA assay
|
[PMID: 33508467]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 29459273]
|
HCT-116
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell survival after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell survival after 48 hrs by MTT assay
|
[PMID: 28494255]
|
HCT-116
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 33668008]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against p53 deficient human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against p53 deficient human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 29137865]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 26890118]
|
HCT-116
|
GI50 |
|
Antiproliferative activity against p53-deficient human HCT-116 cells incubated for 72 hrs and measured by MTT assay
Antiproliferative activity against p53-deficient human HCT-116 cells incubated for 72 hrs and measured by MTT assay
|
[PMID: 35973342]
|
HCT-116
|
IC50 |
0.5 μM
Compound: Adriamycin
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay
|
[PMID: 26222449]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human p53 knockout HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human p53 knockout HCT116 cells after 72 hrs by MTT assay
|
[PMID: 21144624]
|
HCT-116
|
IC50 |
0.55 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31546197]
|
HCT-116
|
GI50 |
|
Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 35533562]
|
HCT-116
|
IC50 |
|
Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay
|
[PMID: 33064004]
|
HCT-116
|
GI50 |
|
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 34634616]
|
HCT-116
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Cytotoxicity against p53 knock out human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against p53 knock out human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 34082225]
|
HCT-116
|
IC50 |
|
Cytotoxicity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against p53 knockout human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 30659997]
|
HCT-116
|
IC50 |
0.62 μM
Compound: doxorubicin
|
Cytotoxicity against human HCT116 cells by SRB assay
Cytotoxicity against human HCT116 cells by SRB assay
|
[PMID: 17194596]
|
HCT-116
|
IC50 |
0.63 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 23291120]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 20399544]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT-116 cells with inactivated p53 gene assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells with inactivated p53 gene assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 32428792]
|
HCT-116
|
IC50 |
0.74 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 26874404]
|
HCT-116
|
GI50 |
|
Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by MTT assay
Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by MTT assay
|
[PMID: 35973342]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
|
[PMID: 29597166]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT-116p53KO subline assessed as growth inhibition measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116p53KO subline assessed as growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 34902732]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 35341920]
|
HCT-116
|
IC50 |
1.01 μM
Compound: Doxorubicin
|
Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay
Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay
|
[PMID: 28923381]
|
HCT-116
|
IC50 |
1.01 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 28554092]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 34323485]
|
HCT-116
|
IC50 |
|
Anticancer activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by SRB assay
Anticancer activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by SRB assay
|
10.1007/s00044-012-0057-3
|
HCT-116
|
IC50 |
1.23 μM
Compound: Doxorubicin
|
Antiproliferative activity against p53-deficient human HCT116 cells after 48 hrs by MTT assay
Antiproliferative activity against p53-deficient human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 28554092]
|
HCT-116
|
IC50 |
1.3 μg/mL
Compound: Doxorubicin, Adriablastina
|
Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B method
Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B method
|
[PMID: 21664013]
|
HCT-116
|
IC50 |
1.38 μM
Compound: Adriamycin
|
Cytotoxicity against human HCT116 cells by MTT assay
Cytotoxicity against human HCT116 cells by MTT assay
|
[PMID: 24182355]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 25244612]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells expressing wild-type p53 after 72 hrs by MTT test
Antiproliferative activity against human HCT116 cells expressing wild-type p53 after 72 hrs by MTT test
|
[PMID: 17276690]
|
HCT-116
|
IC50 |
1.6 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HCT-116 cells by MTT assay
Cytotoxicity against human HCT-116 cells by MTT assay
|
[PMID: 36325400]
|
HCT-116
|
IC50 |
1.78 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT-116 p53-/- cells assessed as reduction in cell viability after 72 hrs by RRA assay
Cytotoxicity against human HCT-116 p53-/- cells assessed as reduction in cell viability after 72 hrs by RRA assay
|
[PMID: 33508467]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 36240546]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay
|
[PMID: 30245395]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells harboring PI3Kalpha H1047R mutant after 72 hrs by CCK8 assay
Antiproliferative activity against human HCT116 cells harboring PI3Kalpha H1047R mutant after 72 hrs by CCK8 assay
|
[PMID: 30071408]
|
HCT-116
|
IC50 |
|
Cytotoxicity against against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30340899]
|
HCT-116
|
IC50 |
19.7 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32771798]
|
HCT-116
|
IC50 |
19.9 nM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay
Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay
|
[PMID: 25499433]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against doxorubicin resistant human HCT-116 cells measured after 72 hrs by MTT assay
Antiproliferative activity against doxorubicin resistant human HCT-116 cells measured after 72 hrs by MTT assay
|
[PMID: 35612499]
|
HCT-116
|
IC50 |
2.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 24 hrs by WST assay
Cytotoxicity against human HCT116 cells after 24 hrs by WST assay
|
[PMID: 25881821]
|
HCT-116
|
IC50 |
2.38 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells by WST-8 assay
Cytotoxicity against human HCT116 cells by WST-8 assay
|
[PMID: 29295796]
|
HCT-116
|
IC50 |
2.4 μM
Compound: Doxorubicin
|
Anticancer activity against human HCT-116 cells by MTT assay
Anticancer activity against human HCT-116 cells by MTT assay
|
[PMID: 33421712]
|
HCT-116
|
IC50 |
2.56 μM
Compound: doxorubicin
|
Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
|
10.1007/s00044-013-0795-x
|
HCT-116
|
IC50 |
2.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
|
[PMID: 31200236]
|
HCT-116
|
GI50 |
21.4 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
|
[PMID: 27614919]
|
HCT-116
|
IC50 |
22 nM
Compound: doxorubicine
|
Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay
Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay
|
[PMID: 23072299]
|
HCT-116
|
IC50 |
22 nM
Compound: Doxorubicine
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
|
[PMID: 21142180]
|
HCT-116
|
IC50 |
3.29 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs
|
[PMID: 34530384]
|
HCT-116
|
IC50 |
3.3 μg/mL
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells after 24 hrs by MTS assay
Antiproliferative activity against human HCT116 cells after 24 hrs by MTS assay
|
[PMID: 20813435]
|
HCT-116
|
IC50 |
3.36 μg/mL
Compound: Doxorubicin
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 34973507]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells assessed as cell viability after 24 hrs by crystal violet staining assay
Cytotoxicity against human HCT116 cells assessed as cell viability after 24 hrs by crystal violet staining assay
|
[PMID: 26706352]
|
HCT-116
|
IC50 |
3.73 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21723735]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 30878835]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against p53-deficient human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against p53-deficient human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 25244612]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human p53 deficient HCT116 p53-/- cells after 72 hrs by MTT test
Antiproliferative activity against human p53 deficient HCT116 p53-/- cells after 72 hrs by MTT test
|
[PMID: 17276690]
|
HCT-116
|
IC50 |
4.8 μM
Compound: Doxorubicin
|
Anticancer activity against human HCT116 cells measured after 48 hrs by SRB assay
Anticancer activity against human HCT116 cells measured after 48 hrs by SRB assay
|
[PMID: 27112448]
|
HCT-116
|
IC50 |
49.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay
|
[PMID: 35271771]
|
HCT-116
|
IC50 |
5 mM
Compound: Adriamycin
|
Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
|
[PMID: 23685942]
|
HCT-116
|
IC50 |
5 mM
Compound: Adriamycin
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 22440624]
|
HCT-116
|
IC50 |
5.1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 34530384]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 37054758]
|
HCT-116
|
IC50 |
|
Anticancer activity against human HCT116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Anticancer activity against human HCT116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 32085964]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
|
[PMID: 30015070]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 36242988]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32527460]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
|
[PMID: 35964425]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 34126285]
|
HCT-116
|
IC50 |
5.23 μM
Compound: Doxorubicin
|
Antitumor activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay
Antitumor activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay
|
[PMID: 33065442]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT116 cells by MTT assay
Antiproliferative activity against human HCT116 cells by MTT assay
|
[PMID: 30216848]
|
HCT-116
|
IC50 |
5.95 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 24 to 96 hrs by MTS assay
Cytotoxicity against human HCT116 cells after 24 to 96 hrs by MTS assay
|
[PMID: 20303768]
|
HCT-116
|
IC50 |
56.6 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay
|
[PMID: 33016067]
|
HCT-116
|
IC50 |
57.77 nM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay
|
[PMID: 34795858]
|
HCT-116
|
IC50 |
6 nM
Compound: doxorubicin
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
|
[PMID: 19655762]
|
HCT-116
|
IC50 |
6.3 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 27894044]
|
HCT-116
|
IC50 |
6.86 μM
Compound: Doxorubicin
|
Antitumor activity against Homo sapiens (human) HCT116 cells assessed as cell growth inhibition after 48 hr by MTT assay
Antitumor activity against Homo sapiens (human) HCT116 cells assessed as cell growth inhibition after 48 hr by MTT assay
|
10.1007/s00044-013-0497-4
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
|
[PMID: 22444025]
|
HCT-116
|
IC50 |
6.86 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22119132]
|
HCT-116
|
IC50 |
6.86 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 22119131]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 35635947]
|
HCT-116
|
IC50 |
7.7 μM
Compound: adriamycin
|
Cytotoxicity against human HCT116 cells after 4 days by MTT assay
Cytotoxicity against human HCT116 cells after 4 days by MTT assay
|
[PMID: 17194586]
|
HCT-116
|
GI50 |
70 nM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay
Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay
|
10.1039/C0MD00179A
|
HCT-116
|
IC50 |
761.45 nM
Compound: Doxorubicin
|
Anticancer activity against human HCT-116 cells overexpressing MMP9/MAO-A by MTT assay
Anticancer activity against human HCT-116 cells overexpressing MMP9/MAO-A by MTT assay
|
[PMID: 34116327]
|
HCT-116
|
IC50 |
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 33360576]
|
HCT-116
|
IC50 |
8.29 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 24 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 24 hrs by SRB assay
|
[PMID: 30096580]
|
HCT-116
|
IC50 |
8.29 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay
|
[PMID: 32361329]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
10.1039/C2MD20270K
|
HCT-116
|
IC50 |
8.7 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 30660827]
|
HCT-116
|
IC50 |
8.8 nM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay
|
[PMID: 30660827]
|
HCT-116
|
IC50 |
80 nM
Compound: Doxorubicin
|
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
|
[PMID: 35213166]
|
HCT-116
|
IC50 |
|
Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr
Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr
|
[PMID: 15456268]
|
HCT-116
|
IC50 |
9.4 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31323616]
|
HCT-116
|
IC50 |
9.63 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 33214036]
|
HCT-116
|
IC50 |
9.74 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay
|
[PMID: 28489373]
|
HCT-15
|
GI50 |
< 10 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
|
10.1039/C5MD00224A
|
HCT-15
|
IC50 |
> 1000 nM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay
|
[PMID: 20690624]
|
HCT-15
|
ED50 |
0.006 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells by sulforhodamine B method
Cytotoxicity against human HCT15 cells by sulforhodamine B method
|
[PMID: 12193011]
|
HCT-15
|
IC50 |
0.009 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 27010926]
|
HCT-15
|
IC50 |
0.01 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells by MTT assay
Cytotoxicity against human HCT15 cells by MTT assay
|
[PMID: 17764956]
|
HCT-15
|
IC50 |
0.02 μg/mL
Compound: doxorubicin
|
Anticancer activity against human HCT15 cells after 72 hrs by sulforhodamine B assay
Anticancer activity against human HCT15 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 19342127]
|
HCT-15
|
IC50 |
0.025 μM
Compound: 1 (Doxorubicin)
|
In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay
In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay
|
[PMID: 14980672]
|
HCT-15
|
IC50 |
0.028 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells by SRB assay
Cytotoxicity against human HCT15 cells by SRB assay
|
[PMID: 20719504]
|
HCT-15
|
IC50 |
0.035 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
|
[PMID: 22483395]
|
HCT-15
|
IC50 |
0.037 μM
Compound: Doxorubicin
|
Anticancer activity against human HCT15 cells by sulforhodamine B assay
Anticancer activity against human HCT15 cells by sulforhodamine B assay
|
[PMID: 19819696]
|
HCT-15
|
IC50 |
0.038 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells by SRB assay
Cytotoxicity against human HCT15 cells by SRB assay
|
[PMID: 20594848]
|
HCT-15
|
ED50 |
0.04 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
|
[PMID: 11325244]
|
HCT-15
|
ED50 |
0.05 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
|
[PMID: 15921415]
|
HCT-15
|
IC50 |
0.05 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells by sulforhodamine B assay
Cytotoxicity against human HCT15 cells by sulforhodamine B assay
|
[PMID: 21684168]
|
HCT-15
|
ED50 |
0.071 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19783438]
|
HCT-15
|
GI50 |
|
Anticancer activity against human HCT-15 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
Anticancer activity against human HCT-15 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method
|
[PMID: 34500188]
|
HCT-15
|
GI50 |
|
Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay
Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay
|
[PMID: 30253887]
|
HCT-15
|
GI50 |
|
Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 28870801]
|
HCT-15
|
IC50 |
0.08 μg/mL
Compound: adriamycin
|
Cytotoxicity against human HCT15 cells by SRB assay
Cytotoxicity against human HCT15 cells by SRB assay
|
[PMID: 15921426]
|
HCT-15
|
IC50 |
0.082 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells by SRB assay
Cytotoxicity against human HCT15 cells by SRB assay
|
[PMID: 22951040]
|
HCT-15
|
GI50 |
|
Cytotoxicity against human HCT15 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HCT15 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 27096046]
|
HCT-15
|
IC50 |
0.09 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells assessed as cell death after 48 hrs by MTT assay
Cytotoxicity against human HCT15 cells assessed as cell death after 48 hrs by MTT assay
|
[PMID: 24215890]
|
HCT-15
|
IC50 |
0.1 μM
Compound: Doxorubicin
|
In vitro cytotoxic activity against HCT15 (colon cancer) cell lines by using SRB assay
In vitro cytotoxic activity against HCT15 (colon cancer) cell lines by using SRB assay
|
[PMID: 9873661]
|
HCT-15
|
IC50 |
0.1077 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells by sulforhodamine B bioassay
Cytotoxicity against human HCT15 cells by sulforhodamine B bioassay
|
[PMID: 25098650]
|
HCT-15
|
IC50 |
0.109 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
|
[PMID: 25981688]
|
HCT-15
|
IC50 |
0.129 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 25466198]
|
HCT-15
|
IC50 |
0.13 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay
Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay
|
[PMID: 23634786]
|
HCT-15
|
IC50 |
0.13 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells by sulforhodamine B assay
Cytotoxicity against human HCT15 cells by sulforhodamine B assay
|
[PMID: 23815260]
|
HCT-15
|
IC50 |
0.164 μM
Compound: doxorubicin
|
Cytotoxicity against human HCT15 cells by SRB assay
Cytotoxicity against human HCT15 cells by SRB assay
|
[PMID: 19435339]
|
HCT-15
|
ED50 |
0.164 μM
Compound: doxorubicin
|
Cytotoxicity against human HCT15 cells by SRB assay
Cytotoxicity against human HCT15 cells by SRB assay
|
[PMID: 18314958]
|
HCT-15
|
GI50 |
0.19 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT15 cells by SRB assay
Antiproliferative activity against human HCT15 cells by SRB assay
|
[PMID: 19394218]
|
HCT-15
|
IC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 28641156]
|
HCT-15
|
IC50 |
0.225 μM
Compound: Doxorubicin
|
Anticancer activity against human HCT15 cells after 48 hrs by SRB assay
Anticancer activity against human HCT15 cells after 48 hrs by SRB assay
|
[PMID: 17070967]
|
HCT-15
|
IC50 |
0.23 μM
Compound: Doxorubicine
|
Inhibitory activity against HCT-15 colon cell line using sulforhodamine B (SRB) protein assay
Inhibitory activity against HCT-15 colon cell line using sulforhodamine B (SRB) protein assay
|
[PMID: 12039588]
|
HCT-15
|
IC50 |
0.251 μM
Compound: doxorubicin
|
Cytotoxicity against human HCT15 cells after 3 days by SRB assay
Cytotoxicity against human HCT15 cells after 3 days by SRB assay
|
[PMID: 18321715]
|
HCT-15
|
IC50 |
0.27 μM
Compound: doxorubicin
|
Cytotoxicity against human HCT15 cells after 48 hrs
Cytotoxicity against human HCT15 cells after 48 hrs
|
[PMID: 17673337]
|
HCT-15
|
ED50 |
0.35 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human HCT15 cells by SRB method
Cytotoxicity against human HCT15 cells by SRB method
|
[PMID: 16252909]
|
HCT-15
|
GI50 |
|
Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 25953156]
|
HCT-15
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay
Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay
|
[PMID: 18063366]
|
HCT-15
|
IC50 |
0.82 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells by SRB assay
Cytotoxicity against human HCT15 cells by SRB assay
|
[PMID: 20176479]
|
HCT-15
|
IC50 |
0.872 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
Cytotoxicity against human HCT15 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay
|
[PMID: 27856237]
|
HCT-15
|
IC50 |
1.03 μM
Compound: Adriamycin
|
Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis
Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis
|
[PMID: 22503656]
|
HCT-15
|
IC50 |
1.08 μM
Compound: Adriamycin
|
Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay
Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay
|
[PMID: 26361737]
|
HCT-15
|
IC50 |
1.08 μM
Compound: Adriamycin
|
Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
|
[PMID: 25481396]
|
HCT-15
|
IC50 |
|
Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 25981689]
|
HCT-15
|
IC50 |
1.2 μM
Compound: Adriamycin
|
Cytotoxicity against human HCT15 cells after 2 days
Cytotoxicity against human HCT15 cells after 2 days
|
[PMID: 21601964]
|
HCT-15
|
IC50 |
1.23 μM
Compound: adriamycin
|
Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay
Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay
|
[PMID: 25936262]
|
HCT-15
|
IC50 |
1.25 μM
Compound: Adriamycin
|
Cytotoxicity against human HCT15 cells by MTT assay
Cytotoxicity against human HCT15 cells by MTT assay
|
[PMID: 21115246]
|
HCT-15
|
IC50 |
1.28 μM
Compound: Adriamycin
|
Cytotoxicity against human HCT15 cells after 2 days
Cytotoxicity against human HCT15 cells after 2 days
|
[PMID: 22318164]
|
HCT-15
|
GI50 |
|
Antiproliferative activity against human HCT15 cells by SRB method
Antiproliferative activity against human HCT15 cells by SRB method
|
[PMID: 24835787]
|
HCT-15
|
GI50 |
|
Antiproliferative activity against human HCT15 cells by SRB assay
Antiproliferative activity against human HCT15 cells by SRB assay
|
[PMID: 22738641]
|
HCT-15
|
IC50 |
1.38 μM
Compound: Adriamycin
|
Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay
|
[PMID: 24013413]
|
HCT-15
|
GI50 |
1.4 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 23964644]
|
HCT-15
|
GI50 |
1.64 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT15 cells by SRB assay
Cytotoxicity against human HCT15 cells by SRB assay
|
[PMID: 19596579]
|
HCT-15
|
IC50 |
1.67 μM
Compound: doxorubicin
|
Cytotoxicity against human HCT15 cells by SRB assay
Cytotoxicity against human HCT15 cells by SRB assay
|
[PMID: 17827007]
|
HCT-15
|
IC50 |
1.67 μM
Compound: Doxorubicin
|
Cytotoxic activity against HCT 15 human colon tumor cell line, using sulforhodamine B (SRB) assay.
Cytotoxic activity against HCT 15 human colon tumor cell line, using sulforhodamine B (SRB) assay.
|
[PMID: 14643344]
|
HCT-15
|
IC50 |
|
Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay
|
[PMID: 22819942]
|
HCT-15
|
ED50 |
1.8 μg/mL
Compound: adriamycin
|
Cytotoxicity against human HCT15 cells by SRB assay
Cytotoxicity against human HCT15 cells by SRB assay
|
10.1021/np960188t
|
HCT-15
|
IC50 |
16.4 nM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT15 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
Antiproliferative activity against human HCT15 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay
|
[PMID: 31655432]
|
HCT-15
|
IC50 |
|
Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay
|
[PMID: 30429098]
|
HCT-15
|
ED50 |
2.4 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human HCT15 cells by SRB assay
Cytotoxicity against human HCT15 cells by SRB assay
|
[PMID: 9392887]
|
HCT-15
|
IC50 |
|
Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay
Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay
|
[PMID: 26334499]
|
HCT-15
|
IC50 |
|
Cytotoxicity against human HCT15 cells after 2 days
Cytotoxicity against human HCT15 cells after 2 days
|
[PMID: 24904965]
|
HCT-15
|
IC50 |
5 nM
Compound: Adriamycin
|
Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
|
[PMID: 22858298]
|
HCT-15
|
GI50 |
6.46 μM
Compound: Doxorubicin hydrochloride, NSC 123127
|
Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
|
[PMID: 23871905]
|
HCT-15
|
GI50 |
6.46 μM
Compound: Doxorubicin
|
Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29102177]
|
HCT-15
|
GI50 |
6.46 μM
Compound: Doxorubicin
|
Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 28329730]
|
HCT-15
|
GI50 |
7.92 μM
Compound: Doxorubicin
|
Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay
Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay
|
[PMID: 19394218]
|
HCT-15
|
IC50 |
81 nM
Compound: doxorubicin
|
Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay
Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay
|
[PMID: 19655762]
|
HCT-29
|
IC50 |
2.5 μM
Compound: Adriamycin
|
Cytotoxicity against human HCT29 cells after 4 days by MTT assay
Cytotoxicity against human HCT29 cells after 4 days by MTT assay
|
[PMID: 21704436]
|
HCT-8
|
IC50 |
|
Cytotoxicity against Homo sapiens (human) HCT8 cells after 72 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HCT8 cells after 72 hr by MTT assay
|
10.1007/s00044-011-9894-8
|
HCT-8
|
IC50 |
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 25147145]
|
HCT-8
|
IC50 |
|
Antineoplastic activity against human HCT8 cells after 72 hrs by MTT assay
Antineoplastic activity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 22000949]
|
HCT-8
|
IC50 |
0.02 μM
Compound: doxorubicin
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 21381705]
|
HCT-8
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 20971532]
|
HCT-8
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 19406535]
|
HCT-8
|
IC50 |
|
Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 31306817]
|
HCT-8
|
IC50 |
0.04 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HCT8 cells after 3 days by MTT assay
Cytotoxicity against human HCT8 cells after 3 days by MTT assay
|
[PMID: 19159272]
|
HCT-8
|
IC50 |
|
Anticancer activity against Homo sapiens (human) HCT8 cells assessed as inhibition of cell survival after 72 hr by MTT assay
Anticancer activity against Homo sapiens (human) HCT8 cells assessed as inhibition of cell survival after 72 hr by MTT assay
|
10.1007/s00044-012-0236-2
|
HCT-8
|
IC50 |
0.04 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 19084293]
|
HCT-8
|
IC50 |
0.04 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 18586355]
|
HCT-8
|
IC50 |
0.04 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 17827021]
|
HCT-8
|
IC50 |
0.04 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 15787450]
|
HCT-8
|
IC50 |
0.05 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 27363939]
|
HCT-8
|
IC50 |
0.06 μg/mL
Compound: Doxo
|
Cytotoxicity against human HCT8 cells for 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells for 72 hrs by MTT assay
|
[PMID: 21334795]
|
HCT-8
|
IC50 |
0.06 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 21115213]
|
HCT-8
|
IC50 |
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 19947600]
|
HCT-8
|
IC50 |
0.09 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT8 cells after 69 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 69 hrs by MTT assay
|
[PMID: 19780590]
|
HCT-8
|
IC50 |
0.1 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT8 cells by colorimetric method
Cytotoxicity against human HCT8 cells by colorimetric method
|
[PMID: 24387625]
|
HCT-8
|
IC50 |
0.1 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 22250891]
|
HCT-8
|
IC50 |
0.13 μM
Compound: Doxorubicin
|
Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 24530030]
|
HCT-8
|
IC50 |
|
Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 26142490]
|
HCT-8
|
IC50 |
0.42 μM
Compound: Adriamycin
|
Cytotoxicity against human HCT8 cells by MTT assay
Cytotoxicity against human HCT8 cells by MTT assay
|
[PMID: 22070654]
|
HCT-8
|
IC50 |
0.8 μM
Compound: adriamycin
|
Cytotoxicity against human HCT8 cells by MTT assay
Cytotoxicity against human HCT8 cells by MTT assay
|
[PMID: 17190442]
|
HCT-8
|
IC50 |
|
Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 27149641]
|
HCT-8
|
IC50 |
1.5 μM
Compound: doxorubicine
|
Cytotoxic activity against human HCT8 cells after 69 hrs by MTT assay
Cytotoxic activity against human HCT8 cells after 69 hrs by MTT assay
|
[PMID: 19788290]
|
HCT-8
|
IC50 |
|
Cytotoxicity against human HCT8 cells under hypoxic condition after 24 hrs by crystal violet method
Cytotoxicity against human HCT8 cells under hypoxic condition after 24 hrs by crystal violet method
|
[PMID: 25375258]
|
HCT-8
|
IC50 |
|
Cytotoxicity against human HCT8 cells under normoxic condition after 24 hrs by crystal violet method
Cytotoxicity against human HCT8 cells under normoxic condition after 24 hrs by crystal violet method
|
[PMID: 25375258]
|
HCT-8
|
IC50 |
|
Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method
Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method
|
[PMID: 25061803]
|
HCT-8
|
IC50 |
7.2 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HCT8 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT8 cells after 48 hrs by MTT assay
|
[PMID: 30660827]
|
HEK293
|
IC50 |
> 100 μM
Compound: Doxorubicin
|
Cytotoxicity against HEK293 cells by MTT assay
Cytotoxicity against HEK293 cells by MTT assay
|
[PMID: 24287557]
|
HEK293
|
IC50 |
> 200 μM
Compound: Doxorubicin
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 4 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 4 hrs by MTT assay
|
[PMID: 30773423]
|
HEK293
|
IC50 |
> 200 μM
Compound: Doxorubicin
|
In vitro cytotoxicity against HEK293 cells assessed as growth inhibition by MTT assay
In vitro cytotoxicity against HEK293 cells assessed as growth inhibition by MTT assay
|
[PMID: 24742385]
|
HEK293
|
IC50 |
0.01 μM
Compound: Adriamycin
|
Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
|
[PMID: 21721528]
|
HEK293
|
IC50 |
|
Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay
|
[PMID: 31431364]
|
HEK293
|
IC50 |
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30340899]
|
HEK293
|
IC50 |
|
Cytotoxic activity against human HEK293 cells by SRB method
Cytotoxic activity against human HEK293 cells by SRB method
|
[PMID: 25611519]
|
HEK293
|
IC50 |
0.064 μM
Compound: Doxorubicin
|
Cytotoxicity against HEK293 cells after 24 hrs by SRB method
Cytotoxicity against HEK293 cells after 24 hrs by SRB method
|
[PMID: 18429610]
|
HEK293
|
IC50 |
|
Cytotoxicity against HEK-293 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
Cytotoxicity against HEK-293 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method
|
[PMID: 34236840]
|
HEK293
|
IC50 |
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 29681486]
|
HEK293
|
IC50 |
0.42 μM
Compound: Adriamycin
|
Cytotoxicity against human HEK293 cells transfected with plasmid expressing MDR1 after 72 hrs by MTT assay
Cytotoxicity against human HEK293 cells transfected with plasmid expressing MDR1 after 72 hrs by MTT assay
|
[PMID: 21721528]
|
HEK293
|
IC50 |
|
Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by formazan dye-based EZ4U assay
Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by formazan dye-based EZ4U assay
|
[PMID: 30108984]
|
HEK293
|
IC50 |
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U Non-radioactive cell proliferation assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U Non-radioactive cell proliferation assay
|
[PMID: 28372935]
|
HEK293
|
IC50 |
|
Antiproliferative activity against human HEK293 cells assessed as cell viability after 48 hrs by formazan EZ4U dye based assay
Antiproliferative activity against human HEK293 cells assessed as cell viability after 48 hrs by formazan EZ4U dye based assay
|
[PMID: 26690914]
|
HEK293
|
IC50 |
|
Toxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U label based assay
Toxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U label based assay
|
[PMID: 26052884]
|
HEK293
|
IC50 |
0.46 μM
Compound: doxorubicin
|
Antiproliferative activity against HEK293 cells at 0.01 to 250 uM after 48 hrs by formazan based EZ4U assay
Antiproliferative activity against HEK293 cells at 0.01 to 250 uM after 48 hrs by formazan based EZ4U assay
|
[PMID: 25868743]
|
HEK293
|
IC50 |
0.69 μM
Compound: Doxorubicin
|
Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
|
[PMID: 25300819]
|
HEK293
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Antiproliferative activity against HEK293 cells after 72 hrs by XTT assay
Antiproliferative activity against HEK293 cells after 72 hrs by XTT assay
|
10.1039/C1MD00234A
|
HEK293
|
GI50 |
|
Antiproliferative activity against human HEK293 cells incubated for 72 hrs and measured by MTT assay
Antiproliferative activity against human HEK293 cells incubated for 72 hrs and measured by MTT assay
|
[PMID: 35973342]
|
HEK293
|
IC50 |
0.9 μM
Compound: doxorubicin
|
Cytotoxicity against transformed human HEK293 cells after 24 to 48 hrs by MTT assay
Cytotoxicity against transformed human HEK293 cells after 24 to 48 hrs by MTT assay
|
[PMID: 21058726]
|
HEK293
|
IC50 |
1 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 35526504]
|
HEK293
|
IC50 |
|
Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay
|
[PMID: 22819942]
|
HEK293
|
IC50 |
1.006 μM
Compound: Doxorubicin
|
Cytotoxicity against HEK293 cells after 24 hrs by MTT assay
Cytotoxicity against HEK293 cells after 24 hrs by MTT assay
|
10.1007/s00044-013-0784-0
|
HEK293
|
IC50 |
1.06 μM
Compound: Adriamycin
|
Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
|
[PMID: 24582982]
|
HEK293
|
IC50 |
|
Antiproliferative activity against human HEK293 cells after 72 hrs by MTT assay
Antiproliferative activity against human HEK293 cells after 72 hrs by MTT assay
|
[PMID: 30429098]
|
HEK293
|
IC50 |
1.34 μM
Compound: Adriamycin
|
Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis
Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis
|
[PMID: 22503656]
|
HEK293
|
IC50 |
1.65 μM
Compound: Doxorubicin
|
Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 34124677]
|
HEK293
|
IC50 |
10 μM
Compound: Doxorubicin
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
|
[PMID: 28818768]
|
HEK293
|
IC50 |
|
Growth inhibition of human HEK293 cells assessed as cell viability incubated for 48 hrs by MTT assay
Growth inhibition of human HEK293 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31648875]
|
HEK293
|
IC50 |
|
Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
|
[PMID: 29852328]
|
HEK293
|
IC50 |
|
Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay
Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay
|
[PMID: 29289880]
|
HEK293
|
IC50 |
16.7 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 35526504]
|
HEK293
|
IC50 |
160 μM
Compound: Doxorubicin
|
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
|
[PMID: 22541068]
|
HEK293
|
IC50 |
2.1 μM
Compound: Doxorubicin
|
Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 28923382]
|
HEK293
|
IC50 |
240 μM
Compound: Doxorubicin
|
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
|
[PMID: 22541068]
|
HEK293
|
IC50 |
3.07 μM
Compound: Adriamycin
|
Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay
Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay
|
[PMID: 24013413]
|
HEK293
|
IC50 |
3.13 μM
Compound: Doxorubicin
|
Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 27816268]
|
HEK293
|
IC50 |
3.9 μM
Compound: Doxorubicin
|
Growth inhibition of HEK293 cells after 48 hrs by MTT assay
Growth inhibition of HEK293 cells after 48 hrs by MTT assay
|
[PMID: 30072225]
|
HEK293
|
IC50 |
41 μM
Compound: Doxorubicin
|
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
|
[PMID: 22541068]
|
HEK293
|
IC50 |
|
Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
|
[PMID: 27108400]
|
HEK293
|
IC50 |
|
Cytotoxicity against HEK293 cells assessed as reduction of cell viability after 48 hrs by formazan dye-based EZ4U test
Cytotoxicity against HEK293 cells assessed as reduction of cell viability after 48 hrs by formazan dye-based EZ4U test
|
[PMID: 24996140]
|
HEK293
|
IC50 |
|
Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
|
[PMID: 31671309]
|
HEK293
|
IC50 |
|
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
|
[PMID: 30576904]
|
HEK293
|
IC50 |
6.1 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 35526504]
|
HEK293
|
IC50 |
6.1 μM
Compound: Doxorubicin
|
Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth after overnight incubation by MTT assay
Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth after overnight incubation by MTT assay
|
[PMID: 32165076]
|
HEK293
|
IC50 |
7.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay
|
[PMID: 27496212]
|
HEK293
|
IC50 |
7.41 μM
Compound: Doxorubicin
|
Cytotoxicity against HEK293 cells after 48 hrs by MTT assay
Cytotoxicity against HEK293 cells after 48 hrs by MTT assay
|
[PMID: 24607876]
|
HEK-293T
|
IC50 |
|
Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay
Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay
|
[PMID: 35612499]
|
HEK-293T
|
IC50 |
0.75 μM
Compound: Doxorubicin
|
Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in presence of 10% FBS
Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in presence of 10% FBS
|
[PMID: 26298501]
|
HEK-293T
|
IC50 |
0.84 μM
Compound: Doxorubicin
|
Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in absence of 10% FBS
Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in absence of 10% FBS
|
[PMID: 26298501]
|
HEK-293T
|
IC50 |
|
Cytotoxicity in HEK293T cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay
Cytotoxicity in HEK293T cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay
|
[PMID: 31542715]
|
HEK-293T
|
IC50 |
1.13 μM
Compound: Doxorubicin
|
Cytotoxicity against HEK293T cells after 48 hrs by MTT assay
Cytotoxicity against HEK293T cells after 48 hrs by MTT assay
|
[PMID: 30170925]
|
HEK-293T
|
CC50 |
1.13 μM
Compound: Doxorubicin
|
Cytotoxicity against HEK293T cells after 48 hrs by MTT assay
Cytotoxicity against HEK293T cells after 48 hrs by MTT assay
|
[PMID: 30103191]
|
HEK-293T
|
IC50 |
|
Cytotoxicity against HEK293T cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against HEK293T cells assessed as inhibition of cell viability after 48 hrs by MTT assay
|
[PMID: 27055942]
|
HEK-293T
|
IC50 |
3.1 μM
Compound: Doxorubicin
|
Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay
Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay
|
[PMID: 27173802]
|
HEK-293T
|
IC50 |
3.59 μM
Compound: Doxorubicin
|
Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay
Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay
|
[PMID: 29573910]
|
HEK-293T
|
IC50 |
3.77 μM
Compound: Doxorubicin
|
Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 35367708]
|
HEK-293T
|
IC50 |
3.77 μM
Compound: Doxorubicin
|
Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 31404864]
|
HEL
|
IC50 |
0.42 μM
Compound: Doxorubicin
|
Antiproliferative activity against HEL cells after 72 hrs by MTT assay
Antiproliferative activity against HEL cells after 72 hrs by MTT assay
|
[PMID: 30500683]
|
HEL
|
IC50 |
2.13 μM
Compound: Doxorubicin
|
Cytotoxicity against HEL cells after 48 hrs by MTT assay
Cytotoxicity against HEL cells after 48 hrs by MTT assay
|
[PMID: 28390228]
|
HeLa
|
GI50 |
< 0.01 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 25827522]
|
HeLa
|
GI50 |
|
Cytotoxicity against human HeLa cells by SRB assay
Cytotoxicity against human HeLa cells by SRB assay
|
10.1007/s00044-013-0855-2
|
HeLa
|
IC50 |
< 1 μM
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
|
10.1007/s00044-011-9884-x
|
HeLa
|
IC50 |
< 1 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 23079527]
|
HeLa
|
IC50 |
< 1 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 21996519]
|
HeLa
|
IC50 |
> 1 μM
Compound: Doxorubicin
|
Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 35059132]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells after 3 days by MTT assay
Cytotoxicity against human HeLa cells after 3 days by MTT assay
|
[PMID: 22520152]
|
HeLa
|
IC50 |
0.01 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as cell survival after 24 hrs by XTT assay
Cytotoxicity against human HeLa cells assessed as cell survival after 24 hrs by XTT assay
|
[PMID: 25059501]
|
HeLa
|
IC50 |
|
Antitumor activity against Homo sapiens (human) HeLa cells assessed as inhibition of cell proliferation after 48 hr by SRB assay
Antitumor activity against Homo sapiens (human) HeLa cells assessed as inhibition of cell proliferation after 48 hr by SRB assay
|
10.1007/s00044-012-0051-9
|
HeLa
|
GI50 |
0.023 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells by SRB assay
Antiproliferative activity against human HeLa cells by SRB assay
|
[PMID: 31546197]
|
HeLa
|
IC50 |
0.03 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay
Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay
|
[PMID: 27080175]
|
HeLa
|
GI50 |
0.031 μM
Compound: Doxorubicin
|
Growth inhibition of human HeLa cells after 48 hrs by SRB assay
Growth inhibition of human HeLa cells after 48 hrs by SRB assay
|
[PMID: 26067381]
|
HeLa
|
IC50 |
0.04 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 20207049]
|
HeLa
|
IC50 |
|
Antitumor activity against human HeLa cells after 72 hrs by MTT assay
Antitumor activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 17935309]
|
HeLa
|
IC50 |
0.04 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 19278239]
|
HeLa
|
GI50 |
0.05 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 27889456]
|
HeLa
|
IC50 |
0.05 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
|
[PMID: 28257197]
|
HeLa
|
IC50 |
0.051 μg/mL
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 34973507]
|
HeLa
|
IC50 |
0.053 μM
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) HeLa cells after 96 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HeLa cells after 96 hr by MTT assay
|
10.1007/s00044-010-9340-3
|
HeLa
|
IC50 |
0.06 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 22555152]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
|
[PMID: 31557614]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 25259516]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 6 days by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 6 days by MTT assay
|
[PMID: 32653698]
|
HeLa
|
IC50 |
0.07 μM
Compound: Doxorubicin
|
Cytotoxicity against human Hela cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human Hela cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 33340938]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay
|
[PMID: 30746062]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 28427016]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 28135634]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 27231128]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 26720155]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 24021462]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 20359789]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 18783950]
|
HeLa
|
IC50 |
0.07 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay
|
[PMID: 19053767]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells by MTT assay
Antiproliferative activity against human HeLa cells by MTT assay
|
[PMID: 16913700]
|
HeLa
|
GI50 |
0.073 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 27209232]
|
HeLa
|
GI50 |
0.073 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay
|
[PMID: 25462234]
|
HeLa
|
GI50 |
0.073 μM
Compound: Doxorubicin
|
Growth inhibition of human HeLa cells after 48 hrs by SRB assay
Growth inhibition of human HeLa cells after 48 hrs by SRB assay
|
[PMID: 25264072]
|
HeLa
|
GI50 |
0.083 μM
Compound: Doxorubicin
|
Growth inhibition of human HeLa cells after 48 hrs by SRB assay
Growth inhibition of human HeLa cells after 48 hrs by SRB assay
|
[PMID: 27964883]
|
HeLa
|
IC50 |
0.09 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
|
[PMID: 36693198]
|
HeLa
|
GI50 |
0.09 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 26994690]
|
HeLa
|
GI50 |
0.093 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 30360625]
|
HeLa
|
ED50 |
0.1 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human HeLa cells after 3 days by MTT assay
Cytotoxicity against human HeLa cells after 3 days by MTT assay
|
[PMID: 16252910]
|
HeLa
|
IC50 |
0.1 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by CCK8 assay
Cytotoxicity against human HeLa cells after 72 hrs by CCK8 assay
|
[PMID: 28398051]
|
HeLa
|
IC50 |
0.1 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT method
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT method
|
[PMID: 25932671]
|
HeLa
|
IC50 |
0.1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 26947606]
|
HeLa
|
IC50 |
0.11 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30389295]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 21496972]
|
HeLa
|
ED50 |
0.14 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human HeLa cells by methylene blue staining method
Cytotoxicity against human HeLa cells by methylene blue staining method
|
[PMID: 15921421]
|
HeLa
|
IC50 |
0.14 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
|
[PMID: 31820973]
|
HeLa
|
IC50 |
0.14 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 24 hrs by XTT assay
Cytotoxicity against human HeLa cells after 24 hrs by XTT assay
|
[PMID: 27227682]
|
HeLa
|
IC50 |
0.154 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 25462279]
|
HeLa
|
IC50 |
0.16 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 18692939]
|
HeLa
|
IC50 |
0.163 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 21158422]
|
HeLa
|
IC50 |
0.19 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 22414612]
|
HeLa
|
IC50 |
0.19 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
|
[PMID: 19647439]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 29459273]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay
Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay
|
[PMID: 31869654]
|
HeLa
|
IC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 34082225]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 33974416]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 30659997]
|
HeLa
|
IC50 |
|
Antiproliferative activity in human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity in human HeLa cells after 72 hrs by MTT assay
|
[PMID: 30268824]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 29137865]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 26633734]
|
HeLa
|
IC50 |
0.2 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 24012378]
|
HeLa
|
IC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 19394829]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 25984840]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 25529742]
|
HeLa
|
IC50 |
0.21 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 72 hrs MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs MTT assay
|
[PMID: 25247772]
|
HeLa
|
ED50 |
0.22 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 15104488]
|
HeLa
|
IC50 |
0.22 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay
Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay
|
[PMID: 25163667]
|
HeLa
|
IC50 |
0.221 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT reduction assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT reduction assay
|
[PMID: 28551177]
|
HeLa
|
IC50 |
0.23 μM
Compound: Doxorubicin
|
Anticancer activity against human HeLa cells after 48 hrs by MTT assay
Anticancer activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 21641694]
|
HeLa
|
IC50 |
0.24 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 21708464]
|
HeLa
|
IC50 |
0.24 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells incubated for 72 hrs by MTT assay
Cytotoxicity against human HeLa cells incubated for 72 hrs by MTT assay
|
[PMID: 32040324]
|
HeLa
|
IC50 |
0.256 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells at 50 uM by MTT reduction assay
Cytotoxicity against human HeLa cells at 50 uM by MTT reduction assay
|
[PMID: 33276991]
|
HeLa
|
IC50 |
0.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26972921]
|
HeLa
|
GI50 |
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 34634616]
|
HeLa
|
IC50 |
0.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 44 hrs by SRB assay
Cytotoxicity against human HeLa cells after 44 hrs by SRB assay
|
10.1007/s00044-013-0788-9
|
HeLa
|
IC50 |
0.32 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 28358196]
|
HeLa
|
GI50 |
0.33 μM
Compound: Doxorubicin
|
Growth inhibition of Homo sapiens (human) HeLa cells after 48 hr by MTT assay
Growth inhibition of Homo sapiens (human) HeLa cells after 48 hr by MTT assay
|
10.1007/s00044-012-0232-6
|
HeLa
|
IC50 |
0.33 μM
Compound: Doxorubicin
|
Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay
Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 25160837]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells by MTT assay
Antiproliferative activity against human HeLa cells by MTT assay
|
[PMID: 20171108]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 25998504]
|
HeLa
|
IC50 |
0.34 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay
|
[PMID: 24941130]
|
HeLa
|
IC50 |
0.36 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 4 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 4 hrs by MTT assay
|
[PMID: 30773423]
|
HeLa
|
IC50 |
0.36 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay
|
[PMID: 24953027]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 24487188]
|
HeLa
|
IC50 |
0.36 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 25453799]
|
HeLa
|
IC50 |
0.37 μM
Compound: Doxorubicin
|
Anticancer activity against human HeLa cells incubated for 24 hrs by MTT assay
Anticancer activity against human HeLa cells incubated for 24 hrs by MTT assay
|
[PMID: 28579122]
|
HeLa
|
IC50 |
0.4 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells incubated for 48 hrs by WST8 assay
Antiproliferative activity against human HeLa cells incubated for 48 hrs by WST8 assay
|
[PMID: 31679979]
|
HeLa
|
IC50 |
0.41 μM
Compound: adriamycin
|
Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay
Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay
|
[PMID: 19072548]
|
HeLa
|
IC50 |
0.429 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 48 hrs by MTT assay
|
[PMID: 36652792]
|
HeLa
|
IC50 |
0.43 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in presence of 10% FBS
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in presence of 10% FBS
|
[PMID: 26298501]
|
HeLa
|
IC50 |
0.45 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 25172420]
|
HeLa
|
IC50 |
0.45 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 23911578]
|
HeLa
|
IC50 |
0.45 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in absence of 10% FBS
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in absence of 10% FBS
|
[PMID: 26298501]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 29685681]
|
HeLa
|
IC50 |
0.451 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 24113366]
|
HeLa
|
IC50 |
0.451 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 23764302]
|
HeLa
|
IC50 |
0.47 μM
Compound: adriamycin
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 26295905]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay
|
[PMID: 25089733]
|
HeLa
|
IC50 |
0.48 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 46 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 46 hrs by MTT assay
|
[PMID: 29138027]
|
HeLa
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
|
[PMID: 32324401]
|
HeLa
|
IC50 |
0.5 μM
Compound: doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTS assay
Cytotoxicity against human HeLa cells after 72 hrs by MTS assay
|
[PMID: 25490132]
|
HeLa
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29702447]
|
HeLa
|
IC50 |
|
Cytotoxic activity against human HeLa cells by MTT method
Cytotoxic activity against human HeLa cells by MTT method
|
[PMID: 25611519]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells by SRB method
Cytotoxicity against human HeLa cells by SRB method
|
[PMID: 29144133]
|
HeLa
|
IC50 |
0.509 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by MTT assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by MTT assay
|
[PMID: 23932340]
|
HeLa
|
IC50 |
0.509 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 24287557]
|
HeLa
|
IC50 |
0.51 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26381063]
|
HeLa
|
IC50 |
0.51 μM
Compound: Doxorubicin
|
In vitro cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay
In vitro cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay
|
[PMID: 24742385]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells measured after 2 days by MTT assay
Cytotoxicity against human HeLa cells measured after 2 days by MTT assay
|
[PMID: 26334499]
|
HeLa
|
IC50 |
0.54 μg/mL
Compound: Doxorubicin
|
Anticancer activity against human HeLa cells by MTT assay
Anticancer activity against human HeLa cells by MTT assay
|
[PMID: 31404864]
|
HeLa
|
IC50 |
0.55 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31546197]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
|
[PMID: 34978808]
|
HeLa
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30679134]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 26386603]
|
HeLa
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 22749279]
|
HeLa
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition by MTT assay
|
[PMID: 27187861]
|
HeLa
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 25241926]
|
HeLa
|
IC50 |
0.606 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 28406643]
|
HeLa
|
IC50 |
0.62 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 19689125]
|
HeLa
|
IC50 |
0.66 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30170925]
|
HeLa
|
CC50 |
0.66 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30103191]
|
HeLa
|
IC50 |
0.68 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 18440233]
|
HeLa
|
IC50 |
0.69 μM
Compound: Doxorubicin
|
Cytotoxicity against p53 repressed human HeLa cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against p53 repressed human HeLa cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 31324563]
|
HeLa
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT asasy
Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT asasy
|
[PMID: 28615134]
|
HeLa
|
GI50 |
|
Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 35533562]
|
HeLa
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 25172418]
|
HeLa
|
IC50 |
0.71 μM
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay
Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay
|
10.1007/s00044-012-0370-x
|
HeLa
|
IC50 |
0.71 μM
Compound: Doxorubicine
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 22014995]
|
HeLa
|
IC50 |
0.73 μM
Compound: doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 19819703]
|
HeLa
|
GI50 |
|
Antiproliferative activity against human HeLa cells incubated for 72 hrs and measured by MTT assay
Antiproliferative activity against human HeLa cells incubated for 72 hrs and measured by MTT assay
|
[PMID: 35973342]
|
HeLa
|
IC50 |
0.78 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 27060757]
|
HeLa
|
IC50 |
0.8 μg/mL
Compound: Adriamycin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 17918910]
|
HeLa
|
IC50 |
0.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 30654238]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTT assay
|
[PMID: 31765156]
|
HeLa
|
IC50 |
0.82 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
|
[PMID: 31404864]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26638041]
|
HeLa
|
IC50 |
0.85 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23992864]
|
HeLa
|
IC50 |
0.88 μM
Compound: adriamycin
|
Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay
Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay
|
[PMID: 25936262]
|
HeLa
|
IC50 |
0.9 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 25462233]
|
HeLa
|
IC50 |
0.93 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
|
10.1039/C5MD00581G
|
HeLa
|
IC50 |
0.97 μM
Compound: Adriamycin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 24182355]
|
HeLa
|
IC50 |
1 x 10 -2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by XTT assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by XTT assay
|
[PMID: 23470139]
|
HeLa
|
IC50 |
1 μM
Compound: Adriamycin
|
Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay
Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay
|
[PMID: 25481396]
|
HeLa
|
IC50 |
1 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells incubated for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells incubated for 48 hrs by MTT assay
|
[PMID: 33421712]
|
HeLa
|
IC50 |
1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 19632833]
|
HeLa
|
IC50 |
1 μM
Compound: Adriamycin
|
Cytotoxicity against human HeLa cells by neutral red method
Cytotoxicity against human HeLa cells by neutral red method
|
[PMID: 26291474]
|
HeLa
|
IC50 |
1 μM
Compound: Adriamycin
|
Cytotoxicity against human HeLa cells after 2 days
Cytotoxicity against human HeLa cells after 2 days
|
[PMID: 21601964]
|
HeLa
|
IC50 |
1.009 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 24 hrs by SRB method
Cytotoxicity against human HeLa cells after 24 hrs by SRB method
|
[PMID: 18429610]
|
HeLa
|
IC50 |
1.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by CCK8 assay
Cytotoxicity against human HeLa cells by CCK8 assay
|
[PMID: 29452840]
|
HeLa
|
IC50 |
1.07 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32866757]
|
HeLa
|
IC50 |
1.089 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28482219]
|
HeLa
|
IC50 |
1.107 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay
|
[PMID: 32707525]
|
HeLa
|
IC50 |
1.1073 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells by MTT assay
Antiproliferative activity against human HeLa cells by MTT assay
|
[PMID: 31404864]
|
HeLa
|
IC50 |
1.12 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
10.1039/C3MD00013C
|
HeLa
|
IC50 |
1.12 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 22182926]
|
HeLa
|
IC50 |
1.17 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells expressing estrogen receptor after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells expressing estrogen receptor after 48 hrs by MTT assay
|
10.1039/C2MD20327H
|
HeLa
|
IC50 |
1.17 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30108986]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 48 hrs by MTT assay
|
[PMID: 25737400]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 25619894]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 24148837]
|
HeLa
|
IC50 |
1.17 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 1 hr by SRB assay
Cytotoxicity against human HeLa cells after 1 hr by SRB assay
|
[PMID: 22770744]
|
HeLa
|
IC50 |
1.2 μM
Compound: Doxorubicin
|
Anticancer activity against human HeLa cells measured after 48 hrs by MTT assay
Anticancer activity against human HeLa cells measured after 48 hrs by MTT assay
|
[PMID: 33421712]
|
HeLa
|
IC50 |
1.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 26398312]
|
HeLa
|
IC50 |
1.2 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 28886509]
|
HeLa
|
IC50 |
1.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 33766771]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 72 hrs by Sulforhodamine B-stain assay
Antiproliferative activity against human HeLa cells after 72 hrs by Sulforhodamine B-stain assay
|
[PMID: 27484508]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30615450]
|
HeLa
|
IC50 |
1.258 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 26301558]
|
HeLa
|
IC50 |
1.28 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
10.1039/C4MD00566J
|
HeLa
|
IC50 |
1.3 μM
Compound: Doxorubicin
|
Cytotoxic activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxic activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 25966052]
|
HeLa
|
IC50 |
1.31 μM
Compound: Adriamycin
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 24582982]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells after 48 hrs by SRB method
Cytotoxicity against human HeLa cells after 48 hrs by SRB method
|
[PMID: 25933593]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells assessed as decrease in cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as decrease in cell viability measured after 72 hrs by MTT assay
|
[PMID: 30763817]
|
HeLa
|
IC50 |
1.45 μM
Compound: Adriamycin
|
Cytotoxicity against human HeLa cells after 2 days
Cytotoxicity against human HeLa cells after 2 days
|
[PMID: 22318164]
|
HeLa
|
IC50 |
1.5 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 24941129]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 22044164]
|
HeLa
|
IC50 |
1.51 μM
Compound: Doxorubicin
|
Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 26330077]
|
HeLa
|
IC50 |
1.59 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 26948541]
|
HeLa
|
IC50 |
1.6 x 10 -2 μM
Compound: adriamycin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 19285863]
|
HeLa
|
IC50 |
1.64 μM
Compound: Adriamycin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 21534590]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 26494582]
|
HeLa
|
IC50 |
1.69 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 30500683]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 29129513]
|
HeLa
|
IC50 |
1.78 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26708114]
|
HeLa
|
IC50 |
1.8 μM
Compound: Doxorubicin
|
Anticancer activity against human HeLa cells by MTT assay
Anticancer activity against human HeLa cells by MTT assay
|
[PMID: 33421712]
|
HeLa
|
IC50 |
1.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT reduction assay
Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT reduction assay
|
[PMID: 33421712]
|
HeLa
|
IC50 |
1.81 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay
|
[PMID: 29409753]
|
HeLa
|
IC50 |
1.82 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 29172084]
|
HeLa
|
IC50 |
1.862 μM
Compound: Doxorubicin
|
Anti-proliferative activity against human HeLa cells measured after 48 hrs by MTT assay
Anti-proliferative activity against human HeLa cells measured after 48 hrs by MTT assay
|
[PMID: 27744185]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 29289881]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32631552]
|
HeLa
|
IC50 |
1.96 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
|
[PMID: 36126331]
|
HeLa
|
IC50 |
1.995 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 29501940]
|
HeLa
|
GI50 |
|
Growth inhibition of human HeLa cells after 48 hrs by SRB assay
Growth inhibition of human HeLa cells after 48 hrs by SRB assay
|
[PMID: 28433679]
|
HeLa
|
IC50 |
10.78 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as cell viability by SRB assay
Cytotoxicity against human HeLa cells assessed as cell viability by SRB assay
|
[PMID: 26022842]
|
HeLa
|
IC50 |
11 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 11473441]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 27597408]
|
HeLa
|
IC50 |
13 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 35526504]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 31015907]
|
HeLa
|
CC50 |
2 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining
Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining
|
[PMID: 20153202]
|
HeLa
|
IC50 |
2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31938458]
|
HeLa
|
IC50 |
2 μM
Compound: adriamycin
|
Cytotoxicity against human HeLa cells under deem light after 96 hrs by MTT assay
Cytotoxicity against human HeLa cells under deem light after 96 hrs by MTT assay
|
[PMID: 17993275]
|
HeLa
|
IC50 |
2.05 μM
Compound: Doxorubicin
|
Growth inhibition of human HeLa cells by MTT assay
Growth inhibition of human HeLa cells by MTT assay
|
[PMID: 28147307]
|
HeLa
|
IC50 |
2.089 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28462842]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
|
[PMID: 34700239]
|
HeLa
|
IC50 |
2.1 μM
Compound: Doxorubicin
|
Anticancer activity against human HeLa cells assessed as growth inhibition incubated for 48 hrs by MTT assay
Anticancer activity against human HeLa cells assessed as growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 34363936]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 23218718]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 29421568]
|
HeLa
|
IC50 |
2.29 μM
Compound: Doxorubicin
|
Anticancer activity against human HeLa cells after 48 hrs by MTT assay
Anticancer activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 25615796]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Alamar blue staining based fluorescence assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Alamar blue staining based fluorescence assay
|
[PMID: 28291684]
|
HeLa
|
IC50 |
2.45 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells treated for 72 hrs by MTT assay
Cytotoxicity against human HeLa cells treated for 72 hrs by MTT assay
|
[PMID: 35344904]
|
HeLa
|
EC50 |
2.5 μM
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay
|
10.1007/s00044-012-0294-5
|
HeLa
|
IC50 |
2.57 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 27015609]
|
HeLa
|
IC50 |
2.63 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 26264845]
|
HeLa
|
IC50 |
2.684 μg/mL
Compound: ADM
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 25862199]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by MTT assay
Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by MTT assay
|
[PMID: 32631524]
|
HeLa
|
IC50 |
2.9 x 10 -1 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
|
[PMID: 20619940]
|
HeLa
|
IC50 |
20.93 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 22818039]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay
|
[PMID: 26649907]
|
HeLa
|
IC50 |
3 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by DAPI staining based assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by DAPI staining based assay
|
[PMID: 33461146]
|
HeLa
|
IC50 |
3.24 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 23835482]
|
HeLa
|
IC50 |
3.24 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa after 24 hrs by MTT assay
Cytotoxicity against human HeLa after 24 hrs by MTT assay
|
[PMID: 20056520]
|
HeLa
|
IC50 |
3.24 μM
Compound: doxorubicin
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 19128861]
|
HeLa
|
IC50 |
3.24 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 24 hrs incubation by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs incubation by MTT assay
|
[PMID: 24856067]
|
HeLa
|
IC50 |
3.3 μM
Compound: adriamycin
|
Cytotoxicity against human HeLa cells after 4 days by MTT assay
Cytotoxicity against human HeLa cells after 4 days by MTT assay
|
[PMID: 17194586]
|
HeLa
|
IC50 |
|
Inhibition of topoisomerase 2 in human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Inhibition of topoisomerase 2 in human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 30846253]
|
HeLa
|
IC50 |
3.33 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 24 hrs by MTT assay
|
[PMID: 36652792]
|
HeLa
|
IC50 |
|
Antineoplastic activity against human HeLa cells measured after 36 hrs by MTT assay
Antineoplastic activity against human HeLa cells measured after 36 hrs by MTT assay
|
[PMID: 30746067]
|
HeLa
|
IC50 |
3.57 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25594739]
|
HeLa
|
IC50 |
|
Antitumor activity against human HeLa cells after 48 hrs by MTT assay
Antitumor activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 20599299]
|
HeLa
|
IC50 |
3.7 μM
Compound: Adriamycin
|
Cytotoxicity against human HeLa cells after 4 days by MTT assay
Cytotoxicity against human HeLa cells after 4 days by MTT assay
|
[PMID: 21704436]
|
HeLa
|
IC50 |
3.9 μM
Compound: doxorubicin
|
Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay
Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay
|
[PMID: 23547843]
|
HeLa
|
IC50 |
3.92 μM
Compound: Doxorubicin
|
Anticancer activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
Anticancer activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 26542964]
|
HeLa
|
IC50 |
3.97 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 31404864]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells measured after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells measured after 48 hrs by MTT assay
|
[PMID: 27639364]
|
HeLa
|
IC50 |
30.21 μM
Compound: Doxorubicin
|
Anticancer activity against human HeLa cells after 48 hrs by SRB assay
Anticancer activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 24077528]
|
HeLa
|
IC50 |
37 nM
Compound: doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay
Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay
|
[PMID: 20180542]
|
HeLa
|
IC50 |
4 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay
|
[PMID: 27618204]
|
HeLa
|
IC50 |
4.1 μM
Compound: doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 23748152]
|
HeLa
|
IC50 |
4.16 nM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as cell viability after 5 days by cell viability analyzer
Cytotoxicity against human HeLa cells assessed as cell viability after 5 days by cell viability analyzer
|
[PMID: 26291039]
|
HeLa
|
IC50 |
4.61 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 35367708]
|
HeLa
|
IC50 |
4.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28254167]
|
HeLa
|
IC50 |
5 mM
Compound: Adriamycin
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 23685942]
|
HeLa
|
IC50 |
5 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 27173802]
|
HeLa
|
IC50 |
5.17 μM
Compound: Doxorubicin
|
Antitumor activity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antitumor activity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 30138804]
|
HeLa
|
IC50 |
5.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 27769619]
|
HeLa
|
IC50 |
5.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 26252628]
|
HeLa
|
IC50 |
5.23 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 29573910]
|
HeLa
|
IC50 |
5.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 22304344]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 37054758]
|
HeLa
|
IC50 |
|
Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 32085964]
|
HeLa
|
IC50 |
5.57 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa after 24 hrs by MTT assay
Antiproliferative activity against human HeLa after 24 hrs by MTT assay
|
[PMID: 30826188]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 36242988]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32527460]
|
HeLa
|
IC50 |
5.57 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 29702448]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells by MTT assay
Antiproliferative activity against human HeLa cells by MTT assay
|
[PMID: 30216848]
|
HeLa
|
IC50 |
5.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay
|
[PMID: 34223162]
|
HeLa
|
IC50 |
55 nM
Compound: doxorubicin
|
Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay
Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay
|
[PMID: 20180542]
|
HeLa
|
IC50 |
|
Antitumor activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antitumor activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 35859879]
|
HeLa
|
IC50 |
6 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 25453802]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
10.1039/C2MD20270K
|
HeLa
|
IC50 |
6.3 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30660827]
|
HeLa
|
GI50 |
|
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 29316526]
|
HeLa
|
IC50 |
6.94 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 24607876]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells measured after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells measured after 24 hrs by MTT assay
|
[PMID: 31104996]
|
HeLa
|
IC50 |
|
Anticancer activity against human HeLa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay
Anticancer activity against human HeLa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay
|
[PMID: 25064350]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay
|
[PMID: 28129977]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HeLa cells after 48 hrs by sulforhodamine B assay
|
10.1039/C5MD00513B
|
HeLa
|
IC50 |
7.4 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 35526504]
|
HeLa
|
GI50 |
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 26513642]
|
HeLa
|
IC50 |
7.71 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 23994327]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 31589431]
|
HeLa
|
IC50 |
71 nM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay
|
[PMID: 28600080]
|
HeLa
|
IC50 |
780 nM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30172625]
|
HeLa
|
IC50 |
8.1 μM
Compound: Doxorubicin
|
Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT based microplate ELISA reader analysis
Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT based microplate ELISA reader analysis
|
[PMID: 34438126]
|
HeLa
|
IC50 |
8.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by trypan blue-based hemacytometer counting analysis
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by trypan blue-based hemacytometer counting analysis
|
[PMID: 28756265]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 30398868]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 19932530]
|
HeLa
|
IC50 |
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 35964425]
|
HeLa
|
IC50 |
8.96 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by WST-8 assay
Cytotoxicity against human HeLa cells by WST-8 assay
|
[PMID: 29295796]
|
HeLa
|
IC50 |
9.03 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 26873414]
|
HeLa
|
IC50 |
90 nM
Compound: Doxorubicin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 35059132]
|
HeLa S3
|
IC50 |
< 0.1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HeLaS3 cells by MTT assay
Antiproliferative activity against human HeLaS3 cells by MTT assay
|
[PMID: 29072457]
|
HeLa S3
|
IC50 |
0.03 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLaS3 cells after 48 hrs by MTT assay
Cytotoxicity against human HeLaS3 cells after 48 hrs by MTT assay
|
[PMID: 26963142]
|
HeLa S3
|
IC50 |
0.03 μM
Compound: Doxorubicin
|
Cytotoxicity against human HeLaS3 cells by MTT assay
Cytotoxicity against human HeLaS3 cells by MTT assay
|
[PMID: 30719909]
|
HeLa S3
|
IC50 |
0.12 μM
Compound: Doxorubicin
|
Cytotoxicity in human HeLaS3 cells incubated for 72 hrs by MTT assay
Cytotoxicity in human HeLaS3 cells incubated for 72 hrs by MTT assay
|
[PMID: 30978023]
|
HeLa S3
|
IC50 |
0.15 μM
Compound: Doxorubicin
|
Cytotoxicity activity against human HeLa S3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity activity against human HeLa S3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 32627543]
|
Hep 3B2
|
IC50 |
0.14 μM
Compound: Doxorubucin
|
Cytotoxicity against human Hep3B cells by MTT assay
Cytotoxicity against human Hep3B cells by MTT assay
|
[PMID: 20718475]
|
Hep 3B2
|
IC50 |
0.2 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human Hep3B cells by MTT assay
Cytotoxicity against human Hep3B cells by MTT assay
|
[PMID: 18973388]
|
Hep 3B2
|
IC50 |
0.27 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human Hep3B cells by MTT assay
Cytotoxicity against human Hep3B cells by MTT assay
|
[PMID: 18590313]
|
Hep 3B2
|
IC50 |
|
Cytotoxicity against human Hep3B cells measured after 48 hrs by MTT assay
Cytotoxicity against human Hep3B cells measured after 48 hrs by MTT assay
|
[PMID: 23290052]
|
Hep 3B2
|
IC50 |
0.31 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human Hep3B cells after 3 days by MTT assay
Cytotoxicity against human Hep3B cells after 3 days by MTT assay
|
[PMID: 15387653]
|
Hep 3B2
|
IC50 |
0.41 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human Hep3B cells after 3 days by MTT assay
Cytotoxicity against human Hep3B cells after 3 days by MTT assay
|
[PMID: 19691312]
|
Hep 3B2
|
IC50 |
0.42 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human Hep3B cells by MTT assay
Cytotoxicity against human Hep3B cells by MTT assay
|
[PMID: 21106454]
|
Hep 3B2
|
IC50 |
0.45 μg/mL
Compound: doxo
|
Cytotoxicity against human Hep3B cells by MTT method
Cytotoxicity against human Hep3B cells by MTT method
|
[PMID: 17417907]
|
Hep 3B2
|
IC50 |
0.48 μM
Compound: Doxorubicin
|
Cytotoxicity against human Hep3B cells after 3 days by MTT assay
Cytotoxicity against human Hep3B cells after 3 days by MTT assay
|
[PMID: 18547115]
|
Hep 3B2
|
IC50 |
0.59 μM
Compound: doxorubicin
|
Cytotoxicity against human Hep3B cells after 3 days by MTT assay
Cytotoxicity against human Hep3B cells after 3 days by MTT assay
|
[PMID: 18419154]
|
Hep 3B2
|
IC50 |
|
Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay
Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay
|
[PMID: 20334960]
|
Hep 3B2
|
IC50 |
0.62 μM
Compound: doxorubicin
|
Cytotoxicity against human Hep3B cells after 72 hrs by MTT colorimetric method
Cytotoxicity against human Hep3B cells after 72 hrs by MTT colorimetric method
|
[PMID: 17622129]
|
Hep 3B2
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human Hep3B cells by MTT assay
Cytotoxicity against human Hep3B cells by MTT assay
|
[PMID: 21425785]
|
Hep 3B2
|
IC50 |
1.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 34838335]
|
Hep 3B2
|
IC50 |
|
Cytotoxicity against human Hep3B cells after 3 days by MTT assay
Cytotoxicity against human Hep3B cells after 3 days by MTT assay
|
[PMID: 21800859]
|
Hep 3B2
|
IC50 |
|
Cytotoxicity against human Hep3B cells by MTT assay
Cytotoxicity against human Hep3B cells by MTT assay
|
[PMID: 28262527]
|
Hep 3B2
|
IC50 |
1.31 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human Hep3B cells by MTT assay
Cytotoxicity against human Hep3B cells by MTT assay
|
[PMID: 22413887]
|
Hep 3B2
|
IC50 |
1.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30660827]
|
Hep 3B2
|
IC50 |
|
Antiproliferative activity against human Hep3B cells for 24 hrs by MTT assay
Antiproliferative activity against human Hep3B cells for 24 hrs by MTT assay
|
[PMID: 24929289]
|
Hep 3B2
|
IC50 |
|
Cytotoxicity against human Hep3B cells measured after 72 hrs by Celltiter-Glo assay
Cytotoxicity against human Hep3B cells measured after 72 hrs by Celltiter-Glo assay
|
[PMID: 31820976]
|
Hep 3B2
|
IC50 |
2.4 μM
Compound: Doxorubicin
|
Growth inhibition of human Hep3B cells by MTT assay
Growth inhibition of human Hep3B cells by MTT assay
|
[PMID: 28916158]
|
Hep 3B2
|
IC50 |
|
Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
|
[PMID: 28865276]
|
Hep 3B2
|
EC50 |
5.6 μM
Compound: doxorubicin
|
Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay
Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay
|
[PMID: 20455578]
|
HEp-2
|
IC50 |
|
Antitumor activity against human Hep2 cells after 72 hrs by MTT assay
Antitumor activity against human Hep2 cells after 72 hrs by MTT assay
|
[PMID: 17935309]
|
HEp-2
|
IC50 |
|
Antiproliferative activity against human Hep2 cell line by MTT assay
Antiproliferative activity against human Hep2 cell line by MTT assay
|
[PMID: 16913700]
|
HEp-2
|
IC50 |
0.4 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human Hep2 cells after 24 hrs
Cytotoxicity against human Hep2 cells after 24 hrs
|
[PMID: 20207452]
|
HEp-2
|
IC50 |
0.42 μM
Compound: doxorubicin
|
Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay
Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay
|
[PMID: 18281125]
|
HEp-2
|
IC50 |
0.42 μM
Compound: doxorubicin
|
Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay
Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay
|
[PMID: 17400463]
|
HEp-2
|
IC50 |
0.51 μM
Compound: Doxorubicin
|
Antiproliferative activity against human Hep2 cells after 48 hrs by neutral red assay
Antiproliferative activity against human Hep2 cells after 48 hrs by neutral red assay
|
[PMID: 29885574]
|
HEp-2
|
IC50 |
1.21 μM
Compound: Doxorubicin
|
Cytotoxicity against human Hep2 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
Cytotoxicity against human Hep2 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
|
[PMID: 29329071]
|
HEp-2
|
IC50 |
1.29 μM
Compound: Doxorubicin
|
Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay
Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay
|
[PMID: 27116711]
|
HEp-2
|
IC50 |
1.3 μM
Compound: Doxorubicin
|
Growth inhibition of human Hep2 cells after 72 hrs by MTT assay
Growth inhibition of human Hep2 cells after 72 hrs by MTT assay
|
[PMID: 28189083]
|
HEp-2
|
IC50 |
1.5 μM
Compound: Adriamycin
|
Cytotoxicity against human Hep2 cells by neutral red method
Cytotoxicity against human Hep2 cells by neutral red method
|
[PMID: 26291474]
|
HEp-2
|
IC50 |
|
Cytotoxicity against against human Hep2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against against human Hep2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30340899]
|
HEp-2
|
IC50 |
6.32 μM
Compound: Doxorubicin
|
Antiproliferative activity against human Hep2 after 24 hrs by MTT assay
Antiproliferative activity against human Hep2 after 24 hrs by MTT assay
|
[PMID: 30826188]
|
HEp-2
|
IC50 |
|
Antiproliferative activity against human HEp-2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Antiproliferative activity against human HEp-2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 37054758]
|
HEp-2
|
IC50 |
8.7 μM
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) Hep2 cells by MTT assay
Cytotoxicity against Homo sapiens (human) Hep2 cells by MTT assay
|
10.1007/s00044-012-0370-x
|
HEp-2
|
IC50 |
8.7 μM
Compound: Doxorubicine
|
Cytotoxicity against human Hep2 cells by MTT assay
Cytotoxicity against human Hep2 cells by MTT assay
|
[PMID: 22014995]
|
HepG2
|
IC50 |
< 2.94 μM
Compound: Doxorubicin
|
Inhibition of proliferation of human HepG2 cells after 72 hrs by XTT assay
Inhibition of proliferation of human HepG2 cells after 72 hrs by XTT assay
|
[PMID: 20810194]
|
HepG2
|
EC50 |
> 10 μM
Compound: doxorubicin
|
Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay
Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay
|
[PMID: 20455578]
|
HepG2
|
IC50 |
> 40 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 12608856]
|
HepG2
|
IC50 |
|
Cytotoxicity against human doxorubicin-resistant HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human doxorubicin-resistant HepG2 cells after 48 hrs by MTT assay
|
[PMID: 27889629]
|
HepG2
|
IC50 |
> 75 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 27843113]
|
HepG2
|
IC50 |
0.007 ug
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by SRB assay
Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by SRB assay
|
[PMID: 27393950]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
|
[PMID: 22520152]
|
HepG2
|
GI50 |
0.01 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 27889456]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 30826510]
|
HepG2
|
IC50 |
0.017 g/L
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay
|
10.1007/s00044-010-9433-z
|
HepG2
|
IC50 |
0.02 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 27886545]
|
HepG2
|
CC50 |
0.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay
|
[PMID: 25282267]
|
HepG2
|
IC50 |
0.04 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
|
[PMID: 31403289]
|
HepG2
|
GI50 |
|
Growth inhibition of human HepG2 cells by MTT assay
Growth inhibition of human HepG2 cells by MTT assay
|
[PMID: 31330449]
|
HepG2
|
IC50 |
0.05 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 22555152]
|
HepG2
|
CC50 |
0.06 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 32088496]
|
HepG2
|
IC50 |
0.06 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 34782182]
|
HepG2
|
IC50 |
0.06 μM
Compound: Adriamycin
|
Cytotoxicity against human HepG2 cells by SRB method
Cytotoxicity against human HepG2 cells by SRB method
|
[PMID: 18181575]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 31999451]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 23802716]
|
HepG2
|
IC50 |
0.1 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by CCK8 assay
Cytotoxicity against human HepG2 cells after 72 hrs by CCK8 assay
|
[PMID: 28398051]
|
HepG2
|
IC50 |
0.1 μM
Compound: doxorubicin
|
Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 18313307]
|
HepG2
|
IC50 |
0.16 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
|
[PMID: 19691312]
|
HepG2
|
IC50 |
0.16 μM
Compound: ADM; DOX
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 31491611]
|
HepG2
|
IC50 |
0.17 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 18590313]
|
HepG2
|
IC50 |
0.17 μM
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells after 6 days by MTT method
Cytotoxicity against human HepG2 cells after 6 days by MTT method
|
[PMID: 16309317]
|
HepG2
|
IC50 |
0.18 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
|
[PMID: 16252914]
|
HepG2
|
IC50 |
0.18 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 22413887]
|
HepG2
|
IC50 |
0.19 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
|
[PMID: 15387653]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
|
[PMID: 23290052]
|
HepG2
|
GI50 |
|
Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 30336023]
|
HepG2
|
GI50 |
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 29705710]
|
HepG2
|
IC50 |
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 21496972]
|
HepG2
|
IC50 |
0.19 μM
Compound: Doxorubucin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 20718475]
|
HepG2
|
IC50 |
0.2 μg/mL
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 18973388]
|
HepG2
|
IC50 |
0.2 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human Hep G2 cells by MTT colorimetric method
Cytotoxicity against human Hep G2 cells by MTT colorimetric method
|
[PMID: 17125220]
|
HepG2
|
IC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 28277681]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 34364164]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 32795774]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 32652409]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32292551]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 30655943]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30092366]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 29885575]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27654395]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay
|
[PMID: 27155463]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 25846065]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 25791675]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 25559208]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicine
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 24946216]
|
HepG2
|
IC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 24650715]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 24080103]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 22889559]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 22608675]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 21852132]
|
HepG2
|
CC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 21741131]
|
HepG2
|
IC50 |
0.2 μM
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 19926173]
|
HepG2
|
IC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 19482476]
|
HepG2
|
IC50 |
0.2 μM
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 17981462]
|
HepG2
|
IC50 |
0.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
Cytotoxicity against human HepG2 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay
|
[PMID: 36970146]
|
HepG2
|
IC50 |
0.21 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 31836446]
|
HepG2
|
IC50 |
0.22 μg/mL
Compound: Doxorubicin
|
Cytotoxic activity against human HepG2 cells by MTT assay
Cytotoxic activity against human HepG2 cells by MTT assay
|
[PMID: 28366267]
|
HepG2
|
IC50 |
0.23 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as survival after 3 days by crystal violet staining
Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as survival after 3 days by crystal violet staining
|
10.1007/s00044-012-0025-y
|
HepG2
|
IC50 |
0.23 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay
Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay
|
10.1007/s00044-011-9903-y
|
HepG2
|
IC50 |
0.23 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 21106454]
|
HepG2
|
IC50 |
0.23 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by fluorescein diacetate dye based fluorometric microculture assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by fluorescein diacetate dye based fluorometric microculture assay
|
[PMID: 28038943]
|
HepG2
|
GI50 |
0.25 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 26561866]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
|
[PMID: 21741833]
|
HepG2
|
IC50 |
0.29 μM
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 21174408]
|
HepG2
|
IC50 |
0.3 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 16724859]
|
HepG2
|
IC50 |
0.3 μM
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 24050254]
|
HepG2
|
IC50 |
0.3 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
10.1039/C5MD00163C
|
HepG2
|
IC50 |
0.3 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 19632833]
|
HepG2
|
EC50 |
0.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
|
[PMID: 26320088]
|
HepG2
|
IC50 |
0.3 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 29975532]
|
HepG2
|
IC50 |
0.36 μM
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 25314138]
|
HepG2
|
IC50 |
0.37 μM
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells after 4 days by MTT assay
Cytotoxicity against human HepG2 cells after 4 days by MTT assay
|
[PMID: 19824618]
|
HepG2
|
IC50 |
0.37 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 20846862]
|
HepG2
|
IC50 |
0.38 μM
Compound: Doxorubicin
|
Growth inhibition of human HepG2 cells incubated for 48 hrs by MTT assay
Growth inhibition of human HepG2 cells incubated for 48 hrs by MTT assay
|
[PMID: 27080187]
|
HepG2
|
IC50 |
0.39 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells by MTT assay
Antiproliferative activity against human HepG2 cells by MTT assay
|
[PMID: 36089748]
|
HepG2
|
IC50 |
0.392 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as cell viability incubated for 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay
Cytotoxicity against human HepG2 cells assessed as cell viability incubated for 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay
|
[PMID: 28797771]
|
HepG2
|
IC50 |
0.4 μg/mL
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay
|
[PMID: 32223924]
|
HepG2
|
IC50 |
0.4 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by neutral red-based assay
Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by neutral red-based assay
|
[PMID: 26469557]
|
HepG2
|
IC50 |
0.4 μM
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay
|
[PMID: 25490132]
|
HepG2
|
IC50 |
0.4 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 25747499]
|
HepG2
|
IC50 |
0.41 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23992864]
|
HepG2
|
IC50 |
0.42 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay
Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay
|
[PMID: 24969014]
|
HepG2
|
IC50 |
0.42 μM
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay
Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay
|
10.1007/s00044-012-0402-6
|
HepG2
|
IC50 |
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 35341920]
|
HepG2
|
IC50 |
0.45 μM
Compound: Doxorubicin
|
Anticancer activity against human HepG2 cells by MTT assay
Anticancer activity against human HepG2 cells by MTT assay
|
[PMID: 31404864]
|
HepG2
|
IC50 |
0.46 μg/mL
Compound: doxo
|
Cytotoxicity against human HepG2 cells by MTT method
Cytotoxicity against human HepG2 cells by MTT method
|
[PMID: 17417907]
|
HepG2
|
IC50 |
0.467 μM
Compound: Doxorubicin
|
Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay
Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay
|
[PMID: 35694689]
|
HepG2
|
IC50 |
0.48 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
|
[PMID: 24852278]
|
HepG2
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 200 uM incubated for 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 200 uM incubated for 24 hrs by MTT assay
|
[PMID: 31926469]
|
HepG2
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 25554367]
|
HepG2
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
|
[PMID: 31148449]
|
HepG2
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 21641694]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 20334960]
|
HepG2
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
10.1039/C3MD00166K
|
HepG2
|
IC50 |
0.5 μM
Compound: Adriamycin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 24182355]
|
HepG2
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 21425785]
|
HepG2
|
IC50 |
0.5 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells by SRB assay
Cytotoxicity against human HepG2 cells by SRB assay
|
[PMID: 29035560]
|
HepG2
|
IC50 |
0.5 μM
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT colorimetric method
Cytotoxicity against human HepG2 cells after 72 hrs by MTT colorimetric method
|
[PMID: 17622129]
|
HepG2
|
IC50 |
0.52 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30389295]
|
HepG2
|
IC50 |
0.54 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27371926]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 28262527]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 29681486]
|
HepG2
|
IC50 |
0.55 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31704206]
|
HepG2
|
IC50 |
0.57 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 26397393]
|
HepG2
|
IC50 |
0.57 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 25019480]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 26386603]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 20399544]
|
HepG2
|
IC50 |
0.59 μM
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 23806110]
|
HepG2
|
IC50 |
0.6 μg/mL
Compound: Doxorubicine
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 24177357]
|
HepG2
|
IC50 |
0.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 24300737]
|
HepG2
|
IC50 |
0.62 μM
Compound: Doxorubicin
|
Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
|
[PMID: 32438251]
|
HepG2
|
IC50 |
0.62 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells after 48 hrs by neutral red assay
Antiproliferative activity against human HepG2 cells after 48 hrs by neutral red assay
|
[PMID: 29885574]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
|
[PMID: 21800859]
|
HepG2
|
IC50 |
0.64 μg/mL
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 34973507]
|
HepG2
|
IC50 |
0.64 μM
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
|
[PMID: 18419154]
|
HepG2
|
IC50 |
0.66 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 34838335]
|
HepG2
|
EC50 |
0.67 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 35567964]
|
HepG2
|
IC50 |
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32996316]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 29421568]
|
HepG2
|
IC50 |
0.68 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTT assay
|
[PMID: 27422336]
|
HepG2
|
IC50 |
|
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 33276990]
|
HepG2
|
IC50 |
|
Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay
Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay
|
[PMID: 16499322]
|
HepG2
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay
|
[PMID: 27300257]
|
HepG2
|
GI50 |
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 34634616]
|
HepG2
|
IC50 |
0.7 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 22749279]
|
HepG2
|
IC50 |
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 31765156]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 30132670]
|
HepG2
|
IC50 |
0.72 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
|
[PMID: 31926469]
|
HepG2
|
IC50 |
0.72 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 30654238]
|
HepG2
|
IC50 |
0.72 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 26874404]
|
HepG2
|
IC50 |
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 35339100]
|
HepG2
|
IC50 |
0.74 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 25419616]
|
HepG2
|
CC50 |
0.77 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 120 hrs by MTS assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 120 hrs by MTS assay
|
[PMID: 32590115]
|
HepG2
|
IC50 |
0.77 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
|
[PMID: 25537271]
|
HepG2
|
IC50 |
0.79 μM
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
10.1007/s00044-013-0777-z
|
HepG2
|
IC50 |
0.79 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25078311]
|
HepG2
|
IC50 |
0.79 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 24836071]
|
HepG2
|
IC50 |
0.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
|
[PMID: 32324401]
|
HepG2
|
IC50 |
0.8 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 26586599]
|
HepG2
|
IC50 |
0.82 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
|
[PMID: 18547115]
|
HepG2
|
IC50 |
|
Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
|
[PMID: 25812966]
|
HepG2
|
IC50 |
0.877 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
|
[PMID: 24231309]
|
HepG2
|
IC50 |
0.9 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by neutral red
Cytotoxicity against human HepG2 cells after 48 hrs by neutral red
|
[PMID: 23891181]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 28704759]
|
HepG2
|
IC50 |
0.919 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells by SRB assay
Cytotoxicity against human HepG2 cells by SRB assay
|
[PMID: 34128674]
|
HepG2
|
IC50 |
0.95 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
10.1039/C3MD00013C
|
HepG2
|
IC50 |
0.954 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 20832916]
|
HepG2
|
IC50 |
0.99 μM
Compound: Doxorubicin
|
Anticancer activity against human HepG2 cells by SRB assay
Anticancer activity against human HepG2 cells by SRB assay
|
[PMID: 34128674]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay
|
[PMID: 21094049]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 32371335]
|
HepG2
|
IC50 |
1 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 28919340]
|
HepG2
|
IC50 |
1 μM
Compound: Doxorubicin
|
Cytotoxicity activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 32627543]
|
HepG2
|
IC50 |
1 μM
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by neutral red assay
Cytotoxicity against human HepG2 cells after 48 hrs by neutral red assay
|
[PMID: 24900509]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 29909338]
|
HepG2
|
IC50 |
1.02 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 23871222]
|
HepG2
|
IC50 |
1.05 μM
Compound: Doxorubicin
|
Anticancer activity against human HepG2 cells by MTT assay
Anticancer activity against human HepG2 cells by MTT assay
|
[PMID: 25743216]
|
HepG2
|
IC50 |
1.07 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 30719909]
|
HepG2
|
IC50 |
|
Anticancer activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by SRB assay
Anticancer activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by SRB assay
|
10.1007/s00044-012-0057-3
|
HepG2
|
IC50 |
1.1 μM
Compound: Doxorubicin
|
Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay
Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay
|
[PMID: 25096298]
|
HepG2
|
IC50 |
1.12 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32866757]
|
HepG2
|
IC50 |
1.13 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells by CCK8 assay
Cytotoxicity against human HepG2 cells by CCK8 assay
|
[PMID: 29452840]
|
HepG2
|
IC50 |
1.15 μM
Compound: Adriamycin
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 24582982]
|
HepG2
|
IC50 |
1.18 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 3 days by microplate reader analysis
Cytotoxicity against human HepG2 cells after 3 days by microplate reader analysis
|
[PMID: 32705864]
|
HepG2
|
IC50 |
|
Antineoplastic activity against human HepG2 cells measured after 36 hrs by MTT assay
Antineoplastic activity against human HepG2 cells measured after 36 hrs by MTT assay
|
[PMID: 30746067]
|
HepG2
|
IC50 |
1.2 μM
Compound: Doxorubicin
|
Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay
|
10.1007/s00044-011-9884-x
|
HepG2
|
IC50 |
1.2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 27797185]
|
HepG2
|
IC50 |
|
Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
|
[PMID: 15730243]
|
HepG2
|
IC50 |
|
Cytotoxicity against human Hep G2 by WST-8 assay
Cytotoxicity against human Hep G2 by WST-8 assay
|
[PMID: 16933868]
|
HepG2
|
IC50 |
1.2 μM
Compound: adriamycin
|
Cytotoxicity against human HepG2 cells by rapid colorimetric assay
Cytotoxicity against human HepG2 cells by rapid colorimetric assay
|
[PMID: 19585998]
|
HepG2
|
IC50 |
1.21 μg/mL
Compound: Doxorubicin
|
Anticancer activity against human cells HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
Anticancer activity against human cells HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 25042338]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 30771605]
|
HepG2
|
IC50 |
1.22 μM
Compound: adriamycin
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay
|
[PMID: 26295905]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
|
[PMID: 25089733]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 34323485]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 26900656]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 31057738]
|
HepG2
|
GI50 |
1.4 μM
Compound: Doxorubicin
|
Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay
Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay
|
[PMID: 26163220]
|
HepG2
|
IC50 |
1.43 μM
Compound: Doxorubicin
|
Cytotoxicity in human HepG2 cells incubated for 72 hrs by MTT assay
Cytotoxicity in human HepG2 cells incubated for 72 hrs by MTT assay
|
[PMID: 30978023]
|
HepG2
|
IC50 |
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 28756264]
|
HepG2
|
IC50 |
1.51 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
|
[PMID: 32682198]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay
Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay
|
[PMID: 21797280]
|
HepG2
|
IC50 |
1.54 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by Alamar blue assay
Cytotoxicity against human HepG2 cells after 48 hrs by Alamar blue assay
|
[PMID: 20931970]
|
HepG2
|
IC50 |
1.54 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 26963142]
|
HepG2
|
IC50 |
1.6 μg/mL
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 21708464]
|
HepG2
|
IC50 |
1.6 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 19583252]
|
HepG2
|
IC50 |
1.61 μM
Compound: Doxorubicin
|
Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
Anticancer activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 25615796]
|
HepG2
|
IC50 |
|
Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as reduction of cell survival after 48 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as reduction of cell survival after 48 hr by MTT assay
|
10.1007/s00044-012-0150-7
|
HepG2
|
IC50 |
1.7 x 10 -1 μM
Compound: doxorubicin
|
Growth inhibition of human HepG2 cells after 72 hrs by SRB assay
Growth inhibition of human HepG2 cells after 72 hrs by SRB assay
|
[PMID: 18512984]
|
HepG2
|
IC50 |
1.8 μM
Compound: Doxorubicin
|
Anticancer activity against human HepG2 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
Anticancer activity against human HepG2 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 34363936]
|
HepG2
|
IC50 |
|
Growth inhibition of human HepG2 cells after 48 hrs by MTT assay
Growth inhibition of human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 29509413]
|
HepG2
|
CC50 |
1.95 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 29792325]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
|
[PMID: 34700239]
|
HepG2
|
IC50 |
|
Anticancer activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
Anticancer activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 31740054]
|
HepG2
|
IC50 |
10 μM
Compound: Doxorubicin
|
Antiproliferative activity against doxorubicin resistant human HepG2 cells for 24 hrs in presence of c-phycocyanin by MTT assay
Antiproliferative activity against doxorubicin resistant human HepG2 cells for 24 hrs in presence of c-phycocyanin by MTT assay
|
[PMID: 34128674]
|
HepG2
|
IC50 |
10.15 μM
Compound: Doxorubicin
|
Cytotoxicity activity against human HepG2 cells by MTT assay
Cytotoxicity activity against human HepG2 cells by MTT assay
|
[PMID: 26873414]
|
HepG2
|
IC50 |
10.4 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31323616]
|
HepG2
|
GI50 |
|
Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
|
[PMID: 29316526]
|
HepG2
|
ED50 |
102 μM
Compound: doxorubicin
|
Antitumor activity against human HepG2 cells after 24 hrs by MTT assay
Antitumor activity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 17482824]
|
HepG2
|
IC50 |
12.5 μM
Compound: Adriamycin
|
Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay
Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 24974349]
|
HepG2
|
IC50 |
130 nM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
|
[PMID: 35213166]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 Cells by MTT/Trypan Blue Exclusion Assay
Cytotoxicity against human HepG2 Cells by MTT/Trypan Blue Exclusion Assay
|
[PMID: 31129455]
|
HepG2
|
IC50 |
17.54 μM
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 21620529]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell viability measured after 24 hrs by MTT assay
|
[PMID: 33183865]
|
HepG2
|
IC50 |
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 29852328]
|
HepG2
|
IC50 |
19 nM
Compound: Doxorubicin
|
Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay
|
[PMID: 21296467]
|
HepG2
|
IC50 |
19 μg/mL
Compound: doxorubicin
|
Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay
|
10.1007/s00044-010-9436-9
|
HepG2
|
IC50 |
2 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 48 hrs by Neutral Red assay
Cytotoxicity against human HepG2 cells after 48 hrs by Neutral Red assay
|
10.1039/C3MD00097D
|
HepG2
|
IC50 |
|
Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 20932754]
|
HepG2
|
IC50 |
2.1 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 26821210]
|
HepG2
|
IC50 |
2.1 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29702447]
|
HepG2
|
IC50 |
2.17 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells after 94 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 94 hrs by MTT assay
|
[PMID: 21868138]
|
HepG2
|
IC50 |
2.3 μM
Compound: Doxorubicin
|
Hepatotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Hepatotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 33439019]
|
HepG2
|
IC50 |
2.32 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 33352388]
|
HepG2
|
IC50 |
2.35 μM
Compound: Doxorubicin
|
Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 34124677]
|
HepG2
|
IC50 |
2.41 x 10 -1 μg/mL
Compound: adriamycin
|
Cytotoxicity against human HepG2 cells after 12 days by methylene blue colorimetric method
Cytotoxicity against human HepG2 cells after 12 days by methylene blue colorimetric method
|
[PMID: 11473425]
|
HepG2
|
IC50 |
2.41 x 10 -1 μg/mL
Compound: Adriamycin
|
Cytotoxicity against human HepG2 cells after 3 days
Cytotoxicity against human HepG2 cells after 3 days
|
[PMID: 11975482]
|
HepG2
|
IC50 |
2.5 mM
Compound: Adriamycin
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 23685942]
|
HepG2
|
IC50 |
2.5 mM
Compound: Adriamycin
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 22440624]
|
HepG2
|
IC50 |
2.5 nM
Compound: Doxorubicin
|
Inhibition of TRK in human HepG2 cells after 48 hrs by ELISA
Inhibition of TRK in human HepG2 cells after 48 hrs by ELISA
|
[PMID: 24013411]
|
HepG2
|
IC50 |
2.511 μM
Compound: Doxorubicin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28462842]
|
HepG2
|
IC50 |
2.594 μM
Compound: Doxorubicin
|
Anti-proliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
Anti-proliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
|
[PMID: 27744185]
|
HepG2
|
IC50 |
|
Inhibition of topoisomerase 2 in human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Inhibition of topoisomerase 2 in human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 30846253]
|
HepG2
|
IC50 |
|
Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
|
[PMID: 27639364]
|
HepG2
|
IC50 |
2.68 μM
Compound: doxorubicin
|
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
|
10.1007/s00044-013-0795-x
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
|
[PMID: 34450496]
|
|